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SUMMARY OF RELATIVE EFFECTIVENESS OF ALECENSA (ALECTINIB) 
Scope 
The scope can be found here: Scope.  
Introduction 
The objective is to assess the relative effectiveness and safety of alectinib as first-line 
monotherapy for adult patients with ALK-positive advanced non-small cell lung cancer (NSCLC) in 
comparison with crizotinib and ceritinib.  
Description of technology and comparators 
Alectinib (Alecensa) is a potent, highly selective, central nervous system (CNS)-active inhibitor of 
anaplastic lymphoma kinase (ALK) which is taken orally. As monotherapy, it is indicated for the 
first-line treatment of adult patients with ALK-positive advanced NSCLC and also for the treatment 
of adult patients with ALK-positive advanced NSCLC previously treated with crizotinib [B0001, 
A0020]. Alectinib demonstrated activity against mutant forms of ALK, including mutations 
responsible for resistance to crizotinib, and is able to distribute itself into and be retained within 
the CNS [B0001]. 
Crizotinib and ceritinib are also approved as first-line monotherapy for ALK-positive advanced 
NSCLC in the European Union (EU). Because ceritinib has been authorised only recently in this 
setting, European guideline published in 2016 currently recommend crizotinib as the standard of 
care. Both compounds are considered as appropriate comparators for alectinib in the first-line 
treatment indication, however [B0001, A0020].  
The claimed benefit of alectinib is related to a significantly longer progression-free survival (PFS), 
irrespective of whether patients had CNS metastases at the baseline; superior efficacy in the CNS 
(reducing the number of patients with new or progressive CNS metastases at 12 months); lower 
incidence of adverse events (AEs) and greater tolerability reported by patients [B0002]. 
The presence of genetic defects affecting ALK (‘ALK-positive’ status) has to be confirmed in 
advance by appropriate methods [B0008]. 
Health problem 
Lung cancer has been the most common cancer overall for several decades and is also the most 
common cause of cancer-related death worldwide. NSCLC is the most frequent type of lung 
cancer, but molecular analysis allows further subdivision of lung cancer. ALK-positive NSCLC is 
more frequent in never smokers, in a specific histologic subtype (i.e., adenocarcinomas) and in 
younger patients (mean age at diagnosis 52–58 years) [A0002].  
Since lung cancers are asymptomatic for long periods, they are usually diagnosed at a late stage. 
Therefore life expectancy of patients with advanced or metastasised NSCLC is low. Less than 5% 
of these patients are alive 5 years after diagnosis, and they usually survive for only about 8–10 
months [A0004]. 
For patients with ALK-positive NSCLC, specific therapies targeting ALK are available. Currently, 
crizotinib therapy is the standard of care in Europe, but development of brain metastases is still 
commonly observed [A0025]. In the European Union, about 313,000 new cases and 270,000 lung 
cancer-related deaths were estimated in 2012. Of the patients involved, about 11,000–12,000 
would be eligible to receive specific ALK-targeted therapy as initial therapy [A0023].  
Methods 
The completed part of the EUnetHTA submission file from the manufacturer was used as the 
starting point. 
For the effectiveness and safety domains, a systematic literature search, according to the 
predefined search strategy, was performed by the marketing authorisation holder (MAH) in 
February 2017 in key clinical electronic databases (the Cochrane Central Register of Controlled 
Trials [CENTRAL], the Database of Abstracts of Reviews of Effects [DARE], the Cochrane 
Database of Systematic Reviews [CDSR], MEDLINE, Embase, MEDLINE in-process and 
electronic publications ahead of print through PubMed) and was critically assessed by the authors 
of this assessment. The search strategy relevant for MEDLINE was reproduced by the authors of 
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this assessment for PubMed. The update of the literature search was conducted in October 2017: 
no other relevant randomised controlled trial (RCT) was identified. 
 
A hand search was also performed on conference proceedings for major oncology and lung 
cancer meetings (2014–2016) and reference lists of included publications and of relevant 
systematic reviews and meta-analyses from 2012 onwards. The following clinical trial registries 
were searched in January 2017: ClinicalTrials.gov (http://www.clinicaltrials.gov/), World Health 
Organization (WHO) International Clinical Trials Registry Platform 
(http://apps.who.int/trialsearch/Default.aspx) and the EU Clinical Trials Register 
(https://www.clinicaltrialsregister.eu/). 
 
A separate guideline update search (Guidelines International Network, National Guideline 
Clearinghouse, TRIP Database and hand search) was performed by the authors in December 
2017. 
 
The health problem and current use of the technology domain and the description and technical 
characteristics of technology domain were only summarised descriptively. Data used for the 
effectiveness and safety domains were extracted from the file submitted by the MAH and verified 
by the authors. The risk of bias at the study level and the outcome level for the RCTs was 
independently assessed by the co-authors according to the Cochrane Risk of Bias tool and the 
quality of evidence according to GRADE. In addition, an indirect comparison using the Bucher 
method and a network meta-analysis (NMA) were performed by the MAH and critically appraised 
by the authors using a technical support document from the Decision Support Unit of the National 
Institute for Health and Care Excellence [1] (Appendix 6. Indirect comparisons – statistical 
aspects). 
One individual patient who was recently diagnosed with ALK-positive NSCLC and being treated 
for four weeks with crizotinib was willing to provide relevant input on the impact of the condition 
and on the most important endpoints through a one hour telephone interview. 
 
Results 
Available evidence 
The assessment of clinical effectiveness and safety is based primarily on three phase III 
randomised active-controlled trials:  
  ALEX (alectinib vs. crizotinib),  
 ASCEND-4 (ceritinib vs. chemotherapy) and  
 PROFILE 1014 (crizotinib vs. chemotherapy).  
The ALEX study thus provides a direct comparison between alectinib and crizotinib, while the 
results from ASCEND-4 and PROFILE 1014 are used in an NMA that also included results from 
ALEX to provide a comparison against the other comparator, ceritinib. In addition, a sensitivity 
analysis was performed that included results from PROFILE 1029 (crizotinib vs. chemotherapy). 
Clinical effectiveness 
For the assessment of clinical effectiveness of alectinib as first-line treatment of ALK-positive 
advanced NSCLC, both direct and indirect comparisons were used. Crizotinib and ceritinib, both 
approved for the first-line treatment of ALK-positive advanced NSCLC, were identified as the most 
relevant comparators.  
For the comparison between alectinib and crizotinib, direct head-to-head data from the clinical 
study ALEX are available. For alectinib and ceritinib, there are no direct comparisons, but an 
indirect comparison was performed via crizotinib and chemotherapy regimens through the studies 
ALEX, ASCEND-4 and PROFILE 1014. It is noted, however, that in ASCEND-4, 4 cycles of 
pemetrexed plus cisplatin or carboplatin therapy, followed by maintenance pemetrexed therapy, 
were used; while in PROFILE 1014 up to 6 cycles of the same regimen were allowed, but there 
was no maintenance therapy with pemetrexed. Differences in the proportion of patients with CNS 
metastasis, an important prognostic factor, also exist between the studies included in the NMA. 
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Because of the uncertainties involved and possible dependencies regarding the heterogeneity 
assumptions on the results in the NMA, these results are considered with caution. 
Overall survival [D0001] 
Alectinib versus crizotinib (ALEX):  
At the data cutoff point, 23% of patients in the alectinib arm and 27% of patients in the crizotinib 
arm had died, with a 1-year survival rate of 84.3% and 82.5%, respectively, with a hazard ratio 
(HR) of 0.76 (95% confidence interval, CI, 0.48, 1.20, p=0.2). Median overall survival (OS) was 
not reached in either treatment arm. Survival analysis has been planned after 50% of events have 
occurred [2]. 
Alectinib versus ceritinib (NMA): 
No statistically significant differences between alectinib and ceritinib were observed in the 
unadjusted NMA OS analysis; HR 0.85 (95% Credible interval, CrI, 0.41, 1.73). 
Disease progression  [D0006] 
Alectinib versus crizotinib (ALEX):  
The trial met its primary endpoint at the primary analysis, demonstrating a statistically significant 
increase in progression-free survival (PFS) by investigator assessment. In the entire population 
the median PFS (investigator assessed) for alectinib was not reached (95% CI, 17.7 months to 
not estimable) versus 11.1 months for crizotinib (95% CI, 9.1, 13.1 months); HR 0.47 (95% CI, 
0.34, 0.65, p<0.0001). 
Independent review committee (IRC)-assessed PFS was also significantly longer with alectinib 
than with crizotinib (median PFS 25.7 months (95% CI, 19.9 months, not estimable] vs. 10.4 
months (95% CI, 7.7, 14.6 months); HR for disease progression or death 0.50 (95% CI, 0.36, 
0.70, p<0.001) [1]. 
The time to CNS progression was significantly longer with alectinib than with crizotinib in the 
intention-to-treat population (cause-specific HR 0.16, (95% CI, 0.10, 0.28), p<0.001); 18 patients 
(12%) in the alectinib group had an event of CNS progression, as compared with 68 patients 
(45%) in the crizotinib group. 
The treatment effect was generally consistent across the subgroups. The PFS benefit was 
consistent for patients with CNS metastases at the baseline (HR 0.40, (95% CI, 0.25, 0.64); 
median PFS for alectinib not estimable (95% CI, 9.2 months to not estimable); median PFS for 
crizotinib 7.4 months (95% CI, 6.6, 9.6 months) and for patients without CNS metastases at the 
baseline (HR 0.51, (95% CI, 0.33, 0.80); median PFS for alectinib not estimable, (95% CI, not 
estimable to not estimable); median PFS for crizotinib 14.8 months, (95% CI, 10.8, 20.3 months), 
indicating benefit of alectinib over crizotinib in both subgroups (MAH submission). 
The relative PFS benefit appeared lower in the subgroups of active smokers and patients with an 
Eastern Cooperative Oncology Group (ECOG) performance status of 2, although the small 
numbers of patients in these subgroups preclude any firm conclusions [1]. 
Alectinib versus ceritinib (NMA): 
Statistically significantly longer PFS in terms of 95% credible intervals (CrI) was observed for 
alectinib versus ceritinib in the NMA, HR 0.41 (95% CrI, 0.25, 0.67). This finding was consistent in 
the subgroup of patients with CNS metastases at the baseline, NMA HR 0.30 (95% CrI, 0.13, 
0.71). The results should be interpreted with caution because of the uncertainties involved. 
Health-related quality of life [D0012, D0013] 
Quality of life  
A trend favouring alectinib over crizotinib was observed for patient-reported global health 
status/health-related quality of life (HRQoL) (HR 0.72, 95% CI, 0.38,1.39). Overall, patients in the 
alectinib arm reported clinically meaningful improvement in HRQoL and improvement in multiple 
lung cancer symptoms for a longer duration of time than patients in the crizotinib arm, but the 
differences were not statistically significant. 
No information was available on HRQoL from the NMA for alectinib versus ceritinib. 
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Safety [C0008] 
The safety results are based on the ALEX trial and the studies included in the NMA. In addition, 
adverse drug reaction (ADR) frequencies are presented from the summaries of product 
characteristics (SmPCs) of Alecensa, Xalkori (crizotinib) and Zykadia (ceritinib). The SmPC 
frequencies reflect the European Medicines Agency (EMA) established safety profile and are 
based on all relevant studies at the approved dose. The most common (≥20%) ADRs for alectinib 
were constipation (35%), oedema (30%; including peripheral oedema, oedema, generalised 
oedema, eyelid oedema, periorbital oedema, face oedema and localised oedema) and myalgia 
(28%; including myalgia and musculoskeletal pain).  
In a naïve comparison of the ADR frequencies in the SmPCs, and without consideration of the 
longer median treatment length for alectinib, the frequencies were lower for alectinib than for 
crizotinib and ceritinib for diarrhoea (16%, 54% and 82%, respectively), vomiting (11%, 51% and 
63%, respectively), nausea (19%, 57% and 75%, respectively), and fatigue (not identified as 
ADR, 30% and 48%, respectively). These are ADRs that impact tolerability and everyday quality 
of life. 
Other reactions that may impact quality of life include, for example, oedema, which was not 
identified as an ADR for ceritinib, but was common with alectinib (30%) and crizotinib (47%), and 
myalgia, which was reported only for alectinib (28%).  
Pneumonitis/interstitial lung disease was also less frequent with alectinib than with crizotinib and 
ceritinib (0.7%, 3% and 2%, respectively). 
All three agents caused anaemia (15%–17%), while crizotinib also caused neutropenia (22%). 
No infections were identified as ADRs for crizotinib, however. 
Vision disorders were similar for alectinib and ceritinib at a rate of 7%–9%, but the rate was 
markedly higher for crizotinib (63%). 
Abnormal liver laboratory results appeared least common with alectinib, while acknowledging 
that a comparison based on the varying items in the SmPCs is difficult. 
The frequencies of severe liver reactions were largely similar across the drugs (drug-induced 
liver injury 0.7% (alectinib), hepatic failure <1% (crizotinib) and hepatotoxicity 1.1% (ceritinib). 
Bradycardia was less common with ceritinib (2%) compared with alectinib (9%) and crizotinib 
(13%). Unlike alectinib, both crizotinib and ceritinib are associated with QT interval prolongation 
(4% and 10%, respectively). This can have potentially serious consequences, including sudden 
death, but such outcomes are very rare. The risk of QT interval prolongation affects the handling 
of patients and may require more monitoring of some patients. 
Rash occurred in 18% of patients treated with alectinib, 13% of patients treated with crizotinib 
and 20% of patients treated with ceritinib.  
Photosensitivity was identified as an ADR for alectinib (9%), but not for the other two ALK 
inhibitors. 
The rates of AEs leading to treatment discontinuation were 11%, 13% and 11% respectively. 
The rates of AEs leading to dose interruption were 19%, 25% and 69% respectively. The NMA 
indicates the presence of significantly fewer grade 3 or 4 AEs with alectinib than with ceritinib, and 
no significant differences were observed for discontinuations due to AEs. 
Ethical, organisational, patient and social and legal aspects 
No specific aspects concerning ethical, organisational, patient and social, or legal aspects were 
identified from the Rapid REA Checklist.  
Patient involvement 
One patient who was involved in this assessment, emphasised that the most important issues 
concerning treatment for NSCLC are life-extension by a new drug, fewer side effects and no 
financial implications for patients. 
Upcoming evidence 
OS results from the ALEX trial will be reported at the 50% event rate. 
PTJA03 - Alectinib as monotherapy for the first line treatment of ALK-positive advanced NSCLC 
Version 1.3, 22th January 2018 EUnetHTA Joint Action 3 WP4 12 
Reimbursement 
The reimbursement status of alectinib, as first-line monotherapy, in different EU countries will be 
decided at the national level after extended marketing authorisation. 
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Table 0.1. Summary of findings for alectinib, primary analysis 9 February 2017 
Outcome Anticipated absolute effects (95% CI) Relative effect 
(95% CI) 
Number of 
participants 
(number of 
studies) 
Quality Comments 
Risk with alectinib  Risk with 
crizotinib 
OS 1-year survival rate 
84.3%  
1-year survival rate 
82.5% 
HR 0.76 (0.48, 
1.20); p=0.24 
303 (1) Low Immature data (interim analysis). At the 
data cutoff point 23% of patients in the 
alectinib arm and 27% of patients in the 
crizotinib arm had died, with a 1-year 
survival rate of 84.3% and 82.5%, 
respectively. Median OS was not 
reached in either treatment arm. Survival 
analysis has been planned after 50% of 
events have occurred 
PFS Median: NE (17.7 
months to NE)  
Median: 11.1 
months (9.1–13.1 
months) 
HR 0.47 (0.34, 
0.65);  p<0.0001 
303 (1) High Of note,  investigator assessed PFS was 
consistent with independently assessed 
PFS. 
ORR 75.5% (67.8%–82.1%)  82.9% (76.0%–
88.5%) 
— 303 (1) High — 
Time to CNS 
progression 
Rate of events of CNS 
progression:  
18 (of 152, 12%) 
Rate of events of 
CNS progression: 
68 (of 151, 45%) 
Cause-specific HR: 
0.16 (0.10, 0.28); 
p<0.0001 
303 (1) High — 
Total proportion 
of patients with 
≥1 AE 
97% 97% — 303 (1) Moderate Open label 
Total proportion 
of patients with 
serious AE 
28% 29% — 303 (1) Moderate Open label 
Time to 
deterioration in 
EORTC QLQ-
C30 global 
health score  
— — HR 0.72 (0.38, 
1.39); p =0.326 
197 (1) Very low Low numbers of completed 
questionnaires at the baseline ; open 
label 
Abbreviations: AE=adverse event; CI=confidence interval; CNS=central nervous system; EORTC=European Organisation for Research and Treatment of Cancer; HR=hazard ratio; NE=not estimable; 
ORR=objective response rate; OS=overall survival; PFS=progression-free survival. 
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Discussion 
The most important limitations in this assessment are the immature OS data in the direct 
comparison of alectinib and the comparator crizotinib, and the high uncertainty in the indirect 
comparison of alectinib with ceritinib.  
Alectinib resulted in a substantial statistically significant increase in PFS compared with crizotinib 
in the ALEX study. While the median PFS was not reached in the alectinib arm for the 
investigator-based PFS, the IRC showed a difference in medians of 15.3 months (25.7 vs 10.4 
months, respectively). 
Concerning further endpoints, the secondary endpoint time to CNS progression also 
demonstrated superiority of alectinib over crizotinib. This is of high clinical relevance as CNS 
metastasis and progression affects both the symptoms and the quality of life, as well as the 
prognosis of the patients. The ORR was numerically higher with alectinib (83% vs 76%) although 
not statistically significantly different. However, the duration of response was significantly longer 
for alectinib with the majority of responses ongoing (median not yet reached vs 11.1 months in the 
crizotinib arm, p<0.0001).  
In the direct comparison of alectinib and the comparator crizotinib, the quality of evidence is high 
for the majority of outcomes (PFS, ORR, Time to CNS progression), moderate for major safety 
outcomes and very low for the outcome related to QoL (i.e. time to deterioration in EORTC QLQ-
30 global health score). The latter is associated with a high risk of bias due to the open-label 
design and low baseline values of completed questionnaires at the baseline. The primary 
investigator-assessed PFS results were consistent with those of the blinded independent 
reviewers, suggesting a lack of bias in investigator assessments. 
Since the population in the ALEX study essentially corresponds to the ALK-positive NSCLC 
population, it can be assumed that the available evidence is applicable. 
In the indirect comparison of alectinib and the comparator ceritinib, the results were derived from 
the fixed effects NMA model. Due to the limited number of studies, no adjustment of patient 
characteristics was made at the study level.  
The same numbers of AEs of any grade were reported for both alectinib and crizotinib (97%) in 
the randomized phase III ALEX trial. Serious AEs occurred at a similar frequency in patients in 
both treatment arms (29% with crizotinib, 28% with alectinib).  
In the ALEX trial the incidence of AEs leading to treatment discontinuation was similar with 
alectinib compared with crizotinib (11% vs. 13%). The patients in the alectinib arm had longer 
exposure to treatment (17.9 months vs. 10.7 months for crizotinib) but a numerically lower 
incidence of treatment interruptions and dose reductions and a lower cumulative frequency of 
grade 3 or higher AEs (41% vs. 50% in the crizotinib arm). 
The only serious AEs which occurred at a higher (2% difference) incidence in the alectinib arm 
were acute kidney injury (3% with alectinib vs. 0% with crizotinib) and lung infection (2% vs. 0%). 
For any grade AEs, myalgia was reported more frequently for alectinib than crizotinib (16% vs. 
2%) and anaemia (20% vs. 5%). 
Alectinib appears to have a more favourable safety profile compared with crizotinib with regard to 
non-serious AEs that tend to affect quality of life, such as nausea, diarrhoea and vomiting. This 
impression is also supported by lower observed frequencies of treatment interruptions and dose 
reductions.  
Indirect comparisons between alectinib and ceritinib were performed using an NMA and a naïve 
comparison of the established AE frequencies as per the SmPCs, respectively. Both analyses 
indicated an overall superior safety profile for alectinib over ceritinib, with the exception of a few 
non-serious AEs. Due to the high degree of uncertainty naturally inherent in any indirect 
comparison, no firm or formal conclusion is possible. Based on the available data, it might be 
considered reasonable to assume that the overall burden of toxicity from alectinib is at least not 
worse than that of ceritinib. 
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The patient involved emphasised that the most important issues concerning treatment for NSCLC 
are life-extension by a new drug, fewer side effects and no financial implications for patients. 
Limitations are that only one patient and not a patient organisation was involved in this rapid REA. 
Thus, a broader patient view is missing, specifically that of patients with specific lung symptoms 
and with a longer treatment duration with crizotinib. This might have impacted on patient's 
experiences with the condition, treatment and answers related to specific questions. 
Conclusion  
From direct comparison, based on high quality of evidence, alectinib demonstrated a substantial 
and statistically significant increase in PFS. It is also associated with a statistically significant 
longer time to CNS progression compared to crizotinib. This is of high clinical relevance as CNS 
metastasis and progression affects both the symptoms and the quality of life, as well as the 
prognosis of the patients. The OS data are immature and therefore preclude firm conclusions. 
From an indirect comparison, an advantage of alectinib versus ceritinib is indicated for PFS, but 
because of uncertainties regarding the adequacy of the comparison, this observed result has to 
be regarded as unsure.  
From direct comparison, the serious adverse events and adverse events leading to treatment 
discontinuation occurred at similar frequencies for both alectinib and crizotinib. Alectinib appears 
to have a more favourable safety profile compared with crizotinib with regard to non-serious 
adverse events that tend to affect quality of life, as well as severe (grade ≥3) events. This notion 
is supported by the lower frequencies of treatment interruptions and dose reductions observed for 
alectinib in the direct comparison to crizotinib. Thus markedly lower frequencies for alectinib were 
reported for diarrhoea, vomiting and nausea. For any grade adverse event, myalgia and anaemia 
were reported more frequently for alectinib than crizotinib. 
While conclusions on relative safety compared with ceritinib should be made with caution, both 
the NMA and the comparison of the established AE profiles in the SmPCs indicate an overall 
superior safety profile of alectinib. 
Patients receiving alectinib had clinically meaningful improvement in HRQoL for a longer duration 
compared with patients receiving crizotinib. Overall a trend favouring alectinib was observed in 
HRQoL, but the difference was not statistically significant. 
As only one patient was interviewed, no general conclusions can be drawn. 
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1 SCOPE 
Table 1.1. Scope according to population, intervention, comparison, outcomes and study 
design analysis 
Description Project scope 
Population   First-line treatment of adult patients with ALK-positive advanced NSCLC 
 ICD-10: C34.xx 
 MeSH terms: carcinoma, non-small-cell lung 
(C04.588.894.797.520.109.220.249; C08.381.540.140.500; 
C08.785.520.100.220.500) 
 A validated ALK assay is necessary for the selection of ALK-positive NSCLC 
patients. ALK-positive NSCLC status should be established before initiation of 
alectinib therapy 
 Subgroup analysis: patients with brain metastases at the baseline 
Intervention   The recommended dose of alectinib is 600 mg (four 150-mg capsules) 
taken twice daily with food (total daily dose of 1200 mg). Treatment with 
alectinib should be continued until there is disease progression or 
unacceptable toxicity 
 Alectinib is a highly selective and potent ALK and RET tyrosine kinase 
inhibitor 
Comparison  Crizotinib (direct comparison), 250 mg twice daily (total daily dose 500 mg), 
is a selective small-molecule inhibitor of the ALK receptor tyrosine kinase 
and its oncogenic variants (i.e., ALK fusion events and selected ALK 
mutations). 
 Ceritinib (indirect comparison, NMA), 750 mg once daily, is an orally highly 
selective and potent ALK inhibitor 
 According to approved first-line indications 
 Since direct study data for alectinib vs. ceritinib are missing, an indirect 
comparison is needed – NMA 
 Rationale: Comparators have been chosen on the basis of information from 
the manufacturer submission file, relevant EPARs [3] [4] and SmPCs [5-7], 
clinical guidelines [8] [9] and EUnetHTA guidelines [10]. 
Outcomes1  Effectiveness domain 
Primary endpoint: overall survival, progression-free survival 
Secondary endpoints: time to CNS progression, objective response rate, 
health-related quality of life, other patient-reported outcomes, CNS 
objective response rate, CNS duration of response 
 Safety domain 
              AEs 
Any AEs, SAE, most frequent AEs and SAEs, death as SAE, 
discontinuation due to AEs, AE leading to dose reduction, AE of special 
interest/grade 3 or higher AEs 
 Rationale: Outcomes are selected on the basis of the recommendations 
from the clinical guidelines [9, 11] and the EUnetHTA guidelines [12]. 
Study design Effectiveness: 
                                                     
1 It should be noted that the priority in terms of primary and secondary endpoints is the priority with regards to this 
EUnetHTA assessment and differs from the study plan. 
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Description Project scope 
 Randomised controlled trials only 
Safety: 
 Randomised controlled trials 
 Nonrandomised controlled trials (if applicable) 
 Prospective studies with or without a control group (if applicable) 
 Post-marketing surveillance data on alectinib-related AEs (if applicable) 
Organisational, ethical, patient and social and legal aspects (if needed): 
qualitative and qualitative studies, reports or opinions according to EUnetHTA 
Core HTA Model 3.0 [13] 
 Only English language studies will be included 
Abbreviations: AE=adverse event; ALK=anaplastic lymphoma kinase; CNS=central nervous system; EPAR=European 
public assessment report; ICD=International Classification of Diseases; MeSH=Medical Subject Headings; NMA=network 
meta-analysis; NSCLC=non-small cell lung cancer; RET=rearranged during transfection; SAE=serious adverse event; 
SmPCs=summaries of product characteristics. 
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2 METHODS AND EVIDENCE INCLUDED  
2.1 Assessment Team 
The main author, TLV, was responsible for writing the effectiveness and safety domains, 
validation of the information provided in the other two domains and performing an extrapolation on 
OS. 
The co-author Agency for Quality and Accreditation in Health Care and Social Welfare (AAZ) was 
responsible for producing the description and technical characteristics of technology domain and 
patient involvement, and the co-author Main Association of Austrian Social Security Institutions 
(HVB) was responsible for the health problem and current use of the technology domain. In 
addition, they both assessed the risk of bias at the study and outcome level, quality of evidence 
(GRADE), statistically validated the information provided in the NMA (HVB), and checked the 
systematic literature search conducted by the MAH (AAZ).  
Dedicated reviewers (NICE, Regione Veneto, Andalusian Agency for Health Technology 
Assessment, and National Institute of Pharmacy and Nutrition) reviewed the draft of the project 
plan and the draft of the assessment report and commented on the draft of the submission file 
from the MAH.  
2.2 Source of assessment elements 
The selection of assessment elements was based on the EUnetHTA Core Model® for Rapid 
Relative Effectiveness Assessment (4.2) [13].  
2.3 Search 
The systematic literature search, including update, was performed by the MAH and the findings 
were included in the submission file. The literature search strategy was checked and validated by 
the authors of this assessment. The reporting of the search strategy followed the EUnetHTA 
guidelines and the requirements of the Preferred Reporting Items for Systematic Review and 
Meta-analysis Protocols (PRISMA-P) statement (slightly modified by the authors of this 
assessment). The systematic search was performed on 2nd February 2017 in the following 
electronic databases or conference abstracts: 
 From database inception in EMBASE (Excerpta Medica Database; 1974) and MEDLINE 
(Medical Literature Analysis and Retrieval System Online) up to 23rd January 2017 (until 
23rd January 2017 for MEDLINE in-process and electronic publications ahead of print 
through PubMed) 
 From database inception in the Cochrane libraries DARE (until database closure in 
April 2015), CDSR (until monthly update in January 2017) and CENTRAL (until monthly 
update in November 2016) 
 In the US National Institutes of Health registry und results database, the WHO 
International Clinical Trials Registry Platform and the EU Clinical Trials Register until 15th 
January 2017 
 Abstracts for the following conferences: American Society of Clinical Oncology Annual 
June Meeting 2016; European Society for Medical Oncology October 2016 Congress; 
European Cancer Congress January 2017; International Association for the Study of Lung 
Cancer World Conference on Lung Cancer December 2016; European Lung Cancer 
Conference April 2016; British Thoracic Oncology Group conferences January 2015, 
2016, and 2017. 
The update of the literature search was conducted on 3rd October 2017 to identify new studies 
that had been indexed since the original search. No other relevant RCT was identified.  
The Patient or Population, Intervention, Comparison, Outcomes and Study design (PICOS) 
approach was used to define the search strategy (see literature search inclusion and exclusion 
criteria in Appendix 2: METHODS AND DESCRIPTION OF THE EVIDENCE USED). All details on 
the search strategy can be found in Appendix 2: METHODS AND DESCRIPTION OF THE 
EVIDENCE USED.  
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Our two objections to the search strategy are related to the simultaneous search of more than one 
database (one search strategy was used for EMBASE and MEDLINE, as well as one search 
strategy for three databases from Cochrane Library) and to fact that in the search strategy for 
EMBASE and MEDLINE, search terms related to EMTREE Thesaurus were used only. Because 
of that, the search strategy relevant for MEDLINE was performed and reproduced on PubMed by 
the authors of this assessment, on the 12th of December 2017. The search results corresponded 
to those presented by MAH.  
 
The following clinical trial registries were searched in January 2017: ClinicalTrials.gov 
(http://www.clinicaltrials.gov/), WHO International Clinical Trials Registry Platform 
(http://apps.who.int/trialsearch/Default.aspx) and the EU Clinical Trials Register 
(https://www.clinicaltrialsregister.eu/). 
 
A separate Guideline (GL) update search (G-I-N, National Guidelines Clearinghouse, TRIP-
Database and hand search) was performed by the authors in December 2017. 
 
2.4 Study selection 
 
Figure 1.1. Flow chart.  
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Records after duplicates removed  
(n=1163) 
Records screened 
(n=1163) 
Records excluded 
(n=1008) 
Full-text articles assessed 
for eligibility  
(n=155) 
Full-text articles excluded, with reasons  
66 articles excluded: Substudy/child 
citation n=17; no relevant outcome n=3; 
population n=2; design n=10; 
duplicate/copy n=22; SR n=12 
Resulted in132 full-text articles 
representing the 34 studies covered all 
treatment lines 
30 studies further excluded as not 
relevant (i.e. 19 studies were not RCTs; 8 
RCTs not include patients naïve to 
treatment; 3 RCTs include mixed 
population and did not report results 
specific to ALK+ patients) 
 
Studies included in qualitative synthesis  
 
RCTs (n=3) 
Studies included in quantitative synthesis 
(NMA) 
RCTs (n=4, 3 in base-case NMA; the 4th in 
sensitivity analysis) 
Additional 43 articles from hand-searching 
n=198 
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Abbreviations: NMA=network meta-analysis; RCT randomised controlled trial; SR=systematic review. 
Figure 1.1 shows the Preferred Reporting Items for Systematic Reviews and Meta-analyses 
(PRISMA) flow chart. In total, 34 unique studies were identified, which covered all treatment lines 
for ALK-positive advanced or metastatic NSCLC patients (i.e., any combination of chemotherapy-
naïve or chemotherapy-experienced or ALK tyrosine kinase inhibitor (TKI) naïve or ALK TKI 
experienced in any treatment line (advanced or metastatic). 
Of the 34 studies, seven RCTs enrolled patients naïve to treatment (both chemotherapy-naïve 
and crizotinib-naïve) within the advanced/metastatic setting. Of these, three studies included 
mixed populations (i.e., ALK and non-ALK treatment-naïve patients) and did not report results 
specific to ALK-positive patients; therefore they were not considered further. These studies 
included CALGB 30406 in the United States [14] (erlotinib vs. erlotinib plus carboplatin/paclitaxel), 
the study of Zhang et al. 2013 [15] in China (pemetrexed plus cisplatin vs. gemcitabine plus 
cisplatin) and EURTAC [16] in Spain, France and Italy (erlotinib vs. standard of care).  
This resulted in three main trials included in the qualitative synthesis and base-case NMA: ALEX 
(alectinib vs. crizotinib), PROFILE 1014 (crizotinib vs. chemotherapy), and ASCEND-4 (ceritinib 
vs. chemotherapy). Four trials were included in the sensitivity analysis of the NMA: ALEX, 
PROFILE 1014, PROFILE 1029 (crizotinib vs. chemotherapy), and ASCEND-4.  
The safety results are based on the ALEX study and the studies included in the NMA. In addition, 
ADR frequencies are presented from the SmPCs of Alecensa, Xalkori and Zykadia. The SmPC 
frequencies reflect the EMA established safety profile and are based on all relevant studies at the 
approved dose. Other RCTs enrolling mixed populations of treatment-naïve and chemotherapy-
experienced ALK-positive patients were considered but ultimately excluded. These studies 
included J-ALEX, which was excluded because of the mixed population (i.e., chemotherapy-naïve 
and chemotherapy experienced patients), the lower dose of alectinib and the Japanese only 
population, and ALTA-1L (brigatinib vs. crizotinib), which was ongoing.  
2.5 Data extraction and analyses 
The submission file as well as an NMA produced by the MAH served as the primary documents 
for this assessment [17]. In addition, all full-text publications referenced in the submission file 
were provided as an additional information source.  
The safety results are based on the ALEX study and the studies included in the NMA. In addition, 
ADR frequencies are presented from the SmPCs of Alecensa, Xalkori and Zykadia. The SmPC 
frequencies reflect the EMA established safety profile and are based on all relevant studies at the 
approved dose. The health problem and current use of the technology domain was cross-checked 
with the full-text publications provided and with further information sources identified by a hand 
search. The results were summarised descriptively. 
Direct comparison 
The efficacy results between alectinib and crizotinib are based on the ALEX study. 
Indirect comparison/NMA 
As a direct comparison of alectinib versus ceritinib was not available, the MAH performed several 
methods for indirect comparison. The following two analyses were considered most relevant for 
this assessment: 
 The base case, which included the ALEX, PROFILE 1014 and ASCEND-4 studies. 
 A sensitivity analysis, which in addition to the studies included in the base case, also 
includes the PROFILE 1029 study.  
First, an indirect treatment comparison using the Bucher indirect comparison method was 
performed for the base case and the sensitivity analysis. Second, a Bayesian fixed effects NMA 
was performed for the base case and the sensitivity analysis. Third, a Bayesian random effects 
NMA was performed for the sensitivity analysis. The results of the Bucher method are considered 
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to be nearly identical to the results of the Bayesian fixed effects NMA because of the simple 
structure of the network. Therefore these results are not shown in this evaluation to avoid 
duplication.  
The Bayesian fixed effects and random effects NMAs were calculated according to Bayesian 
Markov chain Monte Carlo methods with the software program WinBUGS. Here, vague priors 
were used for the treatment effect, whereas the standard deviation of the treatment effect 
estimates is considered to be known. In the Bayesian random effects NMA, a prior, which the 
MAH considers to be vague, was chosen for the between-study standard deviation within each 
treatment comparison. In the Bayesian fixed effects NMA, this quantity is implicitly defined to be 
equal to zero.  
In the evaluation of the results of these differing methods, the Bayesian fixed effects NMA was 
mainly discussed, since in the base case no estimation of the between-study standard deviation 
was possible. In this case it has to be kept in mind that this particular standard deviation is by 
assumption equal to zero. The impact of relaxing this assumption can partly be seen in the results 
of the Bayesian random effects NMA, which simultaneously considers low, moderate and high 
values of the between-study standard deviation.  
A proper sensitivity analysis regarding different informative priors of the between-study standard 
deviation was requested by the authors but not delivered by the MAH. Therefore in the evaluation 
of the indirect evidence it is possible to compare only the Bayesian fixed effects NMA with the 
Bayesian random effects NMA in terms of sensitivity.  
An appendix with extrapolation of survival data has been added to the report; see Appendix 1. 
EXTRAPOLATION OF PFS AND OS/SURVIVAL ANALYSIS. The aim of this section is to discuss 
different extrapolation models of clinical data over time after the observed data in the clinical trial. 
No base case will be chosen; this section has been added for discussion. 
2.6  Quality rating  
The quality rating tool developed by the Cochrane Collaboration (version 5.1.0; March 2011) was 
used to assess the risk of bias in RCTs [18].  
This approach classifies the risk of bias into six different domains:  
 Method used to generate the sequence of randomisation (random sequence generation);  
 Method used to mask the sequence of allocation to treatment (allocation concealment);  
 Measures used to ensure the ‘blindness’ of the study with respect to treatment assignment 
(blinding of participants, medical personnel and outcome assessors);  
 Completeness of the data for each outcome considered (incomplete outcome data);  
 Selective description of the results (selective outcome reporting);  
 Other sources of bias (e.g., bias due to the early interruption of the study because of the 
benefits without an appropriate stopping rule, use of a non-validated measurement 
instrument, incorrect statistical analysis).  
 
For each domain, two independent assessors judged the risk of bias (‘low risk’, ‘high risk’ or 
‘unclear’) on the basis of the information retrieved from the full-text publications, the protocols and 
the submission file. The results of the risk of bias assessment at both the study level and the 
outcome level are presented in Table A19 and Table A20 in Appendix 2: METHODS AND 
DESCRIPTION OF THE EVIDENCE USED.  
For rating the quality of the evidence, GRADE was applied. The quality of the body of evidence is 
rated according to four grades: 
 High: we are very confident that the true effect lies close to that of the estimate of the 
effect. 
 Moderate: we are moderately confident in the effect estimate, the true effect is likely to 
be close to the estimate of the effect, but there is a possibility that it is substantially 
different. 
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 Low: our confidence in the effect estimate is limited, the true effect may be substantially 
different from the estimate of the effect. 
 Very low: we have very little confidence in the effect estimate, the true effect is likely to 
be substantially different from the estimate of effect. In case of disagreement, a third 
individual was involved to resolve the differences. 
The risk of bias at the study level was applied to all studies included in this assessment for direct 
and indirect comparisons. The risk of bias at the outcome level was assessed for all outcomes 
reported in ALEX which had been included in the scope and for the outcomes from the other two 
trials which had been reported in the NMA. GRADE was applied for direct comparisons with 
outcomes considered most relevant for this assessment, namely OS, PFS, time to CNS 
progression, ORR, AEs and health related quality of life (Table A21 in Appendix 2: METHODS 
AND DESCRIPTION OF THE EVIDENCE USED). Since the PROFILE 1029 has not been fully 
published yet, the risk of bias was only assessed on study level.  
The quality of the NMA was also independently assessed by two individuals according to a 
technical support document from NICE’s Decision Support Unit; in the case of disagreement, a 
third individual was involved to resolve this disagreement [1] (see Appendix 6. Indirect 
comparisons – statistical aspects for details).  
The external validity of the included trials was assessed using the EUnetHTA guideline on 
applicability of evidence in the context of a relative effectiveness assessment of pharmaceuticals 
[12] considering the following elements: population, intervention, comparator, outcomes and 
setting. The results of the external validity assessment are presented in Table A15.  
No quality assessment tool was used for the domains description and technical characteristics of 
the technology and health problem and current use of technology. 
2.7 Patient involvement 
An individual patient recently diagnosed with ALK-positive NSCLC and being treated with 
crizotinib was asked to provide input through an one hour telephone interview. Questions posed 
were related to the impact of the condition; experiences with currently available medicines; 
expectations of the medicines being assessed; and additional information considered relevant for 
HTA researchers by the patient.  
The template “Patient Group Submission Template for HTA of Medicines“ developed by HTAi 
[19], was significantly modified by the assessment team. Topics and issues from the Patients and 
Social Domain of the EUnetHTA Core Model 3.0 were included. The adapted document was sent 
to the patient prior to the interview to allow familiarity with the questions related to above 
mentioned sections. 
The entire interview was recorded and fully transcribed in English. The patient provided orally 
informed consent. It was agreed to not share the collected data with any third party and all data 
were stored electronically on encrypted files. No ethical approval was needed. After the interview, 
the fully anonymized transcription was sent to the patient for an accuracy check and for providing 
additional data. 
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2.8 Description of the evidence used 
Table 2.1. Main characteristics of studies included  
Authors 
and year 
(study 
name) 
Study type Number of 
patients 
Intervention (s) Main 
endpoints 
Included in 
clinical 
effectiveness 
and/or safety 
domain 
Peters et al. 
[1], 2017 
(ALEX) 
Phase III, 
open label, 
randomised 
152 alectinib  
151 crizotinib 
Alectinib vs. 
crizotinib 
PFS 
(investigator 
assessed) 
Key 
secondary 
PFS (IRC 
assessed) 
Time to 
CNS 
progression 
ORR 
OS 
Effectiveness 
Safety 
Solomon, et 
al. 2014[20] 
(PROFILE 
1014) 
Phase III, 
open label, 
randomised 
189 crizotinib 
175 
chemotherapy 
Crizotinib vs. 
chemotherapy 
PFS (IRC 
assessed) 
or death 
Key 
secondary 
ORR 
OS 
Effectiveness 
Safety 
Soria et al.  
2017 [51]  
(ASCEND-4) 
Phase III, 
open label, 
randomised 
171 ceritinib 
169 
chemotherapy 
Ceritinib vs. 
chemotherapy 
PFS (IRC) 
or death 
Key 
secondary 
OS 
Effectiveness 
Safety 
Abbreviations: IRC=independent review committee; ORR=objective response rate; OS=overall survival; 
PFS=progression-free survival. 
 
2.9 Deviations from project plan 
1. [B0010] “What kind of data/records and/or registry is needed to monitor the use of the 
alectinib and the comparator” was initially selected as relevant research question in the 
project plan. During the assessment phase, the authors decided that this question was not 
relevant and did therefore not include it in the final assessment. 
2. In the project plan inclusion of a relevant patient organisation was planned. Despite 
repeated efforts by the coordinator this was not possible in an early phase of the 
assessment. An individual patient agreed though to participate in a telephone interview to 
capture some aspects deemed relevant for patients with ALK-positive NSCLC. 
3. According to EUnetHTA procedures and as stated in the project plan, clinical experts as 
well as payers should be included in the assessment. Unfortunately, neither  of these 
groups could be involved.  
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3 DESCRIPTION AND TECHNICAL CHARACTERISTICS OF TECHNOLOGY 
(TEC) 
3.1 Research questions  
Element ID Research question 
B0001 What are alectinib and the comparators – crizotinib and ceritinib? 
A0020 What are the approved indications of alectinib? 
B0002 What is the claimed benefit of alectinib in relation to the comparator(s)? 
B0003 What is the phase of development and implementation of alectinib and the 
comparator(s)? 
B0004 Who administers alectinib and the comparator(s) and in what context and level of care are 
they provided? 
B0008 What kind of special premises are needed for alectinib and the comparator (s)? 
A0021 What is the reimbursement status of alectinib? 
3.2 Results 
Features of the technology and comparators 
[B0001] – What are alectinib and the comparators – crizotinib and ceritinib? 
[A0020] What are the approved indications of alectinib?  
[B0002] – What is the claimed benefit of alectinib in relation to the comparator(s)? 
Alectinib  
Alectinib is a small molecule, CNS-active, highly selective and potent orally administered second-
generation inhibitor of ALK and rearranged during transfection (RET) tyrosine kinase receptors 
which acts as an antineoplastic agent [5]. 
Alectinib demonstrated in vitro and in vivo activity against mutant forms of the enzyme ALK, 
including mutations responsible for resistance to crizotinib. The major metabolite of alectinib (M4) 
has shown similar in vitro potency and activity. On the basis of preclinical data, alectinib is not a 
substrate of P-glycoprotein or breast cancer resistance protein, which are both efflux transporters 
in the blood–brain barrier, and is therefore able to distribute itself into and be retained within the 
CNS. Also, alectinib is not substrate of organic anion-transporting polypeptide 1B1/B3. 
The approved indications for alectinib are: 
 Alectinib as monotherapy is indicated for the first-line treatment of adult patients with ALK-
positive advanced NSCLC. 
 Alectinib as monotherapy is indicated for the treatment of adult patients with ALK-positive 
advanced NSCLC previously treated with crizotinib. 
The claimed benefit of alectinib in relation to the comparators (crizotinib and ceritinib, approved 
first-line monotherapy for ALK-positive advanced NSCLC in the EU) is related to a significantly 
longer PFS, irrespective of whether patients had CNS metastases at the baseline; superior 
efficacy in the CNS (reducing the proportion of patients with new or progressive CNS metastases 
at 12 months); and lower incidence of AEs and greater tolerability reported by patients [17]. 
The main features of the intervention and comparators are listed in Table 3.1 and Table 3.2. 
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Comparators 
Both crizotinib and ceritinib are approved for the first-line therapy of ALK-positive advanced 
NSCLC in the EU. Since ceritinib has been authorised only recently in this setting, European 
guideline published in 2016 currently recommend crizotinib as the standard of care [8]. Both 
compounds are considered as adequate comparators of alectinib for this indication, however.  
Crizotinib 
Crizotinib is an antineoplastic agent intended for treatment of adult patients with advanced 
NSCLC when the NSCLC is ALK positive or ROS1 positive. 
Ceritinib 
Ceritinib is an orally highly selective and potent ALK inhibitor which belongs to the 
pharmacotherapeutic group of antineoplastic and immunomodulating agents. It inhibits 
autophosphorylation of ALK, ALK-mediated phosphorylation of downstream signalling proteins 
and proliferation of ALK-dependent cancer cells both in vitro and in vivo. 
As monotherapy it is indicated for the 
 First-line treatment of adult patients with ALK-positive advanced NSCLC 
 Treatment of adult patients with ALK-positive advanced NSCLC previously treated with 
crizotinib 
Table 3.1. Features of the intervention and comparators 
 Technology Comparator  Comparator  
Nonproprietary name Alectinib Crizotinib Ceritinib 
Proprietary name Alecensa Xalkori Zykadia 
Active substance Alectinib hydrochloride Crizotinib Ceritinib 
Pharmaceutical 
formulation(s) 
150 mg hard capsules 200 mg hard capsules 
250 mg hard capsules 
150 mg hard capsules 
ATC code L01XE36 L01XE16 L01XE28 
Abbreviation: ATC=Anatomical Therapeutic Chemical. 
Sources: Alecensa SmPC (EMA), last updated:11th January 2018; Xalkori SmPC (EMA), last updated 22nd August 2017; 
Zykadia SmPC (EMA), last updated 31st August 2017. 
 
Table 3.2. Administration and dosing of the intervention and comparators 
 Technology: 
alectinib 
Comparator: 
crizotinib 
Comparator: 
ceritinib 
Administration mode Oral use. 
The hard capsules 
should be swallowed 
whole; must not be 
opened or dissolved; 
must be taken with food 
Oral use.  
The capsules should be 
swallowed whole and 
should not be crushed, 
dissolved or opened; 
taken preferably with 
water, with or without 
food 
Oral use. 
The capsules should 
be administered orally 
once daily at the same 
time every day; should 
be swallowed whole 
with water; should not 
be chewed or crushed; 
must be taken on an 
empty stomach and no 
food should be eaten 
for at least 2 hours 
before and 1 hour after 
the dose is taken 
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 Technology: 
alectinib 
Comparator: 
crizotinib 
Comparator: 
ceritinib 
Total volume contained 
in packaging for sale 
Pack size of 224 (four 
packs of 56) hard 
capsules 
56 hard capsules 
240 hard capsules 
Crizotinib 200 mg: 60 
hard capsules per 
bottle/carton 
Crizotinib 250 mg: 60 
hard capsules per 
bottle/carton 
Multipacks containing 
150 (three packs of 50) 
hard capsules and unit 
packs containing 40 
hard capsules 
Dosing The recommended dose 
of alectinib is 600 mg 
(four 150 mg capsules) 
taken twice daily with 
food (total daily dose of 
1200 mg). 
The dose of alectinib 
should be reduced in 
steps of 150 mg twice 
daily on the basis of 
tolerability. Details 
related to dose reduction, 
if needed, and dosing 
interruption can be found 
in the summary of 
product characteristics 
250 mg twice daily (500 
mg daily); taken 
continuously. 
Details related to dose 
reduction, if needed, 
and dosing interruption 
can be found in the 
summary of product 
characteristics 
The recommended 
dose of ceritinib is 750 
mg taken orally once 
daily at the same time 
each day. 
The maximum 
recommended dose is 
750 mg daily.  
Details related to dose 
reduction, if needed, 
and dosing interruption 
can be found in the 
summary of product 
characteristics 
Contraindications Hypersensitivity to 
alectinib or to any of the 
excipients 
Hypersensitivity to 
crizotinib or to any of 
the excipients. 
Severe hepatic 
impairment 
Hypersensitivity to the 
active substance or to 
any of the excipients 
Recommended duration 
of treatment 
Until disease progression 
or unacceptable toxicity 
As long as the patient 
is deriving clinical 
benefit from therapya 
As long as clinical 
benefit is observed 
Sources: Alecensa SmPC (EMA), last updated 11th January 2018; Xalkori SmPC (EMA), last updated: 22nd August 2017; 
Zykadia SmPC (EMA), last updated 31st August 2017. 
aSummary basis of decision for Xalkori (Canada). 
 
 [B0003] What is the phase of development and implementation of alectinib and the 
comparator(s)? 
Alectinib  
In February 2017, alectinib was approved by the EMA as monotherapy for the treatment of adult 
patients with ALK-positive advanced NSCLC previously treated with crizotinib. In March 2017, the 
MAH submitted to the EMA an application to extend the indication for alectinib to first-line 
treatment of adult patients with ALK-positive advanced NSCLC [17]. 
On 12th October 2017 the Committee for Medicinal Products for Human Use (CHMP) adopted a 
positive opinion recommending a change to the terms of the marketing authorisation for the 
medicinal product alectinib. The CHMP adopted an extension to the existing indication as follows: 
‘Alecensa as monotherapy is indicated for the first-line treatment of adult patients with (ALK)-
positive advanced NSCLC’ [21]. The European Commission provided approval for Alecensa 
(alectinib) as first line- treatment for ALK positive lung cancer on the 21st Dec 2017. 
Alectinib was first granted marketing approval in Japan in July 2014 for the treatment of ‘ALK 
fusion gene positive unresectable, recurrent or advanced NSCLC.’ The recommended dosage is 
300 mg twice a day and it is marketed by Chugai Pharmaceutical Co. Ltd. 
In the United States, alectinib was approved by the Food and Drug Administration (FDA) on 
December 2015 for the ‘treatment of patients with ALK-positive, metastatic NSCLC who have 
progressed on or are intolerant to crizotinib’. The recommended dosage is 600 mg twice a day 
and it is marketed by Roche in 150-mg capsules to be taken orally. In May 2017 a rolling 
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supplemental new drug application for the treatment of patients with ALK-positive NSCLC who are 
treatment naïve was submitted to the FDA and was approved in November 2017. 
As of October 2017, alectinib is approved in Japan for the treatment of ALK-positive NSCLC with 
no restriction with respect to treatment line, and in the United States, the EU, and 15 other 
countries (Switzerland, Israel, Canada, South Korea, Kuwait, Hong Kong, Taiwan [marketed by 
Chugai], Australia, Singapore, India, Thailand, Argentina, the United Arab Emirates, Turkey and 
Saudi Arabia) for the treatment of crizotinib-pretreated patients with ALK-positive NSCLC. 
Detailed information on the regulatory status can be found in Table A23 in Appendix 3: 
REGULATORY AND REIMBURSEMENT STATUS [17]. 
To further confirm the efficacy and safety of alectinib in the treatment of patients with ALK-positive 
NSCLC, the MAH should submit the clinical study report of the phase III study ALEX comparing 
alectinib versus crizotinib in treatment-naïve patients with ALK-positive NSCLC. The due date is 
30th April 2018 [5, 22]. 
Crizotinib 
Crizotinib is an antineoplastic agent intended for treatment of adult patients with advanced 
NSCLC when the NSCLC is ALK positive or ROS1 positive [6]. 
Crizotinib can inhibit ALK receptor activation by blocking the ATP binding site [17]. By blocking the 
activity of ALK or ROS proto-oncogene 1 (ROS1), including their genetically altered versions, 
crizotinib inhibits cell proliferation, migration, invasion and motility in tumour or endothelial cells, 
which suggests that crizotinib has an effect on both tumour cell growth and survival, as well as on 
angiogenesis, thereby reducing the growth and spread of the cancer in ALK-positive or ROS1-
positive NSCLC [4, 6]. 
Crizotinib is P-glycoprotein substrate, and after having passively crossed the blood–brain barrier, 
it is actively transported back across it [17]. 
Crizotinib monotherapy is indicated as 
 First-line treatment of adults with ALK-positive advanced NSCLC 
 Treatment of adults with previously treated ALK-positive advanced NSCLC 
 Treatment of adults with ROS1-positive advanced NSCLC 
The initial marketing authorisation for crizotinib (a conditional approval), valid throughout the EU, 
was granted on 3rd October, 2012 for the treatment of adults with previously treated ALK-positive 
advanced NSCLC. The indication was extended to first-line treatment of ALK-positive advanced 
NSCLC on 23th November 2015. On 21st July 2016 the CHMP gave a positive opinion and 
adopted a new indication for crizotinib, indicating this therapy for the treatment of adults with 
ROS1-positive advanced NSCLC. 
Crizotinib is subjected to additional monitoring and restricted medical prescription, with necessary 
submission of periodic safety update reports [4, 6].  
 
Ceritinib 
On 26th February 2015 the CHMP adopted a positive opinion, recommending the granting of a 
conditional marketing authorisation for the medicinal product ceritinib, 150 mg, hard capsule, 
intended for the treatment of adult patients with ALK-positive advanced NSCLC previously treated 
with crizotinib.  
The initial marketing authorisation for ceritinib (a conditional approval), valid throughout the EU, 
was granted in May 2015 as monotherapy for the treatment of adult patients with ALK-positive 
advanced NSCLC previously treated with crizotinib. The indication was extended to first-line 
treatment of ALK-positive advanced NSCLC in June 2017. 
Ceritinib is the subject of additional monitoring with requirements for submission of periodic safety 
update reports for this medicinal product [3, 7]. 
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[B0004] Who administers alectinib and the comparator(s) and in what context and level of 
care are they provided? 
Treatment with alectinib as well as with the comparators crizotinib and ceritinib should be initiated 
in a secondary care (hospital) setting and supervised by a physician experienced in the use of 
anticancer medicinal products. Alectinib, crizotinib and ceritinib are intended for oral use, so they 
are administered by the patients or their caregivers.  
ALK-positive NSCLC status should be established before initiation of alectinib therapy. ALK 
positivity according to reverse transcription polymerase chain reaction, fluorescence in situ 
hybridisation (FISH) screening test or immunohistochemistry (IHC) needs to be confirmed before 
alectinib is prescribed to the patient by laboratories with demonstrated proficiency in the specific 
technology being used. 
In the case of certain side effects, the therapy can be interrupted/stopped or the dose can be 
reduced. More information related to administration and dosing of the technology and 
comparators is presented in Table 3.2 under the assessment element question [B0001] – What 
are alectinib and the comparators – crizotinib and ceritinib [5-7]. 
 
[B0008] What kind of special premises are needed for alectinib and the comparator(s)? 
Alectinib 
The presence of genetic defects affecting ALK (‘ALK-positive’ status) has to be confirmed in 
advance by appropriate methods: reverse transcription polymerase chain reaction, FISH 
screening test or IHC. Assessment for ALK-positive NSCLC should be performed by laboratories 
with demonstrated proficiency in the specific technology being used [5]. 
Crizotinib 
Before initiation of crizotinib therapy, it is necessary to conduct ALK and ROS1 testing with an 
accurate and validated assay to determine ALK-positive or ROS1-positive NSCLC status. 
Assessment should be performed by laboratories with demonstrated proficiency in the specific 
technology being used. When the ALK or ROS1 status of a patient is being assessed, it is 
important that a well-validated and robust method is chosen to avoid false-negative or false-
positive determinations [6]. 
 
Ceritinib 
An accurate and validated ALK assay is necessary for the selection of ALK-positive NSCLC 
patients. ALK-positive NSCLC status should be established before initiation of therapy, and the 
assessment should be performed by laboratories with demonstrated proficiency in the specific 
technology being used [7]. 
 [A0021] What is the reimbursement status of alectinib? 
First-line treatment 
As the CHMP adopted a positive opinion recommending a change to the terms of the marketing 
authorisation for alectinib in October 2017, there are no reimbursement data for first-line indication 
to date. The reimbursement status of alectinib in different EU countries will be decided at the 
national level after marketing authorisation. 
Second-line treatment 
Marketing approval was granted in the EU as well as Iceland, Norway and Liechtenstein on 16th 
February 2017 for the crizotinib treatment failure indication. In European countries, for the 
second-line indication, alectinib is being reimbursed in Denmark, Germany, Luxembourg, the 
Netherlands and Switzerland. Full details on the reimbursement for this indication across 
European countries is provided Table A24 in Appendix 3: REGULATORY AND 
REIMBURSEMENT STATUS [17]. 
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4 HEALTH PROBLEM AND CURRENT USE OF THE TECHNOLOGY (CUR) 
4.1 Research questions 
Element ID Research question 
A0002 What is NSCLC in the scope of this assessment? 
A0003 What are the known risk factors for ALK-positive NSCLC? 
A0004 What is the natural course of (advanced) NSCLC? 
A0005 What are the symptoms and the burden of advanced NSCLC for the patient? 
A0024 
How is (ALK positive advanced) NSCLC currently diagnosed according to published 
guidelines? 
A0025 
How is ALK positive advanced NSCLC in adults currently managed according to 
published guidelines and in practice? 
A0007 What is the target population in this assessment? 
A0023 How many people belong to the target population? 
4.2 Results 
Overview of the disease or health condition 
[A0002] – What is NSCLC in the scope of this assessment? 
Lung cancer is histologically broadly classified in NSCLC and small cell lung cancer. NSCLC 
accounts for approximately 80 – 85% of all lung cancers [23-27].  
Molecular analysis allows further subdivision of NSCLC and thus identification of patients eligible 
for specific targeted therapies, such as alectinib [23]. A number of oncogenic drivers have been 
identified in NSCLC, including rearrangement of the anaplastic lymphoma kinase (ALK) gene. 
ALK gene rearrangements are largely mutually exclusive with epidermal growth factor receptor 
(EGFR) or KRAS mutations, consistent with the notion that ALK gene rearrangements define a 
unique molecular subset of NSCLC [28].  
ALK is a transmembrane receptor tyrosine kinase, a member of the insulin receptor superfamily 
[23]. The most common ALK rearrangements are fusions in the echinoderm microtubule-like 
protein 4 (EML4), which are found in approximately 2%–5% of patients with NSCLC and 3%–7% 
of adenocarcinomas [24, 29, 30].  
ALK rearrangements lead to expression of constitutively active ALK fusion proteins that, in turn, 
activate intracellular signalling cascades, promoting tumour cell growth and survival [23, 24, 27, 
31-33]. 
All lung cancers are staged according to the tumour, node, metastasis (TNM) system (in Europe 
the eighth version was adopted in January 2017 [34]), which takes the extent of the primary 
tumour, the involvement of regional lymph nodes and the presence or absence of distant 
metastases into account. These features are then summarised in four different stage groups (I–
IV) which are linked to survival and also to treatment recommendations. Commonly, ‘advanced 
disease’ refers to stage IIIB and stage IIIC disease, which are associated with metastases in more 
distant lymph nodes and most advanced local disease, respectively, and to stage IV disease with 
distant metastases [9].  
 
[A0003] What are the known risk factors for ALK-positive NSCLC? 
Even though lung cancer is in general diagnosed at an age of about 70 years, with tobacco 
smoking being the main risk factor, ALK rearrangements occur more frequently in never smokers, 
adenocarcinomas and younger patients (mean age at diagnosis 52–58 years). Whether sex has 
an impact remains uncertain because of conflicting evidence [9, 35, 36].  
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[A0004] What is the natural course of (advanced) NSCLC? 
Prognosis depends on several factors; early-stage disease at diagnosis, good performance status 
(ECOG performance status 0–2), weight loss of 5% or less and female sex are factors which 
positively impact prognosis [9]. However, since symptoms do not occur until the tumour is 
advanced or has metastasised, lung cancer is usually diagnosed at a late stage. In this setting, 
the goal of treatment is to prolong survival and to alleviate cancer symptoms. Accordingly, the 5-
year survival in stage IIIB NSCLC is about 5%, and in stage IV NSCLC it remains as lower than 
5%, with a median OS of about 8–10 months [25, 37]. Estimates specifically for ALK-positive 
NSCLC are not available; therefore it remains unclear if the presence of ALK mutations confers a 
better prognosis [35].  
 
Effects of the disease or health condition 
[A0005] What are the symptoms and the burden of advanced NSCLC for the patient? 
The most common symptoms of lung cancer are cough, dyspnoea, weight loss and chest pain [9, 
38, 39]. These symptoms are mainly caused by the intrathoracic location of the tumour itself. 
Extrathoracic symptoms are caused by metastases, with the liver, bones, adrenal glands and 
brain being the most common sites of distant metastases.  
In 7%–10% of patients, brain metastases are present at the time of diagnosis, but they occur 
more often in patients with adenocarcinoma, large primary tumours and involvement of regional 
lymph nodes [40]. They are also more frequently present in ALK-positive NSCLC than in ALK-
negative tumours, with up to 20% of cases being reported at the initial diagnosis of NSCLC and 
50% before initiation of targeted therapy; that is crizotinib therapy [37, 41]. Brain metastases were 
newly diagnosed in 20% of patients during the course of first-line therapy with crizotinib and in 
10% of patients after crizotinib therapy [41, 42]. 
Most common symptoms of brain metastases include seizures, weakness, numbness in parts of 
the body and mental status change. In addition, development of brain metastases is also 
associated with an increase in symptoms; rates of fatigue, shortness of breath, nausea or 
vomiting and headaches showed increases in an analysis of three large administrative databases 
in the United States including 213 patients treated with crizotinib [23]. Also  life expectancy is poor 
of these patients, with a median survival of 1–3 months when untreated [37, 40] and about 4–9 
months when treated with chemotherapy and 7 months when treated with whole-brain radiation 
therapy (WBRT) [37, 43]. 
HRQoL of lung cancer patients is also linked to the prevalence and intensity of physical and 
psychological symptoms, and is being discussed as a potential predictor for OS [44-46]. Loss of 
appetite, cough, pain, shortness of breath and fatigue were correlated with HRQoL [47, 48].  
 
Current clinical management of the disease or health condition 
[A0024] How is ALK-positive advanced NSCLC currently diagnosed according to published 
guidelines and in practice? 
According to guidelines, a complete medical history, including smoking history and comorbidities, 
weight loss, performance status and physical examination, must be recorded for all types of lung 
cancer.  
 
Further, standard tests include laboratory testing (haematological, renal, hepatic and bone 
biochemistry) and a computed tomography (CT) scan of the complete abdomen. In the case of 
neurological symptoms, an assessment of the CNS with CT or – preferably – magnetic resonance 
imaging is performed, and when bone metastases are suspected, also a positron emission 
tomography scan (ideally coupled with CT) has to be performed [8]. 
  
A pathology evaluation is indicated to determine the histological type and the staging parameters 
(i.e., TNM staging) [9]. When the cancer is unresectable, minimally invasive techniques such as 
small biopsy and cytology are recommended for histological diagnosis and molecular testing. In 
Europe, molecular testing for ALK mutations is recommended in all patients with advanced non-
squamous cell carcinoma and in patients with squamous cell carcinoma only for never/former light 
(<15 pack years) smokers [8]. In the United States, ALK testing is recommended for patients with 
adenocarcinomas and for mixed lung cancers with an adenocarcinoma component [49]. 
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According to guidelines, FISH using dual-labelled break-apart probes is the standard for detection 
of ALK mutations and for selecting patients for ALK TKI therapy [8, 49]. 
 
[A0025] How is ALK-positive advanced NSCLC currently managed according to published 
guidelines and in practice? 
The treatment strategy for lung cancer is determined by histology, molecular pathology, age, 
performance status, comorbidities and patient preferences [8]. 
For ALK-positive advanced NSCLC, most guidelines were published before the extension of the 
indication of ceritinib to the first-line setting and before the publication of trial results for alectinib in 
untreated patients (see Table A10, Appendix 2: METHODS AND DESCRIPTION OF THE 
EVIDENCE USED).  
Crizotinib is currently recommended for the first-line therapy for ALK-positive advanced NSCLC in 
Europe according to the 2016 European Society for Medical Oncology guideline [8]. Crizotinib has 
also demonstrated activity in treating brain metastases [50]. However, progression of pre-existing 
brain metastases or development of new intracranial lesions is common [43]. Acquired resistance 
to crizotinib and inadequate exposure because of inadequate CNS penetration have been 
discussed as potentially underlying causes [51]. Other local, nonpharmacological treatment 
options for brain metastases include WBRT, stereotactic radiosurgery and surgical resection, 
either alone or in combination or as sequential treatment. However, for limited brain metastases, 
WBRT is not used very often because of the neurocognitive side effects [9]. The most common 
symptoms in patients with post brain WBRT toxicity syndrome include headache, fatigue, 
somnolence, neurocognitive deficits such as decline in memory and change in mental status [52].  
In the United States, the recently updated National Comprehensive Cancer Network (NCCN) 
guideline on NSCLC (September 2017) already includes ceritinib and alectinib (see Figure 4.1) 
[9]. Ceritinib, crizotinib and alectinib are all category 1 recommendations based on high-level 
evidence (i.e., there is uniform NCCN consensus that the intervention is appropriate) for the first-
line therapy for ALK-positive lung cancer. From voting of NCCN members, alectinib is the 
‘preferred’ option.  
 
Figure 4.1: Treatment algorithm for ALK-positive non-small cell lung cancer.  
Source: [9] 
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Target population 
[A0007, A0023] What is the target population of this assessment and how many people 
belong to the target population? 
The target population comprises treatment-naïve adult patients with ALK-positive advanced 
NSCLC.  
Lung cancer has been the most common cancer overall for several decades worldwide and is the 
most frequently diagnosed cancer in men. In 2012, about 1.8 million new cases were estimated. 
Lung cancer is also the most common cause of cancer-related death worldwide [53]. The 2012 
worldwide estimates of mortality by GLOBOCAN, indicate a total of 1.6 million lung cancer-related 
deaths, accounting for 19.4% (nearly 1 in 5 cancer deaths) of all cancer deaths (except 
nonmelanoma skin cancers) [28, 54]. While mortality is declining in men (by 6% from 2009 to 
2013), death rates increased in women by 7%, thereby approaching those of male counterparts 
[8]. 
 
In the 28 EU countries, 331,725 new lung cancer cases were reported in 2012 [55]. The target 
population of treatment-naïve adult patients with ALK-positive advanced NSCLC was estimated 
from published epidemiology data on the incidence of ALK-positive advanced NSCLC in France, 
Italy, Germany, Spain and the United Kingdom provided by the MAH.  
Based on epidemiology data, the MAH stated in the submission file that 7,637 patients in the EU-
5 and 11,816 in the 28 European countries would be eligible for the first-line therapy with 
alecensa [17]. Since the underlying assumptions could not be reproduced, the absolute numbers 
from the epidemiology data provided for five countries in the submission file were used to 
calculate the respective percentages for each country based on the total lung cancer incident 
population. These probabilities were then applied to calculate a range for the overall numbers in 
Europe based on the total lung cancer incident population by GLOBOCAN.  
This led to slightly lower estimates: NSCLC accounted for 82%–86% of all lung cancers 
diagnosed, of which 81%–85% are de novo advanced or metastatic or are recurrent from early 
stages (see also Table A11 in Appendix 1. EXTRAPOLATION OF PFS AND OS/SURVIVAL 
ANALYSIS). About 3%–5% of these are estimated to be ALK-positive. Taking factors such as 
non-squamous histological type, tissue availability or testing for ALK rearrangements into account, 
1.0%–1.4% of the total lung cancer incident cases are actually treated. Applying these 
probabilities to the total lung cancer incident population, about 11,000 patients would be eligible 
for ALK TKI therapy, whereas a maximum of 5000 patients are expected to be treated in Europe 
(see Table 4.1). 
Table 4.1 Estimated incidence of (ALK-positive) NSCLC in Europe in 2012 
 Proportion, % EU5c EU28d 
Total lung cancer incident populationa 100 214,410 331,725 
Total NSCLC incident population 82–86 175,816–184,393 272,015–285,284 
Total NSCLC patients eligible for first-line 
therapyb 
67–72 143,655–154,375 222,256–238,842 
Total ALK-positive NSCLC patients eligible for 
first-line therapy 
3.4–3.5 7290–7504  11,279–11,610 
Total ALK-positive NSCLC patients treated with 
first-line therapy 
1.0–1.4 2144–3002 3317–4644 
Source: [17] 
aTotal lung cancer incident population was obtained from GLOBOCAN 2012, IARC -27.9.2017.  
bDe novo advanced/metastatic patients and recurrent patients from early stages. 
cFrance, Germany, Italy, Spain, United Kingdom. 
dAll 28 current European Union counties. 
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5 CLINICAL EFFECTIVENESS 
5.1 Research questions 
Table 5.1. Research questions and element IDs 
Element ID Research question 
D0001 What is the effect on overall survival for alectinib compared to other approved treatments 
in the 1st line therapy? 
D0005 How does alectinib affect symptoms and findings (e.g. time to CNS progression, objective 
response rate (ORR), overall survival (OS), health-related quality of life (HRQoL)) of 
adults with ALK-positive advanced NSCLC? 
D0006 How does alectinib affect progression-free survival of adults with ALK-positive advanced 
NSCLC, compared to other approved treatments in the 1st line therapy? 
D0012 What is the effect of alectinib on generic health-related quality of life? 
D0013 What is the effect of alectinib on disease-specific quality of life? 
D0016 How does alectinib affect activities of daily living? 
5.2 Results 
Included studies 
The assessment of clinical effectiveness is based primarily on three phase III randomised active-
controlled trials: ALEX [2] (alectinib vs. crizotinib), ASCEND-4 [56] (ceritinib vs. chemotherapy) 
and PROFILE 1014 [57] (crizotinib vs. chemotherapy). For a tabular summary of the studies, see 
Section 0.  
Direct and indirect evidence 
The ALEX study provides a direct comparison between alectinib and the relevant comparator 
crizotinib, whereas ASCEND-4 and PROFILE 1014 are used in an NMA that also included ALEX 
to provide a comparison against the other most relevant comparator, ceritinib (Figure 5.5).  
The estimations derived from the NMA should be interpreted with caution because of the 
limitations inherent in any across-study comparison (e.g., with regard to potential differences in 
patient populations). In addition, there are some differences between the comparator regimens, 
the impact of which is unknown (see further discussion later). In ASCEND-4, four cycles of 
pemetrexed plus cisplatin or carboplatin therapy, followed by maintenance pemetrexed therapy, 
was used, whereas in PROFILE 1014, up to six cycles of the same regimen were allowed, but 
there was no maintenance pemetrexed therapy. The results of the NMA are therefore viewed 
primarily as supportive of the direct evidence and are discussed in a separate section. A further 
discussion on the comparability of the studies based on the results is provided in the NMA section 
(Table 5.7). 
For comparison with ceritinib, evidence for all the research questions listed above is not available; 
however, results for OS, PFS, ORR and safety are presented in the NMA.  
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Description of individual studies 
The ALEX trial  
This was a phase III multicentre, open-label, randomised study of orally administered alectinib 
(600 mg twice daily) versus crizotinib (250 mg twice daily) in previously untreated adult patients 
with ALK-rearranged (ALK-positive), stage IIIB not amenable for multimodality treatment or IV, 
non-squamous NSCLC with WHO performance status 0–2. Central testing for ALK protein 
expression positivity of tissue samples from all patients by Ventana anti-ALK (D5F3) IHC was 
required before randomisation in the study. The primary endpoint was investigator-assessed PFS. 
Secondary endpoints were IRC-assessed PFS, time to CNS progression, ORR and OS. Per 
protocol, crossover between the trial groups was not allowed. A total of 303 patients were 
included in the trial: 151 patients were randomised to the crizotinib arm and 152 patients were 
randomised to the alectinib arm. Tumour response was assessed every 8 weeks with the use of 
the Response Evaluation Criteria in Solid Tumors (RECIST) 1. [2] [5] [22]. 
The PROFILE 1014 trial 
This was a phase III, randomised, open-label study of the efficacy and safety of crizotinib (250 mg 
BID) until RECIST-defined progression versus pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) 
or carboplatin (area under the curve [AUC] 5 or 6) for up to 6 three-week cycles in previously 
untreated patients with non-squamous carcinoma of the lung harbouring a translocation or 
inversion event involving the ALK gene locus and ECOG/WHO performance score of 0–2. ALK-
positive status was determined by the Abbott Molecular IUO (investigational use only) test 
performed by a central laboratory under US FDA investigational device exemption. Patients 
whose disease progressed while they were receiving chemotherapy were allowed to cross over to 
receive crizotinib treatment. The primary endpoint was IRC-assessed PFS per RECIST 1.1. The 
study included 343 patients (171 of 172 patients randomised to receive crizotinib received 
crizotinib, and 169 of 171 randomised to receive chemotherapy received chemotherapy). 
Crossover to crizotinib therapy was done in 120 patients after progression of their disease while 
they were receiving chemotherapy [4]. 
The ASCEND-4 trial 
This was a phase III multicentre, open-label, randomised study of orally administered ceritinib 
(750 mg once daily, fasted) versus standard chemotherapy in previously untreated adult patients 
with ALK-rearranged (ALK-positive), stage IIIB or IV, non-squamous NSCLC with WHO 
performance status 0-2. Chemotherapy consisted of pemetrexed at 500 mg/m2
 
and cisplatin at 75 
mg/m2 or carboplatin (AUC 5 or 6) for up to 4 three-week cycles, followed by pemetrexed 
maintenance therapy in patients without progressive disease after 4 cycles . ALK-positivity was 
confirmed by the Ventana ALK (D5F3) CDx assay IHC test by a central laboratory. Patients 
enrolled were previously not treated with any systemic anticancer therapy (including an ALK 
inhibitor) with exception of patients who received neoadjuvant or adjuvant therapy if 
progression/relapse had not occurred within 12 months after the end of neoadjuvant or adjuvant 
therapy. Crossover of patients allocated in the chemotherapy arm to the ceritinib treatment arm 
was allowed in the extension treatment phase only after blinded IRC-confirmed RECIST-defined 
progressive disease had been documented. The primary endpoint was IRC-assessed PFS per 
RECIST 1.1. The study included 376 patients (all 189 randomised to receive ceritinib received 
ceritinib, and 175 of 187 randomised to receive chemotherapy received chemotherapy) [3]. 
PROFILE 1029 
This was a phase III, randomised, active-controlled, open-label study comparing crizotinib at a 
dosage of 250 mg twice daily versus pemetrexed (500 mg/m2) and cisplatin (75 mg/m2) or 
carboplatin (AUC 5 or 6) for up to 6 three-week cycles in patients with locally advanced, recurrent 
or metastatic non-squamous NSCLC with ALK positivity determined by FISH with ECOG 
performance status of 2 or less and no prior systemic treatment for NSCLC. Patients with brain 
metastases were included only if they had been treated and were neurologically stable with no 
ongoing requirement for corticosteroids. The primary endpoint was PFS (by IRC assessment). 
This study was excluded from the base case NMA because the study population included Asian 
patients only. It was included in sensitivity analyses, however. 
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Excluded studies 
In addition to ALEX, PROFILE 1014, PROFILE 1029 and ASCEND-4, there was one reported 
study in the ALK-positive first-line setting: J-ALEX (alectinib 300 mg vs. crizotinib). For other, 
ongoing, studies no data were available.  
J-ALEX 
This was a phase III RCT in Japanese patients with advanced stage IIIB/IV ALK-positive NSCLC 
comparing orally administered alectinib at a dosage of 300 mg twice daily against orally 
administered crizotinib at a dosage of 250 mg twice daily. Patients were treatment naïve (64% of 
patients) or had received one line of chemotherapy at the study baseline (36% of patients).  
This study was excluded because of the mixed population (i.e., chemotherapy-naïve and 
chemotherapy-experienced patients), the lower dose of alectinib, and the Japanese-only 
population. 
Baseline characteristics 
Baseline characteristics of the patients in the included studies are shown in Table 5.2.[2]
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Table 5.2. Baseline characteristics of patients across relevant studies 
 ALEX PROFILE 1014 PROFILE 1029a ASCEND-4 
Alectinib Crizotinib Crizotinib PEMpositive 
CIS/CARB 
Crizotinib PEMpositive 
CIS/CARB 
Ceritinib PEMpositiveCIS/CARB positive  
maintenance PEM 
N, randomised 152 151 172 171 104 103 189 187 
Age, years, median (range) 58 (25–
88) 
54 (18–91) 52 (22–76) 54 (19–78) Mean 48.2 Mean 48.9 55 (22–
81) 
54 (22–80) 
Male, n (%) 68 (45) 64 (42) 68 (40) 63 (37) 50 (48.1) 43 (41.7) 87 
(46.0) 
73 (39.0) 
Race, n (%)         
  Asian 69 (45) 69 (46) 77 (45) 80 (47) 104 (100) 103 (100) 76 (40) 82 (44) 
  Other 83 (55) 82 (54) 95 (55) 91 (53) — — 113 (60) 105 (56) 
ECOG/WHO PS, n (%)         
  01 142 (93) 141 (93) 161 (94) 163 (95) 99 (95) 98 (95) 176 (93) 175 (93) 
  2 10 (7) 10 (7) 10 (6) 8 (5) 5 (5) 5 (5) 13 (7) 11 (6)b 
Stage at baseline, n %         
  IIIB/locally advanced 4 (3) 6 (4) 4 (2) 3 (2) NR NR 9 (5) 5 (3) 
  IV/metastatic 148 (97) 145 (96) 168 (98) 168 (98) NR NR 180 (95) 182 (97) 
Histology/cytology, n (%)         
  Adenocarcinoma 136 (90) 142 (94) 161 (94) 161 (94) NR NR 180 (95) 183 (98) 
  Other 16 (10) 9 (6) 11 (6) 10 (6) NR NR 9 (5) 4 (2) 
Smoking history, n (%)         
  Active smoker 12 (8) 5 (3) 10 (6) 5 (3) NR NR 15 (8) 15 (8) 
  Nonsmoker 92 (61) 98 (65) 106 (62) 112 (65) NR NR 108 (57) 122 (65) 
  Past smoker 48 (32) 48 (32) 56 (33) 54 (32) NR NR 66 (35) 50 (27) 
Brain/CNS metastasis, n (%) 64 (42) 58 (38) 45 (26) 47 (27) 21 (20) 32 (31) 59 (31) 62 (33) 
Prior brain radiation, n (%) 26 (17) 21 (14) NR NR NR NR 24 (13) 26 (14) 
Abbreviations: CARBcarboplatin; CIScisplatin; CNScentral nervous system; ECOG PSEastern Cooperative Oncology Group; NRnot reported; PEMpemetrexed; PS=performance status; 
WHOWorld Health Organization 
aNot included in base case network meta-analysis. 
bDoes not sum to 100% because of missing observations. 
Sources: Peters et al. 2017; Solomon et al, 2014; Lu et al 2016a; Soria et al 2017. [17], Table 16 
PTJA03 - Alectinib as monotherapy for the first line treatment of ALK-positive advanced NSCLC 
 
Version 1.3, 22th January 2018 EUnetHTA Joint Action 3 WP4 37 
Most baseline characteristics described in Table 5.2 for the studies included in the NMA were 
largely balanced across study arms and were similar across studies. ECOG performance status 
was 0–1 in approximately 95% of patients across studies, more than 95% had stage IV disease, 
approximately 60%–65% of patients were nonsmokers, and more than 90% had adenocarcinoma 
histological type.  
Differences were observed for age, with slightly higher median age in ALEX (58 vs. 54 years, 
alectinib vs. crizotinib – a small imbalance is noted) compared with PROFILE 1014 (52 vs. 54 
years, crizotinib therapy vs. chemotherapy) and ASCEND-4 (55 vs. 54 years, ceritinib therapy vs. 
chemotherapy).  
The proportion of male patients was largely similar across studies, approximately 37%–48%. In 
ASCEND-4 there was a slightly larger difference between arms in the percentage of males (46% 
vs. 39%, ceritinib therapy vs. chemotherapy). The impact of sex for ALK-inhibitor efficacy has not 
been determined. No consistent trend with regard to efficacy and sex can be observed in first-line 
studies for ceritinib and crizotinib, nor in the second-line setting for alectinib. (In the alectinib 
phase I/II study NP28673, ORR was 51% in male patients and 45% in female patients; in the 
ceritinib study ASCEND-4, PFS HR was 0.41 in male patients and 0.63 in female patients; while 
in the crizotinib study PROFILE 1014, PFS HR was 0.54 in male patients and 0.45 in female 
patients. That is, there is a possible tendency of better efficacy in male patients in the former two 
studies and a possible tendency of better efficacy in female patients in the latter study [3-5].  
The presence of baseline CNS metastasis was largely balanced across study arms, but the 
proportions differed across the three studies included in the NMA. There were higher frequencies 
in the ALEX study (approximately 40%) compared with less than 30% in PROFILE 1014 and 
approximately 30% in ASCEND-4. The higher frequency of CNS metastases at baseline observed 
in the ALEX study may be explained by the requirement for all patients to have CNS imaging at 
baseline. The presence of CNS metastasis confers a poorer prognosis, and these differences 
may therefore affect across-study comparisons.  
Limited baseline data were provided for the excluded study PROFILE 1029. Apart from 100% of 
patients being of Asian race, a somewhat lower median age (48 years) was observed compared 
with the other studies. Furthermore, an imbalance in the proportion of patients with baseline brain 
metastasis is noted, 20% versus 31% (n=21 and n=32) in the crizotinib therapy arm versus the 
chemotherapy arm, respectively. This is expected to affect prognosis, and may have favoured the 
crizotinib therapy arm.  
Mortality 
[D0001] What is the effect on overall survival for alectinib compared to other approved 
treatments in the 1st line therapy? 
Alectinib versus  crizotinib (ALEX trial, direct comparison) 
At the data cutoff point, 23% of patients in the alectinib arm and 27% patients in the crizotinib arm 
had died, with a 1-year survival rate of 84.3% and 82.5%, respectively (HR 0.76; 95% CI: 0.48, 
1.20). Median OS was not reached in either treatment arm. Survival analysis has been planned 
after 50% of events have occurred [17]. 
Table 5.3. Overall survival 
Study 
reference/ID 
Measurement Intervention, 
median, 
months (95% 
CI) 
Outcome 
comparator, 
median, months 
(95% CI) 
Relative 
difference, HR 
(95% CI) 
Comment 
ALEX 
(BO28984)  
Interim overall 
survival, 
unadjusted for 
crossover 
Alectinib 
(N=152) 
NE (19.9 to 
NE) 
Crizotinib 
(N=151) 
NE (17.1 to NE) 
 
0.76 (0.48–1.20); 
p0.24 
Immature 
after 35 (23%) 
deaths had 
occurred in 
152 patients 
Abbreviations: CI=confidence interval; HR=hazard ratio; NE=not estimable. 
Source: [17] 
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Figure 5.1. Overall survival, alectinib versus crizotinib, ALEX trial[2] 
 
Abbreviation: CI=confidence interval. 
Progression-free survival 
[D0006] How does alectinib affect progression-free survival of adults with ALK-positive 
advanced NSCLC, compared to other approved treatments in the 1st line therapy? 
Alectinib versus crizotinib (ALEX trial, direct comparison) 
The trial met its primary endpoint at the primary analysis, demonstrating a statistically significant 
increase in PFS by investigator assessment. In the entire population the median PFS measured 
by the investigator for alectinib was not reached (95% CI, 17.7 months to not estimable) versus 
11.1 months  for crizotinib (95% CI, 9.1, 13.1); HR 0.47 (95% CI, 0.34, 0.65, p<0.0001).  
IRC-assessed PFS was also significantly longer with alectinib than with crizotinib (median PFS 
25.7 months (95% CI 19.9 months to not estimable) vs. 10.4 months (95% CI, 7.7, 14.6 months); 
HR for disease progression or death 0.50, (95% CI, 0.36, 0.70; p<0.001)). 
The PFS benefit was consistent for patients with CNS metastases at the baseline (HR 0.40, 95% 
CI 0.25–0.64) and without CNS metastases at the baseline (HR 0.51, 95% CI, 0.33, 0.80). In both 
subgroups, the median PFS was not reached in the alectinib arm (95% CI 9.2, not estimable; and 
95% CI not estimable, not estimable, respectively), but was estimated for the crizotinib arm at 7.4 
months (95% CI, 6.6, 9.6 months) in the CNS metastasised group and 14.8 months 95% CI, 10.8, 
20.3 months) in the non-CNS metastasised group, respectively [5].  
The treatment effect did not show major differences between the subgroups. The benefit was 
lower in the subgroups of active smokers and patients with an ECOG performance status of 2, 
although the numbers of patients in these subgroups were small [2].  
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Table 5.4. Progression-free survival by investigator and independent review committee 
assessments for alectinib versus crizotinib in the ALEX trial (intent-to-treat population)  
Endpoint Alectinib 
N  152 
Crizotinib 
N  151 
Median duration of follow-up, months (range) 18.6 (0.529.0) 17.6 (0.327.0) 
Primary endpoint   
PFS (investigator)  
Patients with event, n (%) 62 (40.8) 102 (67.5) 
Median, months (95% CI) NE (17.7 to NE) 11.1 (9.1, 13.1) 
HR (95% CI)a 0.47 (0.34, 0.65) 
Stratified log-rank p 0.0001 
1-year event-free rate, % (95% CI) 68.4 (61.0, 75.9) 48.7 (40.4, 56.9) 
Key secondary endpoints   
PFS (IRC)   
Patients with event, n (%) 63 (41.4) 92 (60.9) 
Median, months (95% CI) 25.7 (19.9 to NE) 10.4 (7.7, 14.6) 
Stratified HR (95% CI)a 0.50 (0.36, 0.70) 
Stratified log-rank p 0.0001 
Abbreviations: CI=confidence interval; HRhazard ratio; IRCindependent review committee; NEnot estimable; 
PFSprogressionfree- survival. 
aHR was estimated by Cox regression. 
Stratified HRs and p values were stratified for the covariates race (Asian vs. non-Asian) and central nervous system 
metastases at the baseline by the IRC. 
Notes: Data cutoff: 9th February 2017 (primary analysis). 
Source: [17] 
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Figure 5.2. Kaplan–Meier plot of investigator-assessed progression-free survival [2] 
 
Abbreviation: CI=confidence interval. 
Figure 5.3. Subgroup analysis of progression-free survival for alectinib versus crizotinib, 
ALEX trial [2] 
 
 
Abbreviations: CI=confidence interval; CNS=central nervous system; ECOG Eastern Cooperative Oncology Group; 
yr=years. 
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Morbidity 
[D0005] How does alectinib affect symptoms and findings (e.g. time to CNS progression, 
objective response rate (ORR), health-related quality of life (HRQoL)) of adults with ALK-
positive advanced NSCLC? 
Key secondary outcomes are separated into results in the intent-to-treat (ITT) population referring 
to whole-body outcomes (ORR and duration of response), and CNS results, either as subgroup 
analyses or endpoints specifically addressing CNS efficacy. The results are summarised in Tables 
0.1.  
ORR and duration of response 
Alectinib versus crizotinib (ALEX trial, direct comparison) 
More patients in the alectinib arm than in the crizotinib arm in ALEX were considered responders 
(83% vs. 76%). This difference of approximately 7 percentage points (95% CI -1.7% to 16.5%) 
was not statistically significant (p0.09). In the alectinib arm, 4% of patients were considered 
complete responders compared with 1% in the crizotinib arm (Table 5.5). 
Fewer responders in the alectinib arm than in the crizotinib arm has disease progression or died 
(32% vs. 64%) in ALEX. Because most of responses were ongoing in the alectinib arm, the 
median duration of response (DOR) assessed by the investigator was not yet reached (95% CI 
not estimable) whereas the median was 11.1 months (95% CI 7.9–13.0 months) in the crizotinib 
arm. The difference was statistically significant (p<0.0001) (Table 5.5) [2]. 
Table 5.5. Objective response rate and duration of response, ALEX trial 
Endpoint Alectinib 
N152 
Crizotinib 
N151 
Median duration of follow-up, months (range) 18.6 (0.529.0) 17.6 (0.327.0) 
Key secondary endpoints   
ORR (investigator)   
Response rate, n (%) 126 (82.9) 114 (75.5) 
Response rate, 95% CI, % 75.95–88.51 67.84–82.12 
Difference percentage points (95% CI) 7.40 (–1.71 to 16.50) 
p (Mantel–Haenszel) 
 
Complete response, n (%) 
Partial response, n (%)       
Stable disease                                  
 
0.09 
 
 
              6 (4)                                2 (1)    
           120 (79)                         112 (74)         
              9 (6)                              24 (16) 
Exploratory endpoints  
DOR (investigator) n126 n114 
Patients with event, n (%) 40 (32) 73 (64) 
Median, months (95% CI) NE (NE) 11.1 (7.9–13.0) 
HR (95% CI)a 0.36 (0.24–0.53) 
p (stratified log-rank) <0.0001 
Abbreviations: CI=confidence interval; DORduration of response; HRhazard ratio; NEnot estimable; 
ORRobjective response rate. 
aHR was estimated by Cox regression. 
Notes: Data cutoff 9th February 2017 (primary analysis). 
Source: [17] and [2] 
PTJA03 - Alectinib as monotherapy for the first line treatment of ALK-positive advanced NSCLC 
 
Version 1.3, 22th January 2018 EUnetHTA Joint Action 3 WP4 42 
CNS results 
Alectinib versus crizotinib  
The time to CNS progression was significantly longer with alectinib than with crizotinib in the ITT 
population (cause-specific HR 0.16, (95% CI, 0.10, 0.28)) (Table 5.6) The cumulative incidence 
rate of CNS progression was consistently lower over time with alectinib than with crizotinib, and 
the 12-month cumulative incidence rate of CNS progression was 9.4% (95% CI, 5.4%,14.7%) 
versus 41.4% (95% CI, 33.2%–49.4%) with crizotinib (Figure 5.4). 
In patients without CNS metastases at the baseline, at 12 months, 4.6% of alectinib-treated 
patients versus 31.3% of crizotinib-treated patients had CNS metastases at the time of first 
progression, suggesting alectinib is protective against the development of CNS progression 
(HR 0.14, 95% CI, 0.06, 0.33, p0.0001) [17]. 
In ALEX, intracranial ORR (exploratory endpoint) was numerically improved with alectinib 
compared with crizotinib, irrespective of prior radiotherapy. A total of 122 patients had baseline 
CNS metastasis, 47 of whom had received prior radiotherapy. In patients with baseline 
measurable CNS disease (n= 43), CNS ORR was 85.7% vs 71.4%, respectively, in patients with 
prior radiotherapy, and 78.6% vs 40.0% in patients without prior radiotherapy. In patients with 
measurable and non-measurable CNS disease (n=79) CNS ORR was 36.0% vs 28.6%, 
respectively, in patients with prior radiotherapy, and 74.4% vs 24.3% in patients without prior 
radiotherapy. The substantial difference observed in the previously unirradiated group may 
suggest that the need for radiotherapy with its associated toxicity is reduced or postponed by 
alectinib [58].  
Figure 5.4. Cumulative incidence of central nervous system progression by independent 
review committee for alectinib versus crizotinib in the ALEX trial [2].  
 
Abbreviation: CI=confidence interval; CNS=central nervous system; mo=month. 
*Cumulative incidence of CNS progression, as assessed by the independent review committee according to Response 
Evaluation Criteria in Solid Tumours, version 1.1. Values were adjusted for the competing risks of non-CNS progression 
and death. 
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Table 5.6. Central nervous system efficacy outcomes in the ALEX trial 
Endpoint Alectinib 
N152 
Crizotinib 
N151 
Median duration of follow-up, months (range) 18.6 (0.529.0) 17.6 (0.327.0) 
Key secondary endpoints   
Time to CNS progression (IRC)   
Patients with event, n (%) 18 (11.8) 68 (45.0) 
Cause-specific HR (95% CI)a 0.16 (0.10, 0.28) 
Stratified log-rank p 0.0001 
1-year cumulative incidence rate of CNS 
progression (IRC), % (95% CI) 
 
  9.4 (5.4, 14.7)                           41.4% (33.2%, 49.4%) 
Exploratory endpoints  
CNS ORR for patients with measurable CNS 
lesions at the baseline (IRC) 
n21 n22 
Patients with event, n (%) 17 (81.0) 11 (50.0) 
95% CI (%) 58.1–94.6 28.2–71.8 
CNS complete responseb n (%) 8 (38) 5 (1) 
CNS ORR for patients with measurable and/or 
nonmeasurable CNS lesions at the baseline 
(IRC) 
n64 n58 
Patients with event, n (%) 38 (59.4) 15 (25.9) 
95% CI 46.4–71.5 15.3–39.0 
CNS complete response* n (%) 29 (45) 5 (9) 
CNS DOR for patients with measurable CNS 
lesions at the baseline (IRC)* 
n21 n22 
Median, monthsb 17.3 5.5 
95% CI, monthsb 14.8 to NE 2.1–17.3 
Abbreviations: CI=confidence interval; CNS=central nervous system; DORduration of response; HRhazard ratio; 
IRCindependent review committee; NEnot estimable; ORRobjective response rate; PFSprogression-
free- survival. 
aHR was estimated by Cox regression. 
bData from Peters et al. [1] 
Stratified HRs and p values were stratified for the covariates race (Asian vs. non-Asian) and CNS metastases at the 
baseline by the IRC. 
Notes: Data cutoff 9th February 2017 (primary analysis).  
Source: [17] 
Indirect comparison 
An NMA was performed by the MAH company using Bayesian Markov chain Monte Carlo 
methods in WinBUGS, with a fixed-effects and a random effects model. The NMA MAH base case 
as conducted using a fixed effects model and included the ALEX, ASCEND-4 and PROFILE 1014 
studies. For the sensitivity analysis more than one study (PROFILE 1014 and PROFILE 1029) 
were available to evaluate the comparison between crizotinib and chemotherapy which allowed 
for both a fixed effects and random effects NMA to be conducted. Both sensitivity analyses were 
performed with the results included from the PROFILE 1029 study.  
The results should be interpreted with caution due to limitations in the analyses and data that may 
have affected the results. These are further addressed in Appendix 6. Indirect comparisons – 
statistical aspects.  
PTJA03 - Alectinib as monotherapy for the first line treatment of ALK-positive advanced NSCLC 
 
Version 1.3, 22th January 2018 EUnetHTA Joint Action 3 WP4 44 
Additionally to the Bayesian fixed effects NMA, also indirect comparisons known as the Bucher 
method were presented by the MAH. The results are nearly identical because the network is 
elementary enough, such that the more complex fixed effects NMA does not use its additional 
capabilities in processing the data, compared with the simple Bucher method (see Appendix 6. 
Indirect comparisons – statistical aspects). Thus only the NMA is presented, with focus on the 
MAH base case fixed effects.  
Alectinib versus ceritinib (NMA, indirect comparison) 
See section 5.2 on Included studies for a discussion on the included studies and their baseline 
data.  
Figure 5.5. Studies included in the base case network meta-analysis 
 
Abbreviations: ALECalectinib; ALK+ALK positive; bidtwice daily; CARBcarboplatin; CERceritinib; 
CHEMOchemotherapy; CIScisplatin; CRZcrizotinib; NSCLCnon-small cell lung cancer; PEMpemetrexed; 
q3w=every 3 weeks; qd=once daily. 
Source: [17] 
 
Table 5.7. Summary of objective response rate, duration of response and progression-free 
survival outcomes across studies 
Study 
(assessment) 
Objective response rate, % Duration of response, 
months (95% CI) 
PFS (median), months 
(95% CI) 
ALEX  
(Inva) 
Alectinib Crizotinib Alectinib Crizotinib Alectinib Crizotinib 
83 76 NE (NE) 11.1 
(7.9, 13.0) 
NE  
(17.7 to NE) 
11.1  
(9.1, 13.1) 
(IRC) 78.9 72.2 
 
— — 25.7  
(19.9 to NE) 
10.4  
(7.7, 14.6) 
PROFILE 1014 
(IRC) 
Crizotinib Chemothera
py 
Crizotinib Chemother
apy 
Crizotinib Chemothera
py 
74 45 11.3 
(8.1, 13.8) 
5.3 
(4.1, 5.8) 
10.9  
(8.3, 13.9) 
7.0  
(6.8, 8.2) 
PROFILE 1029b 
(IRC) 
Crizotinib Chemothera
py 
Crizotinib Chemother
apy 
Crizotinib Chemothera
py 
87.5 45.6 — — 11.1  
(8.3, 12.6) 
6.8  
(5.7, 7.0) 
ASCEND-4  
(IRC) 
Ceritinib Chemothera
py 
Ceritinib Chemother
apy 
Ceritinib Chemothera
py 
73 27 23.9 
(16.6 to 
NE) 
11.1 
(7.8, 16.4) 
16.6  
(12.6, 27.2) 
8.1  
(5.8, 11.1) 
Abbreviations: CIconfidence interval; IRCindependent review committee; Invinvestigator; NEnot estimable; 
PFS=progression-free survival. 
a Inv: investigator 
bNot included in base case network meta-analysis. 
Source: [17] 
ALK+ NSCLC: Naive/ 1st-line population
CHEMO 
q3w
PEM + CIS or 
CARB +/-
maintenance
ALEC
600 mg bid
CER 
750 mg qd 
ASCEND-4
ALEX CRZ
250 mg bid
PROFILE 1014
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ORR measures tumour shrinkage and can thereby provide direct information on a therapeutic 
agent’s antitumour effect, particularly for cytotoxic agents. The ORR of the comparator 
chemotherapy arms is essentially the same in the two PROFILE studies (45%), but is markedly 
lower in the ASCEND-4 study (27%) (Table 5.7). In ASCEND-4, only up to 4 cycles of pemetrexed 
plus platinum therapy were administered, followed by maintenance pemetrexed therapy in 
patients without progression, whereas in the PROFILE studies, up to 6 cycles were administered, 
without maintenance therapy. The marked difference in ORR for the chemotherapy arms could 
potentially suggest the presence of important differences in the study populations with regard to 
prognosis, and/or that the maintenance pemetrexed therapy did not result in additional responses 
to outweigh the lower number of standard chemotherapy cycles. (See the discussion on baseline 
characteristics above). On the other hand, the duration of response was considerably longer in 
the chemotherapy arm of ASCEND-4 compared with PROFILE 1014, as might be expected with 
continued, compared with interrupted, treatment. 
The ORR for crizotinib was consistent across the two trials used in the NMA, ALEX (75%) and 
PROFILE 1014 (74%), but was higher in the (excluded) PROFILE 1029 study (87%). The median 
PFS for crizotinib was also consistent across studies (10–11 months), including PROFILE 1029 
(Table 5.7). 
Table 5.8. Summary of treatment effect estimates in the network meta-analysis (base case) 
Comparison 
Endpoint (analysis) 
HR 
(95% credible interval) 
Odds ratio 
(95% credible interval) 
HR  
(95% credible 
interval) 
PFS by IRC in a 
subgroup of 
patients with 
CNS metastases 
at the baseline PFS by IRC OS ORR by IRC DCR by IRC 
Alectinib versus 
chemotherapy 
0.23 
(0.15–0.34) 
0.63 
(0.34–1.15) 
5.06 
(2.51–10.22) 
1.41 
(0.60–3.35) 
0.21 
(0.10, 0.44) 
Alectinib versus 
crizotinib 
0.50  
(0.36–0.70) 
0.76  
(0.49–1.20) 
1.45  
(0.86–2.46) 
0.83  
(0.41–1.69) 
0.37  
(0.22–0.63) 
Alectinib versus 
ceritinib 
0.41  
(0.25–0.67)a 
0.85  
(0.41–1.73) 
0.69  
(0.30–1.61) 
0.72  
(0.26–1.95) 
0.30  
(0.13–0.71)a 
Crizotinib versus 
chemotherapy 
0.45  
(0.35–0.58)a 
0.82  
(0.54–1.24) 
3.49  
(2.21–5.57) 
1.70  
(1.05–2.77) 
0.57  
(0.35–0.93)a 
Ceritinib versus 
chemotherapy 
0.55  
(0.42–0.72) 
0.73  
(0.50–1.06) 
7.30  
(4.68–11.61) 
1.97  
(1.19–3.32) 
0.70  
(0.43–1.11) 
Ceritinib versus 
crizotinib 
1.22 
(0.84–1.79) 
0.90 
(0.52–1.57) 
2.09  
(1.10–3.99) 
1.16  
(0.57–2.35) 
1.22  
(0.62–2.43) 
Abbreviations: CNS=central nervous system; DCR=disease control rate; HR=hazard ratio; IRC=independent review 
committee; OS=overall survival; ORR=objective response rate; PFS=progression free survival. 
Bold indicates significance based on 95% credible intervals.  
Note: HR of 1 indicates no effect, HR<1 indicates lower risk of PFS/OS or better response compared with control.  
Odds ratio of 1 indicates no effect, Odds ratio greater than 1 indicates a better response compared with the control. 
     aThe relative effect of crizotinib versus chemotherapy may be overestimated and thus the effect of alectinib versus ceritinib 
may be overstated because of the inclusion of pemetrexed maintenance therapy in the ASCEND-4 chemotherapy arm. 
Source: [17] 
Mortality – NMA 
Alectinib versus ceritinib (NMA, indirect comparison)  
There were no statistically significant differences in OS between alectinib and ceritinib according 
to the NMA (Figure 5.6). The results may be affected by treatment arm crossover and data 
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immaturity (median OS was not observed for some treatment arms in the trials). See also 
summary efficacy estimates, including OS, for the NMA in Table 5.8.  
Figure 5.6. Caterpillar plot of network meta-analysis hazard ratio for overall survival 
unadjusted (base case, fixed effect) 
 
Abbreviations: ALECalectinib; CERceritinib; CHEMOchemotherapy; CrIcredible interval; CRZcrizotinib; 
HRhazard ratio; OSoverall survival; PFS=progression-free survival.  
Source: [17]  
 
Progression-free survival – NMA 
Alectinib versus ceritinib (NMA, indirect comparison) 
The key efficacy findings for the fixed effects base case (including ALEX, ASCEND 4 and 
PROFILE 1014) were as follows (Figure 5.7;Table 5.8) 
 Significantly longer IRC PFS for alectinib versus ceritinib 
 Significantly longer IRC PFS in the subgroup of patients with CNS metastases at the 
baseline with alectinib versus ceritinib 
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Figure 5.7. Caterpillar plot of network meta-analysis hazard ratio for progression-free 
survival by independent review committee (base case, fixed effect) 
 
Abbreviations: ALECalectinib; CERceritinib; CHEMOchemotherapy; CrIcredible interval; CRZcrizotinib; HRhazard 
ratio. 
Source: MAH submission (network meta-analysis report). 
Quality of life 
[D0016] How does alectinib affect activities of daily living? 
No evidence was available on activities of daily living. 
 [D0012] What is the effect of alectinib on generic health-related quality of life? 
With use of both the self-administered European Organisation for Research and Treatment of 
Cancer quality-of-life questionnaire QLQ-C30 and its lung cancer module QLQ-LC13, the impact 
of disease symptoms and treatment on patients’ functioning and HRQoL were assessed.  
The proportions of compliance at the baseline were similar in both treatment arms, with 64% of 
patients in the alectinib arm and 66% of patients in the crizotinib arm completing the baseline 
patient-reported outcomes assessment. Among patients who had PRO baseline data compliance 
rates were 60% or greater throughout the study with the exception of Week 112 and 116 were 
observed in the alectinib-treated arm. A point change in scale score, reported by a patient, that is 
greater than 10 is considered clinically meaningful. 
The findings of the patient-reported outcomes analyses indicated that patients receiving alectinib 
had clinically meaningful improvement in HRQoL for a longer duration compared with patients 
receiving crizotinib. On average, patients treated with alectinib reported durable clinically 
meaningful improvement in HRQoL (from the baseline) until week 88. For patients treated with 
crizotinib, clinically meaningful improvements in HRQoL (from the baseline) were reported at 
multiple time points until week 68.  
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Figure 5.8. Mean change from the baseline in European Organisation for Research and 
Treatment of Cancer QLQ-30 global health score (ALEX) 
 
Abbreviation: PRO=patient-reported outcome. 
Source: [17] 
No statistical significance of a difference in the time to confirmed deterioration for patient-reported 
global health status/HRQoL was found between treatments (HR 0.72, 95% CI, 0.38, 1.39). The 
proportion of patients with confirmed deterioration events was less than 13.2% in both arms. 
Figure 5.9. Time to deterioration in European Organisation for Research and Treatment of 
Cancer QLQ-30 global health score (intent-to-treat population) (ALEX) 
Abbreviation: CI=confidence interval. 
Source: [17] 
No statistical significance of a difference in the time to deterioration in cognitive functioning was 
found between alectinib and crizotinib. In the alectinib arm, the median time to deterioration in 
cognitive functioning was not reached; in the crizotinib arm it was 20 months (HR 0.85, 95% CI, 
0.55, 1.33). 
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Figure 5.10. Kaplan–Meier plot of European Organisation for Research and Treatment of 
Cancer QLQ-C30 cognitive functioning time to deterioration (intent-to-treat population) 
(ALEX) 
 
Abbreviation: CI=confidence interval. 
Source: [17] 
HRQoL of patients with CNS metastases at the baseline 
The finding that patients receiving alectinib had clinically meaningful improvement in HRQoL for a 
longer duration in comparison with patients receiving crizotinib was particularly evident in the 
predefined subgroup of patients with CNS metastases at the baseline. For this subgroup (starting 
at week 12 and persisting for most assessments to week 84) a lower proportion of patients 
receiving alectinib reported clinically meaningful worsening in HRQoL in comparison to patients 
receiving crizotinib. In addition, fewer patients treated with alectinib reported clinically meaningful 
worsening in cognitive functioning through many assessments between week 4 and week 84. For 
patients with CNS metastases at the baseline, similar patterns were observed for fatigue, physical 
function and social function scores.  
[D0013] What is the effect of alectinib on disease-specific quality of life? 
The analysis indicates that there is no statistically significant difference between alectinib and 
crizotinib regarding clinically meaningful reduction in lung cancer symptoms (including patient-
reported cough, chest pain, pain in other parts, fatigue and dyspnoea). However, on average 
patients receiving alectinib reported clinically meaningful reduction (from the baseline) of multiple 
lung cancer symptoms for a longer duration compared with patients receiving crizotinib  
(see Appendix 5. Health-related quality of life). 
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6 SAFETY 
6.1 Research questions 
Element ID Research question 
C0008 What is the frequency of any adverse events of alectinib compared to other approved 
treatments in the 1st line therapy? 
What are the most frequent AEs of alectinib compared to other approved treatments in 
the 1st line therapy? 
What is the frequency of discontinuation of treatment due to adverse events of alectinib 
compared to other approved treatments in the 1st line therapy?  
What is the frequency of AE leading to dose reduction of alectinib compared to other 
approved treatments in the 1st line therapy? 
What is the frequency and what are serious adverse events (SAE) of alectinib compared 
to other approved treatments in the 1st line therapy?  
What is the frequency of serious adverse events (SAE) leading to death for alectinib 
compared to other approved treatments in the 1st line therapy?  
What is the frequency of adverse events of special interest for alectinib? 
C0005 What are the susceptible patient groups that are more likely to be harmed through the use 
of alectinib? 
6.2 Results 
Included studies 
The safety results are based on the ALEX trial and the SmPC containing pooled data from ALEX 
and two single-arm phase II clinical trials of alectinib (NP28761, NP28673; N=405). 
In the phase II clinical trials (NP28761, NP28673; N=253), the median duration of exposure to  
alectinib was 11 months. In ALEX trial; N=152, the median duration of exposure to alectinib was 
17.9 months, whereas the median duration of exposure to crizotinib was 10.7 months. 
In addition, ADR frequencies are presented from the SmPCs of Xalkori and Zykadia. The SmPC 
frequencies reflect the EMA established safety profile and are based on all relevant studies at the 
approved dose.  
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Patient safety 
Alectinib versus crizotinib (ALEX trial, direct comparison) 
In the ALEX trial the median duration of treatment was shorter in patients in the crizotinib arm 
(10.7 months; range 027 months) compared with patients in the alectinib arm (17.9 months; 
range 029 months); this was mainly driven by fewer treatment discontinuations due to disease 
progression in the alectinib arm. A lower proportion of patients in the crizotinib arm than in the 
alectinib arm completed more than 12 months (45% vs. 66%) and more than 18 months (27% and 
49%) of study treatment.  
 
The mean dose intensity was comparable between treatment arms (92% for crizotinib and 96% 
for alectinib); however, the proportion of patients in the crizotinib arm (42%) who missed at least 
one dose of treatment was higher than the proportion of patients in the alectinib arm (32%) (Table 
6.1). 
Table 6.1.Overview of treatment exposure and incidence of adverse events, ALEX trial 
(safety population)  
 
Crizotinib 
N151 
Alectinib 
N152 
Median treatment duration, months (range) 10.7 (0–27) 17.9 (0–29) 
Patient-years of observation 158.0 194.7 
Proportion of patients treated for >12 months 45% 66% 
Proportion of patients treated for >18 months 27% 49% 
Mean dose intensity, % (SD) 92.4 (14.1) 95.6 (10.3) 
Total number of patients with 1 AE, n (%) 146 (97) 147 (97) 
Total number of AEs, n 1365 1196 
Total number of patients with 1, n (%) 151 (100) 152 (100) 
AE with fatal outcome (grade 5) 7 (5) 5 (3) 
Grade 3 AE 76 (50) 63 (41) 
Serious AE 44 (29) 43 (28) 
Treatment-related AE 134 (89) 117 (77) 
AE leading to treatment discontinuation 19 (13) 17 (11) 
AE leading to dose reduction 31 (21) 24 (16) 
AE leading to drug interruption 38 (25) 29 (19) 
Abbreviations: AE=adverse event; SD=standard deviation. 
Source: [17] 
[C008] What are the most frequent AEs of alectinib compared to other approved treatments 
in the 1st line therapy? 
Alectinib versus crizotinib (ALEX trial, direct comparison) 
The majority of the most common AEs (≥10% of patients in either arm) in the ALEX trial occurred 
in a higher proportion of patients (5% absolute difference) in the crizotinib arm compared with 
the alectinib arm. Crizotinib was associated with higher proportion of gastrointestinal AEs and liver 
enzyme abnormalities than alectinib. The AEs with a higher incidence with alectinib versus 
crizotinib were anaemia, myalgia, increased blood bilirubin level, increased weight, 
musculoskeletal pain and photosensitivity reaction. Constipation, fatigue, arthralgia, and rash 
were reported with a similar frequency (5% absolute difference) between treatment arms (Table 
6.2). 
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Table 6.2. Adverse events with ≥5% difference in incidence between arms, ALEX trial 
 
Event 
Patients with adverse event (%) 
Crizotinib 
N151 
Alectinib 
N152 
Any grade Grade 3–5 Any grade Grade 3–5 
Nausea 72 (48) 5 (3) 21 (14) 1 (1) 
Diarrhoea 68 (45) 3 (2) 18 (12) 0 
Vomiting 58 (38) 5 (3) 11 (7) 0 
ALT level increased 45 (30) 22 (15) 23 (15) 7 (5) 
AST level increased 37 (25) 16 (11) 21 (14) 8 (5) 
Blood bilirubin level increased 2 (1) 0 23 (15) 3 (2) 
Weight increased 
Myalgia 
Dysgeusia 
Anaemia 
Visual impairment 
Dizziness 
Vision blurred 
Photopsia 
Musculoskeletal pain  
Alopecia  
Photosensitivity reaction 
0 
3 (2) 
29 (19) 
7 (5) 
18 (12) 
21 (14) 
11 (7) 
9 (6) 
3 (2) 
11 (7) 
0 
0 
0 
0 
1 (1) 
0 
0 
0 
0 
0 
0 
0 
15 (10) 
24 (16) 
4 (3) 
30 (20) 
2 (1) 
12 (8) 
3 (2) 
0 
11 (7) 
1 (1) 
8 (5) 
1 (1) 
0 
0 
7 (5) 
0 
0 
0 
0 
0 
0 
1 (1) 
GGT level increased 10 (7) 2 (1) 1 (1) 1 (1) 
Peripheral oedema 42 (28) 1 (1) 26 (17) 0 
Abbreviations: ALT  alanine aminotransferase; AST  aspartate aminotransferase, GGT  -glutamyltransferase. 
Source: [17] 
Comparison of ADR frequencies according to the SmPCs of Alecensa, Xalkori and 
Zykadia 
In a naïve comparison of the ADR frequencies in the SmPCs, and without consideration of the 
longer median treatment length for alectinib, the frequencies were lower for alectinib than for 
crizotinib and ceritinib for diarrhoea (16%, 54% and 82%, respectively), vomiting (11%, 51% and 
63%, respectively), nausea (19%, 57% and 75%, respectively), and fatigue (not identified as 
ADR, 30% and 48%, respectively). These are ADRs that impact tolerability and everyday quality 
of life. 
Other reactions that may impact quality of life include oedema, which was not identified as an 
ADR for ceritinib, but was common with alectinib (30%) and crizotinib (47%), and myalgia, which 
was reported only for alectinib (28%).  
Pneumonitis/interstitial lung disease was also less frequent with alectinib than with crizotinib and 
ceritinib (0.7%, 3% and 2%, respectively). 
For all three agents the frequency of anaemia was 15%–17%, while neutropenia also occurred 
with crizotinib (22%). No infections were identified as ADRs for crizotinib, however. 
The frequencies of vision disorders were similar for alectinib and ceritinib at 7%–9%, but the 
frequency was markedly higher for crizotinib (63%). 
Abnormal liver laboratory results appeared least common with alectinib, while acknowledging 
that a comparison based on the varying items in the SmPCs is difficult. 
The frequencies of severe liver reactions appeared largely similar across the drugs (drug-
induced liver injury 0.7% (alectinib), hepatic failure <1% (crizotinib) and hepatotoxicity 1.1% 
(ceritinib). 
Bradycardia was less common with ceritinib (2%) compared with alectinib (9%) and crizotinib 
(13%). Unlike alectinib, both crizotinib and ceritinib are associated with QT interval prolongation 
(4% and 10%, respectively). This can have potentially serious consequences, including sudden 
death, but such outcomes are very rare. The risk of QT interval prolongation affects the handling 
of the patients however, and may require more monitoring of some patients. 
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Rash occurred in 18% of patients treated with alectinib, 13% of patients treated with crizotinib 
and 20% of patients treated with ceritinib.  
Photosensitivity is identified as an ADR for alectinib (9%), but not for the other two ALK 
inhibitors. 
See the full list of ADRs in Table 6.3. 
 
Table 6.3. Summary of adverse drug reaction frequencies across summaries of product 
characteristics of Alecensa, Xalkori and Zykadia 
 ADR frequencies, % 
System organ class 
ADRs (MedDRA)  
Alecensa 
(alectinib) 
N=405 
Xalkori 
(crizotinib) 
N=1722 
Zykadia 
(ceritinib) 
N=925  
Blood and lymphatic system disorders 
Neutropenia — 22 — 
Anaemia 17 15 15 
Leukopenia — 15 — 
Metabolism and nutrition disorders  
Decreased appetite  — 30 39 
Hyperglycaemia  — — 9 
Hypophosphataemia  — 6 5 
Nervous system disorders 
Neuropathy  — 25 — 
Dysgeusia 5 21 — 
Eye disorders 
Vision disorders 9 63 7 
Cardiac disorders 
Dizziness  — 26 — 
Bradycardia 9 13 2.3 
Pericarditis  — — 6 
Electrocardiogram QT interval 
prolonged  
— 4 10 
Syncope — 3 — 
Cardiac failure — 1 — 
Respiratory, thoracic and mediastinal disorders 
Interstitial lung disease/pneumonitis 0.7 3 2.1 
Gastrointestinal disorders 
Constipation  35 43 24 
Nausea  19 57 75 
Diarrhoea  16 54 82 
Vomiting  11 51 63 
Abdominal pain — 21 46 
Dyspepsia  — 8 — 
Stomatitis 3.0 — — 
Oesophagitis/oesophageal disorder — Oesophagitis  
2 
Oesophageal disorder 
14 
Gastrointestinal perforation  — <1 — 
Pancreatitis  — — 0.5 
Hepatobiliary disorders (including investigations) 
Liver laboratory test abnormalities — — 60 
Elevated levels of transaminases  — 32 — 
Abnormal liver function test results — — 2.2 
    Increased bilirubin level 18 — — 
    Increased AST level  15 — — 
    Increased ALT level  14 — — 
    Increased alkaline phosphatase 
level 
6.2 7 — 
DILI/hepatotoxicity (including DILI)  DILI 
0.7 
— Hepatotoxicity 
1.1 
Hepatic failure  — <1 — 
Skin and subcutaneous tissue disorders 
    Rash 18 13 20 
    Photosensitivity 9.1 — — 
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 ADR frequencies, % 
System organ class 
ADRs (MedDRA)  
Alecensa 
(alectinib) 
N=405 
Xalkori 
(crizotinib) 
N=1722 
Zykadia 
(ceritinib) 
N=925  
Musculoskeletal and connective tissues disorders 
Myalgia 28 — — 
Increased blood creatine 
phosphokinase level 
10 — — 
Renal and urinary disorders (including Investiga—tions) 
Blood creatinine level increased 7.2 8 22 
Renal cyst — 3 — 
Acute kidney injury 1.0 — — 
Acute renal failure/renal failure  — <1/<1 1.8 
Renal impairment — — 1.0 
General disorders and administration site conditions 
Oedema 30 47 — 
Fatigue  — 30 48 
Investigations 
Weight increased 12 — — 
Weight decreased  — — 28 
Lipase level increased  — — 4.8 
Amylase level increased  — — 7 
Blood testosterone decreased — 2 — 
Abbreviations: ADR=adverse drug reaction; ALT=alanine aminotransferase; AST=aspartate aminotransferase; 
DILI=drug-induced liver injury; MedDRA=Medical Dictionary for Regulatory Activities. 
Note: Frequencies ≥5% have been abbreviated to have no decimal.  
Source: Alecensa SmPC, Xalkori SmPC, Zykadia SmPC. 
 
Table 6.4. Overview of adverse events across relevant studies 
 ALEX ASCEND-4 
 Alectinib (N=152) Crizotinib (N=151) Ceritinib (N=189) 
Total number of AEs 1196 1365 NA 
Total number of deaths 35 (23) 40 (27) 48 (25.4)  
Any AE, n (%) 147 (97) 146 (97) 189 (100) 
Serious AE, n (%) 43 (28) 44 (29) 70 (37) 
Related AE, n (%) 117 (77) 134 (89) 184 (97) 
AE leading to treatment 
discontinuation, n (%) 
17 (11) 19 (13) 21 (11) 
AE leading to dose reduction, n 
(%) 
24 (16) 31 (21) 152 (80)a 
AE leading to dose interruption, n 
(%) 
29 (19) 38 (25) 131 (69) 
AE leading to withdrawal from 
study, n (%) 
0 2 (1) NA 
Grade 3 AE, n (%)b 63 (41) 76 (50) 148 (78) 
AE with fatal outcome (grade 5), 
n(%) 
5 (3) 7 (5) 11 (6) 
Abbreviations: AE=adverse event; NA=not available. 
aDose adjustment or interruption in ASCEND-4. 
bGrade 3 or 4 in ASCEND-4. 
Sources: [17], Zykadia EPAR variation II/12. 
In the ALEX trial serious AEs (SAEs) occurred at a similar frequency in patients in both treatment 
arms (28% with alectinib, 29% with crizotinib). 
 
Common individual SAEs included pneumonia (3% of patients in the alectinib arm vs. 3% of 
patients in the crizotinib arm), pneumonitis (1% vs. 3%), pulmonary embolism (1% vs. 2%) and 
increased alanine aminotransferase level (1% vs. 3%). 
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The only SAEs which occurred at a higher (2% difference) incidence in the alectinib arm were 
acute kidney injury (3% with alectinib vs. 0% with crizotinib) and lung infection (2% vs. 0%). 
Nausea was more frequent among patients receiving crizotinib ((0% vs. 2%) [17]. 
 
Table 6.5. Serious adverse events in the safety population occurring in greater than 2% 
patients in either arm, ALEX trial  
 Alectinib  
(N=152) 
Crizotinib  
(N=151) 
Patients with an SAE, n (%) 43 (28) 44 (29) 
Pneumonia, n (%) 5 (3) 4 (3) 
Lung infection, n (%) 3 (2) 0 (0) 
Pneumonitis, n (%) 2 (1) 4 (3) 
Pulmonary embolism, n (%) 2 (1) 3 (2) 
Pyrexia, n (%) 1 (1) 3 (2) 
ALT level increased, n (%) 1 (1) 4 (3) 
Acute kidney injury, n (%) 4 (3) 0 (0) 
Nausea, n (%) 0 (0) 3 (2) 
Abbreviations: ALT=alanine aminotransferase; SAE=serious adverse event. 
Source: Supplementary appendix from ALEX trial 
Network meta-analysis  
Alectinib versus ceritinib (NMA, indirect comparison) 
The MAH performed a Bayesian fixed effects NMA and an indirect comparison according to the 
Bucher method. The results are nearly identical because the network is elementary enough, such 
that the more complex fixed effects NMA does not use its additional capabilities in processing the 
data, compared to the simple Bucher method; see the efficacy section (5.2). Thus only the NMA is 
presented, with focus on the MAH base case fixed effects.  
The NMA performed by the MAH indicates: 
 Significantly fewer grade 3 or 4 AEs with alectinib than with ceritinib. 
 Significantly more grade 3 or 4 AEs with ceritinib than with chemotherapy. 
 Significantly more dose reductions or treatment interruptions with alectinib, ceritinib and 
crizotinib than with chemotherapy. This result is driven by the PROFILE 1014 crizotinib 
versus chemotherapy comparison. In PROFILE 1014, data are Grade 3 or 4 elevations of 
ALT managed with dose interruptions or dose reductions. For ASCEND-4 and ALEX, data 
are any treatment interruptions or dose reductions due to an AE. Additionally, the 
differences in dose reductions or treatment interruptions may be due to differences in time 
on treatment/drug exposure. 
 No significant differences for discontinuations due to AEs. 
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Figure 6.1. Network meta-analysis odd ratios for grade 3 or 4 adverse events (base case) 
 
Red line: Odds ratio of 1 is the line of no effect and odds ration less than 1 indicates lower odds of event (fewer adverse 
events) compared with the control. 
Abbreviations: AEadverse event; ALECalectinib; CERceritinib;CHEMOchemotherapy; CrIcredible interval; 
CRZcrizotinib. 
Source: [17]. 
Table 6.6. Network meta-analysis summary of safety (base case)  
Comparison 
Endpoint (analysis), odds ratio (credible interval) 
Grade 3 or 4 AEs Discontinuation due to AEs 
Treatment interruption or 
dose reduction 
Alectinib versus 
chemotherapy 
0.81 (0.44–1.52) 0.50 (0.20–1.27) 5.25 (1.73–22.92) 
Alectinib versus 
crizotinib 
0.65 (0.41–1.04) 0.87 (0.43–1.77) 0.71 (0.44–1.15) 
Alectinib versus 
ceritinib 
0.36 (0.16–0.79) 0.62 (0.19–2.05) 1.02 (0.30–4.68) 
Crizotinib versus 
chemotherapy 
1.24 (0.81–1.91) 0.58 (0.31–1.05) 7.36 (2.72–29.50) 
Ceritinib versus 
chemotherapy 
2.25 (1.42–3.61) 0.81 (0.38–1.67) 5.15 (3.26–8.39) 
Ceritinib versus 
crizotinib 
1.82 (0.96–3.44) 1.41 (0.54–3.61) 0.70 (0.16–2.15) 
Abbreviation: AE  adverse event. 
Note: Odds ratio of 1 indicates no effect, and odds ratio of less than 1 indicates lower odds of an event compared with the 
control. Bold indicates significance based on 95% credible intervals. 
Source: [17] 
 
[C0008] What is the frequency of adverse events of special interest for alectinib? 
Hy’s law is a set of clinical and laboratory signs indicating drug-induced liver injury. Cases were 
defined as increases of aspartate aminotransferase or alanine aminotransferase level of more 
than three times the upper limit of normal or baseline value (if baseline values were already 
increased), together with concomitant increases of total bilirubin level of more than two times the 
upper limit of normal in the absence of cholestasis. The scatter plot analysis of total bilirubin level 
versus alanine aminotransferase and aspartate aminotransferase level revealed five patients (two 
in the crizotinib arm and three in the alectinib arm) falling into the potential Hy’s law quadrant.  
Two patients (both in the alectinib arm) did not qualify as true Hy’s law cases after detailed review 
because there was not a close temporal relationship between the increase of the levels of the 
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aminotransferases and bilirubin, or being indicative of cholestasis and underlying hepatic 
pathology. One of these patients experienced grade 4 drug-induced liver injury, which was 
considered treatment related, and treatment was permanently discontinued because of the event. 
On review, the other three patients (two patients in the crizotinib arm and one patient in the 
alectinib arm) met Hy's law criteria. 
The two patients in the crizotinib arm experienced grade 4 drug-induced liver injury; both events 
were considered treatment related. One of these patients permanently discontinued treatment 
because of the event. One had discontinued treatment because of grade 4 elevated alanine 
aminotransferase level before the diagnosis of drug-induced liver injury. The patient in the 
alectinib arm experienced grade 4 hepatoxicity; this was considered treatment related and led to 
treatment discontinuation [17] . 
[C0005] What are the susceptible patient groups that are more likely to be harmed through 
the use of alectinib? 
Generally, patients with an preexisting condition that overlaps the toxicity profile of alectinib might 
be considered at greater risk by the treatment. Patients with bradycardia may thus have an 
increased risk of symptomatic toxicity, since the preexisting bradycardia might be aggravated with 
alectinib. 
Patients with moderate to severe hepatic impairment may be more likely to be harmed since the 
elimination of alectinib is predominantly through metabolism in the liver, and hepatic impairment 
may increase the plasma concentration of alectinib and/or its major metabolite M4. On the basis 
of a population pharmacokinetic analysis, alectinib and M4 exposures were similar in patients with 
mild hepatic impairment and normal hepatic function, however. 
Age, body weight, race and sex had no clinically meaningful effect on the systemic exposure of 
alectinib and M4 [5]. 
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7 PATIENT INVOLVEMENT  
HTA doers recognise that patients and those who support them have unique knowledge about 
what it is like to live with a specific disease or medical condition. Patients can help to understand 
unique perspectives by presenting patients’ and carers/care-givers’ views and experiences. 
Patients can describe advantages and disadvantages of health interventions based on patients’ 
experiences and values concerning a new intervention [19]. Thus, one patient could be identified 
who volunteered to participate in this assessment. 
With this patient, an one hour telephone interview was performed on the 5th of January 2018. The 
patient provided orally informed consent.  
The patient was diagnosed with ALK-positive advanced NSCLC and with bone but not CNS 
metastases in fall 2017. The patient had received crizotinib for four weeks, prescribed by an 
oncologist. The patient had never smoked and has no further chronic diseases.  
The summary of the most important answers related to the different questions on the impact of 
condition; experience with currently available medicines; expectations of the medicines being 
assessed; and additional information which the patient believed would be helpful to the HTA 
researchers are provided in Table 7.1.  
Table 7.1 Main results from the interview 
Questions related to  Patient's (ALK-positive advanced NSCLC) view 
Impact of ALK-positive 
advanced NSCLC 
The patient highlighted that dealing with advanced NSCLC has a significant 
impact on physical, psychological and emotional well-being (such as uncertainty 
and mood oscillation) as well as quality of life. Difficulties in daily activities like 
housework, office work or sports activities (swimming, walking and cycling) were 
prominent at the beginning of the disease, before starting a specific therapy and 
pain medications primarily for pain related to bone metastases. The patient has 
almost no lung cancer symptoms (two times chest pain in the morning) and 
acknowledges the importance of sport activities and healthy nutrition for a better 
physical and emotional life during the illness. The impact on informal caregivers 
(i.e., partner, mother and father) was also recognised, especially the emotional 
part. No financial implications were currently expected. The patient emphasised 
that lack of specific lung symptoms could have impacted on experiences and 
answers related to specific questions. 
Experience with 
currently available 
medicines (crizotinib) 
The patient highlighted the importance of reducing pain related to bone 
metastases, decreasing pain medication and increasing physical well-being and 
quality of life for emotional well-being. Even light sporting activities become 
possible.  
The twice daily oral administration did not cause problems. After four weeks of 
crizotinib treatment, an increase in liver enzymes necessitated treatment 
interruption for one week.  
At the beginning of the treatment the patient described vision problems of short 
duration four times. A number of times patient had a sort of strange feeling in left 
arm, described as very annoying (like arm did not belong to the body; not when 
touch it [arm], but more mentally). The patient emphasised that this short 
treatment duration with crizotinib could impact on experiences and answers 
related to specific questions. 
Expectations of the 
medicine being 
assessed (alectinib) 
The patient identified three highly important expectations concerning new 
treatment options: life extension, fewer side effects and a better quality of life. 
The patient does not have brain metastases but read about them on a Facebook 
group where new treatment options and clinical trials are discussed; patients with 
brain metastases are highly interested in alectinib.  
The patient mentioned that access should not be constrained due to financial 
restriction, especially for people with brain metastases. The patient highlighted 
that that lack of specific lung symptoms and the short treatment duration with 
crizotinib could impact on experiences and answers related to specific questions. 
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Additional information 
which patient believe 
would be helpful to the 
HTA researchers 
No further issues were raised by the patient. 
 
The patient could not envisage any special group of patients with particular issues in managing 
their condition, with using currently available medicines or who could benefit the most from 
alectinib. The patient stressed the importance of a good communication with physicians 
concerning information on the condition, treatment choices, adverse effects, treatment plans and 
the overall process; patients want to be good informed and need to have a trust in physicians who 
have the knowledge and the main responsibility.  
At the end of the interview the patients was asked for the key messages. The patient stressed the 
importance of extending the life, fewer side effects and no financial implications for patients.  
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8 DISCUSSION 
Efficacy 
Direct comparison with crizotinib 
Alectinib first-line therapy for patients with ALK-positive NSCLC was compared with crizotinib 
therapy in one open-label randomised phase III trial. Alectinib therapy resulted in a substantial 
and statistically significant increase in PFS (the primary outcome) compared with crizotinib 
therapy in the ALEX study. While the median PFS was not reached in the alectinib arm for the 
investigator-based PFS, the IRC showed a difference in medians of 15.3 months (25.7 vs 10.4 
months, respectively).The PFS curves for alectinib and crizotinib from the ALEX study did not 
separate until 6 months. Possible causes or explanations for this pattern could be: 
- A difference in the propensity for secondary resistance to the two agents. This is supported 
by the longer duration of response observed for alectinib versus crizotinib, and might 
potentially be the primary mechanism for the overall difference in efficacy. 
- The presence of subpopulations within the study population with more aggressive tumours 
progressing early. The pattern could thus indicate less (and similar) efficacy of both agents 
in more aggressive tumours. Theoretically it could be caused by primary resistance to both 
agents.  
The PFS benefit was consistent for patients with CNS metastases at the baseline. The results for 
the key secondary endpoint of time to CNS progression clearly demonstrated superiority of 
alectinib over crizotinib. This is of high clinical relevance as CNS metastasis and progression 
affects both the symptoms and the quality of life, as well as the prognosis of the patients. This 
finding may partly be explained by the fact that crizotinib unlike alectinib is a substrate for the P-
glycoprotein efflux pump, which is responsible for transporting substances over the blood–brain 
barrier. 
Median OS was not reached in either treatment arm; the event rate was 23% and 27%, for 
alectinib and crizotinib respectively. The OS analysis was outside the test hierarchy since the 
previous secondary endpoint (ORR) was not statistically significant. The study was not powered 
to demonstrate any statistically significant difference in OS between alectinib and crizotinib. Also, 
even though further OS analyses will be conducted, the results of this endpoint will be impacted 
by subsequent therapies. With the caveat that applying GRADE to an interim outcome might 
scientifically be not sound, the results presented for OS have currently a high degree of 
uncertainty ('low quality of evidence").  
In the direct comparison of alectinib and the comparator crizotinib, the quality of evidence is high 
for the majority of outcomes (PFS, ORR, Time to CNS progression), moderate for major safety 
outcomes and very low for the outcome related to QoL - Time to deterioration in EORTC QLQ-30 
global health score. The latter is associated with a high risk of bias due to the open-label design 
and low baseline values of completed questionnaires at the baseline. The primary investigator-
assessed PFS results were consistent with those of the blinded independent reviewers, 
suggesting a lack of bias in investigator assessments. More patients in the alectinib arm than in 
the crizotinib arm in ALEX were considered responders, but the difference was not statistically 
significant.  
Indirect comparison with ceritinib  
Alectinib also resulted in a statistically significant increase in PFS compared with ceritinib in an 
indirect comparison. No significant differences were observed between alectinib and ceritinib with 
regard to OS. The OS results may be affected by treatment arm crossover and data immaturity 
(median OS was not observed for some treatment arms in the trials). Because of the limited 
number of studies, no adjustment of patient characteristics was made at the study level. The NMA 
model in the base case presented by the MAH assumes no between-study heterogeneity. This 
assumption cannot be validated through a data-derived heterogeneity estimation because of the 
inclusion of only a single study in each direct treatment comparison. Analyses to check the 
sensitivity of the results for varying heterogeneity are not included in the submission, except for 
the computation of a random effects NMA with a vague a priori between-study-heterogeneity 
assumption.  This analysis showed wide credible intervals leading to non-significant results and 
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therefore reveals the dependency of the the fixed effects NMA results on the assumed between-
study-heterogeneity. In conclusion, the results derived from the fixed effects NMA model are 
partly based on an unvalidated assumption. 
In the absence of a direct comparison, despite the uncertainties involved, the results of the NMA 
are presented in the assessment of relative efficacy compared with the relevant comparator 
ceritinib. Because of the uncertainties described above, regarding the adequacy of the 
comparison, the observed results have to be regarded as unsure.  
Additional limitations to interpretation of the NMA results included 
 The potential confounding of OS data due to cross-over that was allowed in three of the 
trials (PROFILE 1014, PROFILE 1029 and ASCEND-4) and immaturity of OS data reported  
 The differences in the chemotherapy arms of the ASCEND-4 and PROFILE trials 
 The results from the PROFILE 1029 clinical study were excluded in the base case result of 
the NMA. In an alternative analysis where the results from PROFILE 1029 were included in 
the NMA, the HRs were slightly lower. Therefore, the exclusion of PROFILE 1029 does not 
affect the results in a major way. In addition, a Bucher analysis was done, showing similar 
results as the NMA. 
Safety 
Direct comparison with crizotinib 
The same numbers of AEs of any grade were reported for both alectinib and crizotinib (97%) in 
the randomized phase III ALEX trial. Serious AEs occurred at a similar frequency in patients in 
both treatment arms (29% with crizotinib, 28% with alectinib).  
In the ALEX trial the incidence of AEs leading to treatment discontinuation was similar with 
alectinib compared with crizotinib (11% vs. 13%). The patients in the alectinib arm had longer 
exposure to treatment (17.9 months vs. 10.7 months for crizotinib) but numerically lower incidence 
of treatment interruptions and dose reductions and a lower cumulative frequency of grade 3 or 
higher adverse events (41% vs. 50% in the crizotinib arm). 
The only serious AEs which occurred at a higher (2% difference) incidence in the alectinib arm 
were acute kidney injury (3% with alectinib vs. 0% with crizotinib) and lung infection (2% vs. 0%). 
For any grade AE, myalgia was reported more frequently for alectinib than crizotinib (16% vs. 2%) 
and anemia (20% vs. 5%). 
Alectinib appears to have a more favourable safety profile compared with crizotinib with regard to 
non-serious AEs that tend to affect quality of life, such as nausea, diarrhoea and vomiting, as well 
as severe (Grade ≥3) events. This impression is also supported by lower observed frequencies of 
treatment interruptions and dose reductions.  
Since there was a very small proportion of patients who were older than 65 years, the information 
about AEs in this group is limited. However, as the ALK-positive patient population is generally 
younger, this is of minor importance.  
Because of limited patient numbers included in the studies and because of limited follow-up times, 
the final safety profiles of the products remain to be established. Given that all approvals are 
based on phase III RCTs, it appears very unlikely that major differences in the frequencies of 
common AEs will be seen, however.  
Also a naïve comparison of established AE frequencies in the SmPCs was made in the report in 
order to investigate the safety of the products in a broader population, since several other studies 
were included. The lower frequencies for alectinib of diarrhoea, vomiting and nausea noted in the 
ALEX study, were supported in this analysis.  
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Indirect comparison with ceritinib  
Indirect comparisons between alectinib and ceritinib were performed using NMA and a naive 
comparison of the established AE frequencies as per the SmPCs, respectively. Both analyses 
indicated an overall superior safety profile for alectinib over ceritinib, with the exception of a few 
non-serious AEs. Due to the high degree of uncertainty naturally inherent in any indirect 
comparison, no firm or formal conclusion is possible. Based on the available data, it might be 
considered reasonable to assume that the overall burden of toxicity from alectinib is at least not 
worse than that of ceritinib. 
Quality of life 
A statistically non-significant trend favouring alectinib over crizotinib was observed for patient-
reported global health status/health-related quality of life (HRQoL) (HR 0.72, 95% CI, 0.38–1.39). 
In both arms a clinically meaningful improvement in HRQoL and multiple lung cancer symptoms 
was observed. The duration of such improvement was markedly longer in the alectinib arm. This 
is not unexpected, given the longer progression-free interval and the reduced risk of, and time to, 
CNS-metastases observed for the alectinib patients. As the design of the study was open label, 
there is a risk that the results of the patient-reported AEs and the quality of life could be skewed, 
affecting the validity of the results. Only 65% of the patients answered the quality-of-life questions 
at the baseline, potentially affecting the reliability of the results.  
Extrapolation 
In addition to the assessment of relative efficacy and safety, an extrapolation of survival data was 
performed. Such data can be used for modelling within health economics. The aim of this section 
is to discuss extrapolation models, estimating survival data over time.  
There is uncertainty about the treatment sequence after progression that affects the extrapolation 
results. In the publication of the ALEX trial the following was written: ‘Per protocol, crossover 
between trial groups was not allowed; patients assigned to crizotinib may have received alectinib 
after disease progression (in countries where alectinib was already approved or available).’ Data 
were not collected and reported in the study. The efficacy of crizotinib after failure of alectinib 
therapy is presently unknown. From a pharmacological point of view, activity of crizotinib in a 
post-alectinib setting might not necessarily be assumed, while activity in subsets of patients, 
depending on resistance mechanisms, may at this point not be ruled out. Moreover, no 
statistically significant increase of OS has yet been shown for any of the currently approved ALK 
inhibitors.  
Patient involvement  
Even though patient groups with ALK-positive NSCLC could not be involved in this assessment, 
thankfully one individual patient living with ALK-positive NSCLC agreed to participate in a one 
hour telephone interview. The most important issues concerning new therapeutic options life 
extension, fewer side effects and no financial implications for patients.  
Limitations of including only one patient in this rapid REA are related to the lack of the broader 
patient view. Specifically, due to the of lack of specific lung symptoms and a short treatment 
duration with crizotinib the patient's experiences with the condition, treatment and expectations 
might not be applicable to heavily pre-treated patients with severe symptoms. 
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9 CONCLUSION 
From direct comparison, based on high quality evidence, alectinib demonstrated a substantial and 
statistically significant increase in PFS. It is also associated with a statistically significant longer 
time to CNS progression compared to crizotinib. This is of high clinical relevance as CNS 
metastasis and progression affects both the symptoms and the quality of life, as well as the 
prognosis of the patients. The OS data are immature and therefore preclude firm conclusions. 
From an indirect comparison, an advantage of alectinib versus ceritinib is indicated for PFS, but 
because of uncertainties regarding the adequacy of the comparison, this observed result has to 
be regarded as unsure.  
From direct comparison, the serious AEs and AEs leading to treatment discontinuation occurred 
at similar frequencies for both alectinib and crizotinib. Alectinib appears to have a more favourable 
safety profile compared with crizotinib with regard to non-serious AEs that tend to affect quality of 
life as well as severe (grade ≥3) events. This notion is supported by the lower frequencies of 
treatment interruptions and dose reductions observed for alectinib in the direct comparison to 
crizotinib. Thus markedly lower frequencies for alectinib were reported for diarrhoea, vomiting and 
nausea. For any grade AEs, myalgia and anaemia was reported more frequently for alectinib than 
crizotinib. 
While conclusions on relative safety compared with ceritinib should be made with caution, both 
the NMA and the comparison of the established adverse events profiles in the SmPCs indicate an 
overall superior safety profile of alectinib. 
Patients receiving alectinib had clinically meaningful improvement in HRQoL for a longer duration 
compared with patients receiving crizotinib. Overall a trend favouring alectinib was observed in 
HRQoL, but the difference was not statistically significant. 
As only one patient was interviewed, no general conclusions can be drawn. 
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APPENDIX 1. EXTRAPOLATION OF PFS AND OS/SURVIVAL ANALYSIS 
Introduction 
The aim of this section is to discuss extrapolation models, estimating survival data over time. 
Assessing interventions that have an impact on survival requires accurate estimation of the 
survival benefit associated with the new intervention. This is often difficult since clinical trials 
commonly have a limited observation period and censored survival data; therefore extrapolation 
techniques need to be used to obtain the estimates of the full survival benefit. Where such 
analyses are not completed, estimates of the survival benefit will be restricted to what is directly 
observed in relevant clinical trial(s). This will most likely represent an underestimation of the true 
survival gain [59].  
There are a number of methods available to extrapolate survival data, such as the exponential, 
Weibull, Gompertz, log-logistic, log-normal and gamma parametric models, as well as the more 
complex or flexible models. The different methods have varying functional distributions and often 
result in diverse survival estimates, especially when an extensive amount of the observed survival 
data needs to extrapolated. Consequently it is important to justify the particular extrapolation 
method that is selected[59].  
Statistical tests are often used to compare different extrapolation models and their relative fit to 
the observed trial data. This is important when the observed data are mature and have a small 
amount of censoring present and the extrapolation required is negligible. When a large portion of 
the survival curves need to be extrapolated, it is of even greater importance to justify the 
plausibility of the extrapolated portion of the survival model chosen, as this is likely to have a very 
large impact on the estimated mean survival. Techniques used for validation may include external 
data sources, the biological plausibility of the extrapolated survival curves or clinical expert 
opinions [59].  
The clinical and statistical assessment performed by the MAH concludes that the two most 
plausible options for Progression Free Survival (PFS) and three most plausible options for Overall 
Survival (OS) were identified and shown in the summary table (Table A1). In all of these scenarios 
a survival benefit for alectinib compared to crizotinib was estimated. The estimated mean increase 
in PFS ranged from 18.9 months to 32.3 months while the estimated mean increase in OS ranged 
from 13.4 to 47.5 months. It can be seen that when considering the observed survival time, only a 
small amount of the total expected gain can be observed.  
Table A1. Summary of estimated mean survival in months 
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Model Description 
Model framework 
The model that the MAH has used is a partitioned survival model often referred to as an area 
under the curve (AUC) model, where health states are based on the partitioning of overall survival 
(OS) into progression free survival (PFS) and post progression survival (PPS). At each discrete 
point in time, the proportion of patients in the progressed health state is assumed to be the 
difference between OS and PFS (progression=OS – PFS). At randomisation, all patients are 
assumed to be alive and progression free and can either remain within the same health state or 
move to the progressed or death states at the end of each subsequent cycle.  
Figure A1. Model structure. 
 
 
Abbreviations: OS=overall survival; PFS=progression-free survival. 
Cycle Length 
The cycle length used in the model is one week. As stated by the MAH, shorter cycle lengths 
allow a more accurate estimation of the time patients remain in each health state.  
Time Horizon 
The model allows for a time horizon of up to 30 years, so the expected lifetime horizon of a non 
small lung cancer patient can be captured. 30 years was chosen because 95% or more of the 
patients are dead at this time, independent of the OS extrapolation. 
Discounting 
In the analysis, there is no discounting of future health benefits. However, the model allows for 
different discount rates to be applied, which are applied after the first year and on a yearly basis 
thereafter.  
Statistical Analysis of Survival Data 
The parametric functions assessed in this model include log-logistic, Weibull, log-normal, 
generalised gamma, Gompertz and exponential functions. The AUC can be calculated on the 
basis of:  
1. A parametric function from randomisation extrapolated to lifetime 
2. Kaplan–Meier data with a parametric extrapolation of the tail 
The model allows for the option where the extrapolated treatment effect of alectinib is not 
maintained; thus after a user-defined time point the hazards of alectinib and crizotinib are set 
equal.  
Survival data in ALEX 
The PFS benefit of alectinib versus crizotinib was statistically significant in the log-rank test 
stratified for the covariates race (Asian vs. non-Asian) and CNS metastases at the baseline. PFS 
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results were consistent in both investigator (INV) and Independent Review Comittee (IRC) 
assessments. At the date of data cutoff, death had occurred in 75 patients in the ITT population 
(35 patients, 23%, in the alectinib group and 40 patients, 26%, in the crizotinib group). The HR of 
death was 0.76 (95% CI 0.48–1.20), and the median OS was not estimable in either group. Table 
A2 summarises the PFS and OS results. Figure A2 and   
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Figure A3 show the Kaplan–Meier curves for PFS and OS, respectively. 
Table A2. Progression-free survival and overall survival summaries 
 
Abbreviations: CI confidence interval; CNS=central nervous system; EP=endpoint; INV=investigator assessed; 
IRC=independent review committee; OS=overall survival; NR=not reached: PFS=progression-free survival, 
Source: MAH extrapolation file. 
Figure A2. Kaplan–Meier plot of investigator-assessed progression-free survival (intent-to-treat 
population)  
 
Abbreviations: CI=confidence interval; CNS=central nervous system; IRC=independent review committee. 
Source: MAH extrapolation file. 
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Figure A3. Kaplan–Meier plot of overall survival (intent-to-treat population) 
 
Abbreviations: CI=confidence interval; CNS=central nervous system; IRC=independent review committee. 
Source: MAH extrapolation file. 
Selection of Parametric Function  
Cumulative Hazard Plots and Interpretation 
Cumulative hazard plots are analysed to assess whether each treatment arm should be analysed 
separately or both treatment arms should be analysed jointly. The proportional hazards 
assumption is thought to hold if the lines are parallel. Figure A4 and Figure A5 show the log-
cumulative hazard plots for PFS and OS, respectively, which are transformations of the Kaplan–
Meier plots. The plots intersect at multiple points, indicating that the proportional hazards 
assumption may not hold and that each treatment arm should be analysed separately for the 
purpose of extrapolation.  
Figure A4. Log-cumulative hazard plots of PFS (INV) (cutoff date February 9th 2017) 
 
Source: MAH extrapolation file. 
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Figure A5. Log-cumulative hazard plots of overall survival (cutoff date February 9th 2017) 
 
Source: MAH extrapolation file. 
Parametric Extrapolations and Statistical Fit 
Statistical measures such as Akaike’s information criterion (AIC) and the Bayesian information 
criterion (BIC) as well as hazard and residual plots are methods of assessing the fit of alternative 
models to underlying data from the clinical trial. In addition, visual inspection is used to assess the 
clinical plausibility of the outcomes when different extrapolation methods are applied. However, 
the use of such measures is useful only for determining the fit of the models to the observed data 
– these measures do not tell us anything about the plausibility of the extrapolations [59].  
Because of the non-parallel log-cumulative hazards indicating that the proportional hazards 
assumption does not hold, separate parametric models were fitted to the observed trial data by 
the MAH. Parametric functions were assessed on the basis of model goodness of fit with the use 
of (AIC) and (BIC), as well as a visual assessment of each parametric function. On the basis 
solely of AIC and BIC statistics (the lowest being the best fit), the log-normal function had the best 
fit for both the alectinib arm and the crizotinib arm for PFS.  
Similarly to PFS, OS displayed intersecting log-cumulative hazards. Separate parametric models 
were therefore fitted to each treatment arm. On the basis of statistical goodness of fit, the 
exponential model provides the best fit for alectinib and the log-normal model provides the best fit 
for crizotinib. 
Table A3. Parametric functions goodness of fit for ALEX PFS (INV) 
Parametric Model PFS  Alectinib arm Crizotinib arm 
AIC BIC AIC BIC 
Exponential 372.50 (5) 375.52 (4) 381.97 (6) 384.99 (5) 
Weibull 370.83 (4) 376.88 (5) 375.26 (4) 381.30 (4) 
Log-normal 363.61 (2) 369.66 (1) 368.66 (1) 374.70 (1) 
Generalised gamma 362.42 (1) 371.50 (2) 370.66 (3) 379.72 (3) 
Log-logistic 367.43 (3) 373.48 (3) 370.66 (2) 376.69 (2) 
Gompertz 374.50 (6) 380.55 (6) 381.20 (5) 387.23 (6) 
Abbreviations: AIC=Akaike’s information criterion; BIC=Bayesian information criterion; PFS=progression-free survival. 
Source: MAH extrapolation file. 
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Table A4. Parametric functions foodness of fit for ALEX OS 
Parametric Model OS Alectinib arm Crizotinib arm 
AIC BIC AIC BIC 
Exponential 246.59 (1) 249.61 (1) 234.24 (5) 237.26 (2) 
Weibull 247.98 (4) 254.03 (4) 232.71 (3) 238.74 (4) 
Log-normal 247.97 (2) 254.03 (3) 230.88 (1) 236.91 (1) 
Generalised gamma 249.79 (6) 258.86 (6) 232.79 (4) 241.84 (6) 
Log-logistic 247.91 (3) 253.96 (2) 232.10 (2) 238.13 (3) 
Gompertz 248.60 (5) 254.63 (5) 234.72 (6) 240.76 (5) 
Abbreviations: AIC=Akaike’s information criterion; BIC=Bayesian information criterion; OS=overall survival. 
Source: MAH extrapolation file. 
Hazard trends 
Table A3 and   
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Table A4 provide the hazard trends for each extrapolation and treatment arm. 
Table A5. Hazard trends of investigator-assessed progression-free survival 
 
Source: MAH extrapolation file. 
Table A6. Hazard trends of overall survival 
 
Source: MAH extrapolation file. 
Results for Preferred Extrapolation Models 
Preferred PFS extrapolation models 
According to the MAH PFS, based on statistical fit, visual inspection and external validation, three 
models were considered to have an optimal fit – exponential, Weibull and log-normal models 
(illustrated in Figure A6 and Table A7).  
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Figure A6. Progression-free survival extrapolations 
 
 
Abbreviations: KM=Kaplan–Meier; PFS=progression-free survival. 
Source: MAH extrapolation file. 
Table A7. Results of selected progression-free survival extrapolations 
 
Abbreviations: AIC=Akaike’s information criterion; BIC=Bayesian information criterion; PFS=progression-free survival. 
Source: MAH extrapolation file. 
As stated by the MAH, the log-normal function has a statistically and visually good fit with regards 
to the observed data. However, the longer tail after the observed period is considered clinically 
implausible on the basis of clinical feedback; the results are also inconsistent with PFS for 
crizotinib in the randomised controlled trial PROFILE 1014. In this context the MAH argues that 
the most plausible extrapolations are either exponential or Weibull functions for both arms with 
either investigator or individual review committee datasets. 
According to the MAH the exponential parametric model for both treatment arms had a good fit on 
the basis of clinical feedback. The feedback was that the proportion of patients with PFS within a 
five year time frame, as predicted in the model, was considered realistic and potentially clinically 
plausible. From a technical point of view, the MAH recognises that the use of the exponential 
distribution results in a constant hazard, which inevitably leads to proportional hazards that 
apparently does not hold on the basis of the log-cumulative hazards crossing. The MAH argues 
that it is not sufficient to exclude the parametric distribution solely on the basis of the log-
cumulative hazard plots. The choice should also be based on:  
 Clinical plausibility of the model predictions 
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 Whether the log-cumulative hazard plots are relatively straight lines (implies that a Weibull 
model would be appropriate) 
 Whether they indicate radical fluctuations or shifts that require piecewise or more flexible 
models 
 Whether each model sufficiently fits the observed data both statistically and visually 
Taking these elements into account, the MAH considers the exponential function as an 
appropriate option for PFS extrapolation, despite its limitations.  
 Discussion regarding the PFS extrapolations  
The authoring team discussed the methods used for extrapolating PFS for comparing alectinib 
with crizotinib, in the context of the identified pros and cons of using the parametric functions 
presented by the MAH.  
When reviewing the exponential function, the authoring team agrees that it has a suboptimal fit to 
the observed data with regard to the AIC and BIC statistics. Another limitation when extrapolating 
both treatment arms with the exponential function is that it results in a constant hazard ratio 
throughout the model’s time horizon. A constant hazard contradicts the cumulative hazards plot 
that indicated a nonparallel log-cumulative hazard with multiple intersecting points.  
The authoring team does, however, agree with the MAH that the exponential function results in a 
clinically plausible relative effectiveness between alectinib and crizotinib. Even though the log-
cumulative hazards plot indicates that the proportional hazards assumption does not hold, it is 
important to understand that the exponential function might still be the best extrapolation method 
when considering the results it generates.  
The Weibull function has a better fit when compared with the exponential function with regard to 
the goodness of fit statistics from AIC and the BIC. The Weibull function results in a decreasing 
momentary (cycle to cycle) hazard ratio in the model, which could indicate a plausible method of 
extrapolation when considering the results from the log-cumulative hazards plot. However, when 
the PFS curves are extrapolated with the Weibull function, the momentary (cycle to cycle) hazard 
ratio ranges from 0.98 (cycle 6) to 0.063 at the end of the model’s time horizon. While the 
authoring team agrees with the MAH that the Weibull function results in a clinically plausible 
scenario, there is a degree of uncertainty that the hazard ratio would continue to decrease 
throughout the model’s time horizon and result in such so low hazard ratios.  
Although the log-normal function has the best statistical fit, the function results in a long tail. The 
authoring team recognises the lack of evidence that would support such a tail and the 
extrapolation method results in a clinically implausible PFS as stated by the clinical expert that the 
MAH consulted.  
Preferred OS extrapolation models 
The different options for extrapolating OS are shown in Figure A7 and Table A8. 
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Figure A7. Extrapolation options for progression-free survival and overall survival 
 
Abbreviations: KM=Kaplan–Meier: OS=overall survival; PFS=progression-free survival. 
Source: MAH extrapolation file. 
 
Table A8. Results of selected extrapolation models 
 
Abbreviations: HR=hazard ratio; OS=overall survival; PFS=progression-free survival. 
Source: MAH extrapolation file. 
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Given the immaturity of the OS data (as of February 9th 2017, 27% of patients in the crizotinib 
arm had died and 23% of patients in the alectinib arm had died), applications of Kaplan–Meier 
curves with parametric tails would add no additional value in the extrapolation according to the 
MAH.  
Option 1 
As stated by the MAH, option 1 has a good statistical and visual fit for both arms. The concern 
with using the exponential function for OS in both arms is that there are few long-term survivors 
and the long-term predictions for the crizotinib arm are lower than what was observed in the 
PROFILE 1014 clinical trial; see Table A9 
Option 2 
The generalised gamma extrapolation for both alectinib and crizotinib generates a plausible 
scenario, firstly because it satisfies the clinical feedback that the curves need to start converging 
in the long run, rather than being separated further apart. Secondly, the estimated OS benefit of 
crizotinib (based on ALEX) is closer to the 4-year landmark analysis of crizotinib in the PROFILE 
1014 study.  
Option 3 
According to the MAH, it was deemed implausible to use the log-normal function for OS because 
of a greater separation of the curves at around 150 months compared with 50 months. In addition 
to option 3, a scenario was assessed assuming no additional OS benefit beyond the mean 
extrapolated PFS (approximately 35 months). According to the MAH, this scenario was 
considered conservative.  
External Data 
Given the short-term OS data for ALEX, more long-term OS data for crizotinib were sought to 
validate the most appropriate distribution. In September 2017, updated results from the PROFILE 
1014 study were received. PROFILE 1014 and ALEX are different studies and differ, for example, 
in the proportion of patients with brain metastases at the baseline (27% in PROFILE 1014 vs 40% 
in ALEX). The Kaplan–Meier curve from PROFILE 1014 was digitised and assessed against the 
OS predictions of the parametric models used for crizotinib, in order to validate the results 
Table A9. Crizotinib overall survival model comparisons with PROFILE 1014 
 
Abbreviation: KM=Kaplan–Meier. 
Source: MAH extrapolation file. 
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Discussion regarding the OS extrapolations (authoring team) 
According to the MAH, the exponential and generalised gamma functions are reasonable 
extrapolation methods for OS. The exponential function has the best statistical and visual fit for 
the alectinib arm, and the log-normal function has the best statistical and visual fit for the crizotinib 
arm. The results indicate that the different treatment arms could be fitted with separate parametric 
functions (e.g., exponential and generalised gamma functions). The authoring team does, 
however, agree with the MAH that the treatment arms should be modelled with the same 
parametric function but with different fits, as it would require substantial justification to use 
differently shaped distributions.  
The MAH does, however, highlight a concern that the exponential function underestimates the 
crizotinib arm when compared with long-term results from the PROFILE 1014 study. Although this 
is true, the difference between the exponential and generalised gamma functions is small, roughly 
2%. From these results it is not fully clear which parametric function generates the most plausible 
outcome.  
The authoring team does, however, agree that the generalised gamma function results in a more 
plausible long-term extrapolation with regard to the converging effect of the survival curves. There 
is a degree of uncertainty regarding the relative effectiveness between alectinib and crizotinib: the 
relative effectiveness continues to increase and is at its largest after what was observed in the 
ALEX study. The exponential function might result in a more plausible relative effectiveness, but 
as discussed in the PFS section, this results in a constant hazard ratio, which the log-cumulative 
hazard plot does not support.  
The authoring team agrees with the MAH that the log-normal function results in an implausible 
separation of the survival curves.  
Another aspect that needs to be considered when the OS benefit is discussed, is the importance 
of the follow-up therapy options available for patients. Clinicians will have three first-line options to 
choose from (alectinib, crizotinib and ceritinib), and it is hard to predict what the optimal treatment 
sequence will be. Therefore it is hard to predict long-term survival outcomes.  
Impact of follow-up-therapy and treatment switching 
Impact of follow-up-therapy 
At the time of the data cut-off, a greater proportion of patients in the crizotinib arm (68%) had 
progressed or died compared to the alectinib arm (41%). Of the 90 and 54 patients with a disease 
progression event, 61% of the patients in the crizotinib arm and 67% of the patients in the 
alectinib arm had at least one anti-cancer treatment administered after progression, including trial 
treatment exposure for at least 30 days beyond progressive disease.  
Overall, 40 patients in the crizotinib arm and five patients in the alectinib arm had isolated 
asymptomatic CNS progression, where local therapy could be given (e.g., stereotactic 
radiotherapy or surgery) followed by continuation of either crizotinib therapy (in the crizotinib arm) 
or alectinib therapy (in the alectinib arm) until systemic disease progression or symptomatic CNS 
progression.  
Treatment switching 
Ten patients in the crizotinib arm switched to alectinib therapy after they had discontinued the 
assigned trial treatment. As a substitute for a naïve per-protocol analysis, the MAH used a 
discount method approach to assess the potential impact of treatment switching on the intention 
to treat (ITT) comparison for OS [60]. The argument is that the patients who were treated with 
crizotinib and then switched to alectinib might benefit from the new treatment, and this could in 
turn lead to an underestimation of the OS advantage of alectinib.  
To assess the potential impact of treatment switching, the MAH multiplied (discounted) the 
observed survival time after the first dose of alectinib until censoring or death by 0.1–1.2 for the 
10 patients in the crizotinib arm who switched to alectinib. Thereafter the MAH calculated the 
hazard ratio (HR) between treatment arms with the total duration (for the crizotinib arm, time to 
first dose of alectinib positive multiplied observed time until censoring or death, and for the 
alectinib arm, time to event without any adjustments).  
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As of the data cutoff of 9th February 2017, the median time patients had received alectinib 
therapy was 5.2 months (interquartile range 2.3–7.9 months) for patients switching from crizotinib. 
If the MAH assumed that the treatment effect of alectinib after switching from crizotinib was as 
large as a HR of 0.2, the estimated (stratified) OS HR for the ITT comparison was 0.75 (95% CI 
0.47–1.18) as compared with an estimated (stratified) OS HR of 0.76 (95% CI 0.48–1.20) when 
treatment switching is ignored. 
The MAH argues that it may not be necessary to perform an adjustment for treatment switching at 
this stage, since the beneficial effect of treatment switching is minimal. However, the MAH argues 
that it might be worthwhile to apply a rank-preserving structural failure time model (RPSFTM) 
when more long-term OS data become available.  
 
Figure A8. Impact of treatment switching on the OS hazard ratio 
Abbreviations: CI=confidence interval; HR=hazard ratio. 
Source: MAH extrapolation file. 
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APPENDIX 2: METHODS AND DESCRIPTION OF THE EVIDENCE USED 
DOCUMENTATION OF THE SEARCH STRATEGIES 
 
Literature search inclusion and exclusion criteria 
Inclusion criteria Population: Adult patients (18 years) with ALK-positivea metastatic NSCLC (if 
mixed lung cancer type, at least 80% had to be NSCLC); oligometastatic 
populations; patients with brain or CNS metastases; any combination of 
chemotherapy naïve or chemotherapy experienced or ALK TKI treatment naïve or 
ALK TKI treatment experienced in any treatment line (advanced or metastatic); 
subgroups of interest: patients with brain metastases, Asian versus non-Asian 
patients 
Intervention(s) and comparator(s): Licensed or investigational doses or 
formulations of pharmacological interventions in at least one treatment arm 
(chemotherapy or targeted therapy) for ALK-positive metastatic NSCLC; 
comparison with another pharmacological treatment, standard of care or placebo; 
combination with other agents eligible; chemotherapy studies not reporting 
subgroup results by ALK status were excluded 
Outcomes: At least one primary or secondary outcome of efficacy (PFS, TTP, OS, 
response, DOR, duration of benefit after stopping treatment, CNS response); 
patient-reported outcomes; HRQoL; serious AEs; grade III/IV/V AEs (grouped); 
prespecified AEs of interest ; duration of treatment and duration of treatment 
beyond progression; tolerability (dose reductions and interruptions, 
discontinuation). Not all time points might have been included in the NMA 
Study design: Prospective parallel design phase II–IV RCTs with active or placebo 
controls; parallel randomised studies allowing for crossover; in the SLR, also other 
clinical studies (interventional, prospective, nonrandomised) and case series were 
included 
Language restrictions: Any foreign language article with an English abstract if 
sufficient information present to ensure the eligibility criteria are metb 
Other search limits or restrictions: Systematic reviews and NMAs limited by 
searches from 2012 onwards; individual studies not limited 
Exclusion criteria Population: Not ALK-positive NSCLC (unselected NSCLC population with no ALK-
positive subgroup data reported; primary EGFR mutation [not ALK]; wild-type ALK 
or wild-type EGFR; single other types of mutation, e.g., ROS1, KRAS or RET); 
paediatric populations or mixed paediatric/adult populations (adult population 
sought only); mixed ALK-positive/non-ALK-positive population (80% of the 
enrolled patients are ALK positive and the results are not reported separately for 
the ALK-positive patient subset); mixed stage population (80% of the enrolled 
patients are advanced/metastatic disease patients and the results are not reported 
separately for the advanced/metastatic disease patient subset); mixed line of 
treatment (80% of enrolled patients have a specific line of therapy and the results 
not reported separately per line) 
Intervention(s) and comparator(s): No comparator of interest; whole-brain 
radiotherapy or cranial radiotherapy as comparator or in combination with an ALK 
TKI treatment of interest (treatments of interest were any pharmacological agents) 
Outcomes: Articles that do not report at least one outcome of interest or do not 
report an outcome of interest sufficiently specified such as week of follow-up or 
intent-to-treat/modified intent-to-treat population (to avoid biased outcome data 
entering the dataset) 
Study design: Not an RCT (phase II, III, IV), or a nonrandomised controlled trial or 
a single-arm study; phase I studies only, or phase I/II studies reporting only the 
phase I data; observational, real-world, expanded access programme, or database 
studies, retrospective analyses, retrospective medical record reviews (prospective 
interventional studies of interest only); case series may be relevant but not 
individual case reports; PK/PD studies only (no outcome of interest); cluster 
randomised trials (individual participants not randomised); non-systematic reviews 
(any particularly interesting clinical-type reviews may be noted for discussion in the 
report but, in general, non-systematic reviews were excluded); naïve indirect 
comparisons of single-arm studies, particularly where no adjustment is made 
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(comparative trials of interest only); systematic reviews (relevant systematic 
reviews and meta-analyses were kept in at the first pass for cross-referencing 
purposes but were excluded after the second pass.); post hoc pooled analyses (to 
avoid the same data being included twice. The original trials going into the pooled 
analysis, if relevant, were included.); pilot studies (not powered to detect significant 
differences); economic analyses or budget impact analyses (clinical outcomes 
only); in vitro studies or animal studies (human in vivo only); extension studies and 
post-marketing safety surveillance studies (intended to be captured by the search 
strings for listing purposes so were tagged during screening but were excluded) 
Language restrictions: Full text in language outside of language capabilities 
(English, French, German, Spanish, Portuguese, Italian, Hungarian, Polish, Czech) 
Other search limits or restrictions applied: Publication type not of interest, e.g., 
editorials, commentaries, letters, notes, protocol-only articles (excluded but tagged 
and listed in the report alongside the ClinicalTrials.gov search); exact duplicates or 
copy abstracts; date limit of 2012 for systematic reviews/meta-analyses, 2007 for 
RCTs/trials; child abstract or sub-study with no unique data 
Abbreviations: AEadverse event, ALKanaplastic lymphoma kinase; CNS=central nervous system; DORduration of 
response; HRQoLhealth-related quality of life; NMAnetwork meta-analysis; NSCLCnon-small cell lung cancer; 
OSoverall survival; PDpharmacodynamic; PFSprogression-free survival; PKpharmacokinetic; RCTrandomised 
controlled trial; SLRsystematic literature review; TKItyrosine kinase inhibitor; TTPtime to progression. 
aEither single or multiple mutation. If non-mutation specific, ALK-positive subgroup data had to be reported separately or 
at least 80% (cutoff could be revised during screening and the rationale documented) of patients had to have ALK-positive 
NSCLC; if mixed, at least 80% must be advanced (stage IIIB) and/or metastatic (stage IV). 
bEnglish, Czech, French, German, Hungarian, Italian, Polish, Portuguese and Spanish. 
Source: [17] 
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The search was done on 2nd February 2017 in the following databases: 
Database Platform Span of search Date searched 
Embase Embase.com Database 
inception (1974) 
to date of search 
2nd February 2017 
MEDLINE Embase.com From 1966 to 
date of search 
2nd February 2017 
MEDLINE in-
process and 
electronic 
publications 
ahead of print 
PubMed interface 
http://www.ncbi.nlm.nih.g
ov/pubmed/ 
From inception to 
the day before 
the searches 
2nd February 2017 and alerts 
followed to cutoff date of 20th 
March 2017 
Cochrane 
Library 
DARE 
http://onlinelibrary.wiley.c
om/cochranelibrary/searc
h/ 
From database 
inception to Issue 
2 of 4, April 2015 
(database was 
closed as of 31st 
March 2015) 
2nd February 2017 
Cochrane 
Library 
CDSR 
http://onlinelibrary.wiley.c
om/cochranelibrary/searc
h/ 
From database 
inception to Issue 
2 of 12, February 
2017 (database 
updated monthly) 
2nd February 2017 
Cochrane 
Library 
CENTRAL 
http://onlinelibrary.wiley.c
om/cochranelibrary/searc
h/ 
From database 
inception to Issue 
1 of 12, January 
2017 (CENTRAL 
is updated 
monthly) 
2nd February 2017 
US NIH registry 
and results 
database 
https://clinicaltrials.gov # 15th January 2017 
WHO ICTRP 
registry 
http://apps.who.int/trialse
arch/ 
§ 15th January 2017 
EU CTR https://www.clinicaltrialsre
gister.eu/ 
¶ 15th January 2017 
Abbreviations: CDSR=Cochrane Database of Systematic Reviews; CENTRAL=Central Register of Controlled Trials 
CTR=Clinical Trials Register; DARE=Database of Abstracts of Reviews of Effects; EU=European Union; 
ICTRP=International Clinical Trials Registry Platform; NIH=National Institues of Health; WHO=World Health Organization. 
# ALK AND EXACT "Interventional" [STUDY-TYPES] AND ( advanced NSCLC OR metastatic NSCLC ) [DISEASE] AND 
EXACT ( Adult OR Senior ) [AGE-GROUP] AND EXACT ( Phase 2 OR Phase 3 OR Phase 4 ) [PHASE] 
§ ALK AND NSCLC in Condition / Recruitment Status is ALL / Phase 2 or 3 or 4 
¶ ALK AND NSCLC / Adult or elderly / Phase 2 or 3 or 4 
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Databases: Embase and MEDLINE  
Platform: Embase.com 
*URL: www.embase.com 
Date searched: 2nd February 2017 
Hits: 998 
 
No. Query Results 
#1  'non small cell lung cancer'/exp OR 'lung metastasis'/exp OR 'brain metastasis'/exp OR 'central nervous system metastasis'/exp OR ((lung OR 
poumon) NEAR/3 (neoplasm* OR cancer* OR carcinoma* OR adenocarcinoma* OR angiosarcoma* OR chrondosarcoma* OR sarcoma* OR 
teratoma* OR blastoma* OR microcytic* OR carcinogenesis OR tumour* OR tumor* OR metasta* OR métastasé OR métastatique OR avancé OR 
'progression localisée')):ab,ti OR nsclc*:ab,ti OR mnsclc*:ab,ti OR 'm nsclc':ab,ti OR ansclc*:ab,ti OR 'a nsclc':ab,ti OR msqnsclc*:ab,ti OR 'msq 
nsclc':ab,ti OR nonsqnsclc:ab,ti OR 'non sqnsclc':ab,ti OR 'non sq nsclc':ab,ti OR sqclc*:ab,ti OR 'ns nsclc':ab,ti OR nsnsclc*:ab,ti OR 'n s nsclc':ab,ti 
OR 'la nsclc':ab,ti OR lansclc*:ab,ti OR cpnpc*:ab,ti OR (lac NEAR/3 (lung OR adenocarcinoma)):ab,ti OR ((scc NEAR/3 'squamous cell 
carcinoma'):ab,ti AND lung:ab,ti) OR (non NEAR/3 small NEAR/3 cell NEAR/3 lung NEAR/3 (cancer* OR carcinoma*)):ab,ti OR (('non small' OR 
nonsmall) NEAR/3 lung NEAR/3 cell NEAR/3 (cancer* OR carcinoma*)):ab,ti OR (('non small' OR nonsmall) NEAR/3 cell NEAR/3 lung NEAR/3 
(cancer* OR carcinoma*)):ab,ti OR (bronchial NEAR/3 ('non small' OR nonsmall) NEAR/3 cell NEAR/3 (cancer* OR carcinoma*)):ab,ti OR ('non small 
cell' NEAR/3 (lung OR bronchial OR pulmonary OR bronchopulmonary OR bronchus) NEAR/3 (cancer* OR carcinoma*)):ab,ti OR ('non small' NEAR/3 
cell NEAR/3 (cancer* OR carcinoma*) NEAR/3 lung*):ab,ti OR (pulmonary NEAR/3 'non small cell' NEAR/3 (cancer* OR carcinoma*)):ab,ti OR (large 
NEAR/3 cell NEAR/3 lung NEAR/3 (cancer* OR carcinoma*)):ab,ti OR ((squamous OR non-squamous OR 'non squamous') NEAR/5 (cell OR 'non 
small cell') NEAR/3 lung NEAR/3 (cancer* OR carcinoma*)):ab,ti OR (bronchus NEAR/3 squamous NEAR/3 cell NEAR/3 (cancer* OR 
carcinoma*)):ab,ti OR (lung NEAR/3 epidermoid NEAR/3 (cancer* OR carcinoma*)):ab,ti OR (lung NEAR/3 squamous NEAR/3 cell NEAR/3 (cancer* 
OR carcinoma*)):ab,ti OR (lung:ab,ti OR poumon:ab,ti AND (nsclc*:ab,ti OR cpnpc*:ab,ti OR 'non small':ab,ti OR nonsmall:ab,ti OR large:ab,ti OR 
squamous:ab,ti OR 'non squamous':ab,ti OR non-squamous:ab,ti OR 'non à petites cellules':ab,ti)) OR ((adenocancer OR adenocarcinoma) NEAR/3 
(lung OR pulmonary)):ab,ti OR (((cancer OR tumeur) NEAR/3 (poumon OR bronchique)):ab,ti AND ('non à petites cellules':ab,ti OR 'non-lié à de 
petites cellules':ab,ti)) OR ((brain OR cns OR 'central nervous system' OR cerebral) NEAR/3 (metastasis OR metastases OR metastatic)):ab,ti 
333,209 
#2  'anaplastic lymphoma kinase'/exp OR alk:ab,ti OR alkfusion:ab,ti OR eml4alk*:ab,ti OR (anaplastic NEAR/3 lymphoma NEAR/3 kinase*):ab,ti OR 
(alk*:ab,ti AND (anaplastic:ab,ti OR lymphoma:ab,ti OR kinase:ab,ti)) 
22,200 
#3  l1196m:ab,ti OR c1156y:ab,ti OR l1152*:ab,ti OR 1151tins:ab,ti OR g1202r:ab,ti OR v118l:ab,ti OR i1171t:ab,ti OR s1206y:ab,ti OR f1174c:ab,ti OR 
d1203n:ab,ti OR g1269a:ab,ti OR g1123s*:ab,ti OR ((crizotinib* OR ceritinib* OR alectinib* OR 'alk tki' OR alktki OR alki) NEAR/3 (experienced OR 
treated OR pretreated OR 'pre treated' OR 'previously treated' OR 'treated previously' OR resistan* OR refractory OR naïve)):ab,ti 
783 
#4  #2 OR #3 22,257 
#5  anaplastic lymphoma kinase inhibitor'/exp OR 'alk tki':ab,ti OR alktki:ab,ti OR (alk NEAR/3 (inhibitor OR inhibitors)):ab,ti OR ((anaplastic NEAR/3 
lymphoma NEAR/3 kinase):ab,ti AND (inhibitor:ab,ti OR inhibitors:ab,ti)) OR alectinib*:ab,ti OR 'af 802':ab,ti OR af802:ab,ti OR 'ch 5424802':ab,ti OR 
ch5424802:ab,ti OR ro5424802:ab,ti OR rg7853:ab,ti OR alecensa:ab,ti OR crizotinib*:ab,ti OR 'pf 02341066':ab,ti OR pf02341066:ab,ti OR 'pf 
1066':ab,ti OR pf1066:ab,ti OR 'pf 2341066':ab,ti OR pf2341066:ab,ti OR xalkori:ab,ti OR ceritinib*:ab,ti OR 'ldk 378':ab,ti OR ldk378:ab,ti OR 'nvp ldk 
5751 
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378':ab,ti OR 'nvp ldk378':ab,ti OR 'nvp ldk378nx':ab,ti OR zykadia:ab,ti OR entrectinib*:ab,ti OR 'nms e 628':ab,ti OR 'nms e628':ab,ti OR 'rxdx 
101':ab,ti OR rxdx101:ab,ti OR brigatinib*:ab,ti OR 'ap 26113':ab,ti OR ap26113:ab,ti OR lorlatinib*:ab,ti OR 'pf 06463922':ab,ti OR pf06463922:ab,ti 
OR 'tsr 011':ab,ti OR tsr011:ab,ti OR 'cep 37440':ab,ti OR cep37440:ab,ti OR 'x 396':ab,ti OR x396:ab,ti OR 'x 276':ab,ti OR x276:ab,ti OR 'asp 
3026':ab,ti OR asp3026:ab,ti OR 'nvp tae 684':ab,ti OR 'nvp tae684':ab,ti OR 'tae 684':ab,ti OR tae684:ab,ti OR 'cep 28122':ab,ti OR cep28122:ab,ti 
OR 'cep 14083':ab,ti OR cep14083:ab,ti OR 'cep 14513':ab,ti OR cep14513:ab,ti OR 'gsk 1838705a':ab,ti OR gsk1838705a:ab,ti 
#6  'heat shock protein 90 inhibitor'/exp OR 'heat shock protein 90'/exp OR 'hsp 90 inhibitor':ab,ti OR 'hsp90 inhibitor':ab,ti OR luminespib*:ab,ti OR 'auy 
922':ab,ti OR auy922:ab,ti OR 'nvp auy 922':ab,ti OR 'nvp auy922':ab,ti OR 'ver 52296':ab,ti OR ver52296:ab,ti OR ganetespib*:ab,ti OR 'sta 
9090':ab,ti OR sta9090:ab,ti OR onalespib*:ab,ti OR 'at 13387':ab,ti OR at13387:ab,ti OR ribociclib*:ab,ti OR 'lee 011':ab,ti OR lee011:ab,ti OR 'ipi 
504':ab,ti OR ipi504:ab,ti OR retaspimycin:ab,ti OR tanespimycin*:ab,ti OR 'kos 953':ab,ti OR kos953:ab,ti OR 'nsc 330507':ab,ti OR nsc330507:ab,ti 
OR geldanamycin*:ab,ti OR 'nsc 122750':ab,ti OR nsc122750:ab,ti OR gamendazole*:ab,ti OR gambogic*:ab,ti OR 'beta guttiferin':ab,ti OR 'guttic 
acid':ab,ti OR celastrol*:ab,ti OR tripterin:ab,ti OR 'biib 028':ab,ti OR biib028:ab,ti OR alvespimycin:ab,ti OR 'bms 826476':ab,ti OR bms826476:ab,ti 
OR 'kos 1022':ab,ti OR kos1022:ab,ti OR 'nsc 707545':ab,ti OR nsc707545:ab,ti OR debio0932:ab,ti OR 'debio 0932':ab,ti 
15,999 
#7  'protein kinase b'/exp OR ((akt OR 'c akt') NEAR/3 (kinase OR protein OR proteins)):ab,ti 67,167 
#8  'gold standard'/exp OR ((gold OR golden) NEAR/3 standard):ab,ti OR 'best supportive care':ab,ti OR 'standard of care':ab,ti OR (bsc NEAR/3 (best OR 
supportive OR care)):ab,ti OR (soc NEAR/3 (standard OR care)):ab,ti 
118,767 
#9  'placebo'/exp OR placebo*:ab,ti 386,174 
#10  'docetaxel'/exp OR 'paclitaxel'/exp OR daxotel:ab,ti OR dexotel:ab,ti OR docefrez:ab,ti OR docetaxel*:ab,ti OR 'lit 976':ab,ti OR lit976:ab,ti OR 
deacetyltaxol:ab,ti OR 'nsc 628503':ab,ti OR nsc628503:ab,ti OR oncodocel:ab,ti OR 'rp 56976':ab,ti OR rp56976:ab,ti OR taxoter:ab,ti OR 
taxotere*:ab,ti OR texot:ab,ti OR taxespira:ab,ti OR 'abi 007':ab,ti OR abi007:ab,ti OR abraxane:ab,ti OR anzatax:ab,ti OR asotax:ab,ti OR biotax:ab,ti 
OR 'bms 181339':ab,ti OR bms181339:ab,ti OR bristaxol:ab,ti OR britaxol:ab,ti OR coroxane:ab,ti OR formoxol:ab,ti OR genexol:ab,ti OR 'genexol 
pm':ab,ti OR hunxol:ab,ti OR ifaxol:ab,ti OR infinnium:ab,ti OR intaxel:ab,ti OR 'mbt 0206':ab,ti OR mbt0206:ab,ti OR medixel:ab,ti OR mitotax:ab,ti 
OR 'nab paclitaxel':ab,ti OR 'nsc 125973':ab,ti OR nsc125973:ab,ti OR oncogel:ab,ti OR onxol:ab,ti OR pacitaxel:ab,ti OR paclitaxel*:ab,ti OR 
'paclitaxel nab':ab,ti OR pacxel:ab,ti OR padexol:ab,ti OR parexel:ab,ti OR paxceed:ab,ti OR paxene:ab,ti OR paxus:ab,ti OR praxel:ab,ti OR 
taxocris:ab,ti OR taxol:ab,ti OR taxus:ab,ti OR taycovit:ab,ti OR yewtaxan:ab,ti 
114,807 
#11  'pemetrexed'/exp OR 'carboplatin'/exp OR 'cisplatin'/exp OR 'gemcitabine'/exp OR 'navelbine'/exp OR pemetrexed*:ab,ti OR alimta*:ab,ti OR 
ciambra:ab,ti OR elimta:ab,ti OR 'ly 231514':ab,ti OR ly231514:ab,ti OR blastocarb:ab,ti OR boplatex:ab,ti OR carboplat:ab,ti OR carboplatin*:ab,ti OR 
carbosin:ab,ti OR 'carbosin lundbeck':ab,ti OR carbotec:ab,ti OR carplan:ab,ti OR cbdca:ab,ti OR cycloplatin:ab,ti OR 'delta west carboplatin':ab,ti OR 
erbakar:ab,ti OR ercar:ab,ti OR ifacap:ab,ti OR 'jm 8':ab,ti OR kemocarb:ab,ti OR 'nsc 241240':ab,ti OR oncocarbin:ab,ti OR paraplatin*:ab,ti OR 
platinum*:ab,ti OR abiplatin:ab,ti OR biocisplatinum:ab,ti OR biocysplatinum:ab,ti OR blastolem:ab,ti OR briplatin:ab,ti OR 'cddp ti':ab,ti OR 'cis 
ddp':ab,ti OR 'cis diamine dichloroplatinum':ab,ti OR 'cis diaminechloroplatinum':ab,ti OR 'cis diaminedichloroplatinum':ab,ti OR 'cis diammine 
dichloroplatinum':ab,ti OR 'cis diamminedichloroplatinum':ab,ti OR 'cis dichloridiammineplatinum':ab,ti OR 'cis dichloroadiamine platinum':ab,ti OR 'cis 
dichlorodiamine platinum':ab,ti OR 'cis dichlorodiammineplatinum':ab,ti OR 'cis platinous diamino dichloride':ab,ti OR 'cis platinum':ab,ti OR (cis* 
NEAR/3 platinum*):ab,ti OR cisplatin*:ab,ti OR cisplatyl:ab,ti OR citoplatino:ab,ti OR cytoplatin:ab,ti OR cytosplat:ab,ti OR 'diamine 
dichloroplatinum':ab,ti OR diaminodichloroplatinum:ab,ti OR diamminedichloroplatinum:ab,ti OR 'dichlorodiamine platinum':ab,ti OR 
dichlorodiammineplatinum:ab,ti OR docistin:ab,ti OR elvecis:ab,ti OR kemoplat:ab,ti OR lederplatin:ab,ti OR lipoplatin:ab,ti OR 'liposomal 
cisplatin':ab,ti OR 'mpi 5010':ab,ti OR mpi5010:ab,ti OR neoplatin:ab,ti OR niyaplat:ab,ti OR 'nk 801':ab,ti OR noveldexis:ab,ti OR 'nsc 119875':ab,ti 
231,814 
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OR platamine:ab,ti OR 'platamine rtu':ab,ti OR platiblastin:ab,ti OR platidiam:ab,ti OR platimine:ab,ti OR platinex:ab,ti OR platinil:ab,ti OR 
platinol*:ab,ti OR platinoxan:ab,ti OR platiran:ab,ti OR platistil:ab,ti OR platistin:ab,ti OR platosin:ab,ti OR randa:ab,ti OR romcis:ab,ti OR sicatem:ab,ti 
OR 'spi 077':ab,ti OR tecnoplatin:ab,ti OR gemcitabine*:ab,ti OR gemzar*:ab,ti OR difluorodeoxycytidine:ab,ti OR gemcite:ab,ti OR 'ly 188011':ab,ti 
OR ly188011:ab,ti OR vinorelbine*:ab,ti OR noranhydrovinblastine:ab,ti OR anhydrovinblastine:ab,ti OR 'anx 530':ab,ti OR anx530:ab,ti OR 
eunades:ab,ti OR exelbine:ab,ti OR 'kw 2307':ab,ti OR kw2307:ab,ti OR navelbin:ab,ti OR navirel:ab,ti OR vinbine:ab,ti OR vinelbine:ab,ti 
#12  'programmed death 1 ligand 1'/exp OR 'nivolumab'/exp OR 'pembrolizumab'/exp OR 'avelumab'/exp OR 'atezolizumab'/exp OR 'durvalumab'/exp OR 
'ticilimumab'/exp OR 'pd l1':ab,ti OR pdl1:ab,ti OR 'pd 1':ab,ti OR pd1:ab,ti OR nivolumab*:ab,ti OR 'bms 936558':ab,ti OR bms936558:ab,ti OR 'mdx 
1106':ab,ti OR mdx1106:ab,ti OR 'ono 4538':ab,ti OR ono4538:ab,ti OR opdivo:ab,ti OR pembrolizumab*:ab,ti OR keytruda:ab,ti OR 
lambrolizumab:ab,ti OR 'mk 3475':ab,ti OR mk3475:ab,ti OR avelumab*:ab,ti OR 'msb 0010718c':ab,ti OR msb0010718c:ab,ti OR atezolizumab*:ab,ti 
OR 'mpdl 3280a':ab,ti OR mpdl3280a:ab,ti OR 'rg 7446':ab,ti OR rg7446:ab,ti OR durvalumab*:ab,ti OR medi4736:ab,ti OR 'medi 4736':ab,ti OR 
ticilimumab*:ab,ti OR tremelimumab*:ab,ti OR 'cp 675 206':ab,ti OR 'cp 675, 206':ab,ti OR 'cp 675206':ab,ti OR 'cp675 206':ab,ti OR 'cp675, 206':ab,ti 
OR cp675206:ab,ti 
17,470 
#13  'rabusertib'/exp OR 'prexasertib'/exp OR rabusertib*:ab,ti OR ly2603618:ab,ti OR 'ly 2603618':ab,ti OR prexasertib*:ab,ti OR 'ly 2606368':ab,ti OR 
ly2606368:ab,ti OR (('chk 1' OR chk1) NEAR/3 inhibitor*):ab,ti 
680 
#14  'somatomedin c receptor'/exp OR 'figitumumab'/exp OR figitumumab*:ab,ti OR 'cp 751871':ab,ti OR cp751871:ab,ti OR 'insulin like growth factor':ab,ti 
OR 'igf type 1':ab,ti OR 'igf 1r':ab,ti OR igf1r:ab,ti OR 'igf 1 receptor':ab,ti 
48,419 
#15  'epidermal growth factor receptor kinase inhibitor'/exp OR afatinib:ab,ti OR canertinib:ab,ti OR dacomitinib:ab,ti OR erlotinib:ab,ti OR gefitinib:ab,ti OR 
genistein:ab,ti OR icotinib:ab,ti OR lapatinib:ab,ti OR naquotinib:ab,ti OR nazartinib:ab,ti OR neratinib:ab,ti OR olmutinib:ab,ti OR osimertinib:ab,ti OR 
pelitinib:ab,ti OR poziotinib:ab,ti OR rociletinib:ab,ti OR sapitinib:ab,ti OR tarloxotinib:ab,ti OR varlitinib:ab,ti OR (('egf receptor' OR 'epidermal growth 
factor receptor') NEAR/3 inhibit*):ab,ti 
61,728 
#16  'bevacizumab'/exp OR bevacizumab*:ab,ti OR altuzan:ab,ti OR avastin:ab,ti OR 'nsc 704865':ab,ti OR nsc704865:ab,ti 43,708 
#17  'antineoplastic agent'/exp OR 'immunotherapy'/exp OR 'drug therapy'/exp OR 'protein tyrosine kinase inhibitor'/exp 3,448,065 
#18  #5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17 3,866,381 
#19  'systematic review'/exp OR 'meta analysis'/exp OR metaanalysis:ab,ti OR 'meta analysis':ab,ti OR 'systematic review':ab,ti OR 'adjusted indirect 
comparison':ab,ti OR (systematic* NEAR/3 review*):ab,ti OR ((mixed OR indirect) NEAR/3 treatment* NEAR/3 comparison*):ab,ti OR (simulated 
NEAR/3 (treatment* OR tx) NEAR/3 comparison*):ab,ti OR (match* NEAR/4 adjust* NEAR/3 (indirect OR comparison*)):ab,ti OR (nma NEAR/3 
(network OR metaanalysis OR 'meta analysis')):ab,ti OR (itc NEAR/3 (indirect OR treatment* OR comparison*)):ab,ti OR (mtc NEAR/3 (mixed OR 
treatment* OR comparison*)):ab,ti OR (maic NEAR/4 (match* OR adjust* OR indirect OR comparison*)):ab,ti OR (stc NEAR/3 (simulated OR 
treatment* OR comparison*)):ab,ti OR (nma NEAR/3 (fp OR 'fractional polynomial')):ab,ti AND [2012-2017]/py 
143,380 
#20  #19 AND 'conference abstract'/it 29,641 
#21  #19 NOT #20 113,739 
#22  'controlled clinical trial'/exp OR randomized:ab,ti OR randomised:ab,ti OR randomly:ab,ti OR placebo:ab,ti OR trial:ab,ti OR 'randomized controlled 
trial':de OR 'controlled clinical trial':de 
1,548,897 
#23  'case study'/exp OR (('single arm' OR 'single agent') NEAR/3 (trial OR study)):ab,ti OR (historical* NEAR/3 control*):ab,ti OR ('case series':ab,ti AND 
prospective*:ab,ti) 
66,025 
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#24  'phase 2 clinical trial'/exp OR 'phase 3 clinical trial'/exp OR 'phase 4 clinical trial'/exp OR 'open study'/exp OR 'postmarketing surveillance'/exp OR 
bayesian:ab,ti OR 'expanded access':ab,ti OR ((postmarketing OR 'post marketing') NEAR/2 surveillance):ab,ti OR (('2 arm' OR '3 arm' OR '4 arm' OR 
'non inferiority' OR superiority OR 'proof of concept' OR 'proof of principle' OR 'proof of correlation' OR 'phase 1 2' OR 'phase1 2' OR 'phase i ii' OR 
'phasei ii' OR 'phase ii' OR 'phaseii' OR 'phase 2' OR 'phase2' OR 'ph ii' OR phii* OR 'ph 2' OR ph2* OR 'phase 2 3' OR 'phase2 3' OR 'phase ii iii' OR 
'phaseii iii' OR 'phase iii' OR phaseiii* OR 'phase 3' OR phase3* OR 'ph 3' OR ph3* OR 'ph iii' OR phiii* OR 'phase iv' OR phaseiv* OR 'phase 4' OR 
phase4* OR 'ph 4' OR ph4* OR 'ph iv' OR phiv* OR pivotal OR efficacy OR adaptive) NEAR/5 (trial OR study OR design)):ab,ti OR (extension NEAR/3 
(trial OR study OR phase)):ab,ti OR (control* NEAR/3 ('clinical trial' OR 'clinical study')):ab,ti 
329,469 
#25  #22 OR #23 OR #24 1,749,894 
#26  'phase 1':ti OR 'phase i':ti OR 'phase 1a':ti OR 'phase 1b':ti OR 'phase ia':ti OR 'phase ib':ti OR phase1:ti OR phasei:ti NOT ('phase 1 2':ti OR 'phase 
1b 2':ti OR 'phase 1b 2a':ti OR 'phase i ii':ti OR 'phase ib ii':ti OR 'phase ib iia':ti OR 'phase i iia':ti OR 'phase1 2':ti OR 'phase1b 2':ti OR 'phase1b 2a':ti 
OR 'phase 1 2a':ti OR 'phasei ii':ti OR 'phaseib ii':ti OR 'phaseib iia':ti OR 'phasei iia':ti OR 'phase 1 and 2':ti OR 'phase i and ii':ti) 
19,334 
#27  #25 NOT #26 1,737,354 
#28  #21 OR #27 1,809,557 
#29  #1 AND #4 AND #18 AND #28 1024 
#30  #29 AND ('chapter'/it OR 'conference review'/it OR 'editorial'/it OR 'letter'/it OR 'note'/it) 26 
#31  #29 NOT #30 998 
* Individuals may be redirected based on individual licensing 
 
Databases: MEDLINE in-process and electronic publications ahead of print 
Platform: PubMed 
URL: http://www.ncbi.nlm.nih.gov/pubmed/ 
Date searched: 2nd February 2017 
Hits: 104 (from search on 2nd February 2017) 
Two further publications [61] [55] identified from e-alerts tracked from 3rd February 2017 to 20th March 2017 (cutoff date) 
One further publication noted after cutoff date, for the J-ALEX study [62] 
 
No. Query Results 
#1 Search ("Carcinoma, Non-Small-Cell Lung”[mh] OR ((lung[tiab] OR poumon[tiab]) AND (neoplasm*[tiab] OR cancer*[tiab] OR carcinoma*[tiab] OR 
adenocarcinoma*[tiab] OR angiosarcoma*[tiab] OR chrondosarcoma*[tiab] OR sarcoma*[tiab] OR teratoma*[tiab] OR blastoma*[tiab] OR 
microcytic*[tiab] OR carcinogenesis[tiab] OR tumour*[tiab] OR tumor[tiab] OR tumors[tiab] OR metasta*[tiab] OR métastasé[tiab] OR 
métastatique[tiab] OR avancé[tiab] OR “progression localisée”[tiab])) OR NSCLC*[tiab] OR mNSCLC*[tiab] OR “m NSCLC”[tiab] OR aNSCLC*[tiab] 
OR “a NSCLC”[tiab] OR msqNSCLC*[tiab] OR “msq NSCLC”[tiab] OR nonsqNSCLC[tiab] OR “non sqNSCLC”[tiab] OR “non sq NSCLC”[tiab] OR 
SqCLC*[tiab] OR “ns NSCLC”[tiab] OR nsNSCLC*[tiab] OR “n s NSCLC”[tiab] OR “la NSCLC”[tiab] OR laNSCLC*[tiab] OR CPNPC*[tiab] OR 
(LAC[tiab] AND (lung[tiab] OR adenocarcinoma[tiab])) OR ((SCC[tiab] AND “squamous cell carcinoma”[tiab]) AND lung[tiab]) OR (non[tiab] AND 
253,817 
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small[tiab] AND cell[tiab] AND lung[tiab] AND (cancer*[tiab] OR carcinoma*[tiab])) OR ((“non small”[tiab] OR nonsmall[tiab]) AND lung[tiab] AND 
cell[tiab] AND (cancer*[tiab] OR carcinoma*[tiab])) OR ((“non small”[tiab] OR nonsmall[tiab]) AND cell[tiab] AND lung[tiab] AND (cancer*[tiab] OR 
carcinoma*[tiab])) OR (bronchial[tiab] AND (“non small”[tiab] OR nonsmall[tiab]) AND cell[tiab] AND (cancer*[tiab] OR carcinoma*[tiab])) OR (“non 
small cell”[tiab] AND (lung[tiab] OR bronchial[tiab] OR pulmonary[tiab] OR bronchopulmonary[tiab] OR bronchus[tiab]) AND (cancer*[tiab] OR 
carcinoma*[tiab])) OR (“non small”[tiab] AND cell[tiab] AND (cancer*[tiab] OR carcinoma*[tiab]) AND lung*[tiab]) OR (pulmonary[tiab] AND “non small 
cell”[tiab] AND (cancer*[tiab] OR carcinoma*[tiab])) OR (large[tiab] AND cell[tiab] AND lung[tiab] AND (cancer*[tiab] OR carcinoma*[tiab])) OR 
((squamous[tiab] OR non-squamous[tiab] OR “non squamous”[tiab]) AND (cell[tiab] OR “non small cell”[tiab]) AND lung[tiab] AND (cancer*[tiab] OR 
carcinoma*[tiab])) OR (bronchus[tiab] AND squamous[tiab] AND cell[tiab] AND (cancer*[tiab] OR carcinoma*[tiab])) OR (lung[tiab] AND 
epidermoid[tiab] AND (cancer*[tiab] OR carcinoma*[tiab])) OR (lung[tiab] AND squamous[tiab] AND cell[tiab] AND (cancer*[tiab] OR carcinoma*[tiab])) 
OR ((lung[tiab] OR poumon[tiab]) AND (NSCLC*[tiab] OR CPNPC*[tiab] OR “non small”[tiab] OR nonsmall[tiab] OR large[tiab] OR squamous[tiab] OR 
“non squamous”[tiab] OR non-squamous[tiab] OR “non à petites cellules”[tiab])) OR ((adenocancer[tiab] OR adenocarcinoma[tiab]) AND (lung[tiab] 
OR pulmonary[tiab])) OR (((cancer[tiab] OR tumeur[tiab]) AND (poumon[tiab] OR bronchique[tiab])) AND (“non à petites cellules”[tiab] OR “non-lié à 
de petites cellules”[tiab])) OR ((brain[tiab] OR CNS[tiab] OR “central nervous system”[tiab] OR cerebral[tiab]) AND (metastasis[tiab] OR 
metastases[tiab] OR metastatic[tiab]))) 
#2 Search ("anaplastic lymphoma kinase" [Supplementary Concept] OR ALK[tiab] OR ALKfusion[tiab] OR EML4ALK*[tiab] OR (anaplastic[tiab] AND 
lymphoma[tiab] AND kinase*[tiab])) 
6615 
#3 Search (L1196M[tiab] OR G1269A[tiab] OR C1156Y[tiab] OR L1152*[tiab] OR 1151Tins[tiab] OR G1202R[tiab] OR V118L[tiab] OR I1171T[tiab] OR 
S1206Y[tiab] OR F1174C[tiab] OR D1203N[tiab] OR G1269A[tiab] OR G1123S*[tiab] OR ((crizotinib*[tiab] OR ceritinib*[tiab] OR alectinib*[tiab] OR 
“alk tki”[tiab] OR alktki[tiab] OR alki[tiab]) AND (experienced[tiab] OR treated[tiab] OR pretreated[tiab] OR “pre treated”[tiab] OR “previously 
treated”[tiab] OR “treated previously”[tiab] OR resistan*[tiab] OR refractory[tiab] OR naïve[tiab]))) 
708 
#4 Search (#2 OR #3) 6713 
#5 Search ("ceritinib" [Supplementary Concept] OR "CH5424802" [Supplementary Concept] OR "AP26113" [Supplementary Concept] OR "CM-118" 
[Supplementary Concept] OR “ALK TKI”[tiab] OR ALKTKI[tiab] OR (ALK[tiab] AND (inhibitor[tiab] OR inhibitors[tiab])) OR ((anaplastic[tiab] AND 
lymphoma[tiab] AND kinase[tiab]) AND (inhibitor[tiab] OR inhibitors[tiab])) OR alectinib*[tiab] OR “af 802”[tiab] OR af802[tiab] OR “ch 5424802”[tiab] 
OR ch5424802[tiab] OR RO5424802[tiab] OR RG7853[tiab] OR Alecensa[tiab] OR crizotinib*[tiab] OR “pf 02341066”[tiab] OR pf02341066[tiab] OR 
“pf 1066”[tiab] OR pf1066[tiab] OR “pf 2341066”[tiab] OR pf2341066[tiab] OR xalkori[tiab] OR ceritinib*[tiab] OR “ldk 378”[tiab] OR ldk378[tiab] OR 
“nvp ldk 378”[tiab] OR “nvp ldk378”[tiab] OR “nvp ldk378nx”[tiab] OR zykadia[tiab] OR entrectinib*[tiab] OR “nms e 628”[tiab] OR “nms e628”[tiab] OR 
“rxdx 101”[tiab] OR rxdx101[tiab] OR brigatinib*[tiab] OR “ap 26113”[tiab] OR ap26113[tiab] OR lorlatinib*[tiab] OR “pf 06463922”[tiab] OR 
pf06463922[tiab] OR “tsr 011”[tiab] OR tsr011[tiab] OR “asp 3026”[tiab] OR asp3026[tiab] OR “CEP 37440”[tiab] OR CEP37440[tiab] OR “X 396”[tiab] 
OR X396[tiab] OR “X 276”[tiab] OR X276[tiab] OR “asp 3026”[tiab] OR asp3026[tiab] OR “nvp tae 684”[tiab] OR “nvp tae684”[tiab] OR “tae 684”[tiab] 
OR tae684[tiab] OR “CEP 28122”[tiab] OR CEP28122[tiab] OR “CEP 14083”[tiab] OR CEP14083[tiab] OR “CEP 14513”[tiab] OR CEP14513[tiab] OR 
“GSK 1838705A”[tiab] OR GSK1838705A[tiab] OR CM118[tiab] OR “CM 118”[tiab]) 
2338 
#6 Search ("HSP90 Heat-Shock Proteins"[mh] OR “hsp 90 inhibitor”[tiab] OR “hsp90 inhibitor”[tiab] OR luminespib*[tiab] OR “auy 922”[tiab] OR 
auy922[tiab] OR “nvp auy 922”[tiab] OR “nvp auy922”[tiab] OR “ver 52296”[tiab] OR ver52296[tiab] OR ganetespib*[tiab] OR “sta 9090”[tiab] OR 
sta9090[tiab] OR onalespib*[tiab] OR “AT 13387”[tiab] OR AT13387[tiab] OR ribociclib*[tiab] OR “lee 011”[tiab] OR lee011[tiab] OR “IPI 504”[tiab] OR 
IPI504[tiab] OR retaspimycin[tiab] OR tanespimycin*[tiab] OR “kos 953”[tiab] OR kos953[tiab] OR “nsc 330507”[tiab] OR nsc330507[tiab] OR 
7766 
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geldanamycin*[tiab] OR “nsc 122750”[tiab] OR nsc122750[tiab] OR gamendazole*[tiab] OR gambogic*[tiab] OR “beta guttiferin”[tiab] OR “guttic 
acid”[tiab] OR celastrol*[tiab] OR tripterin[tiab] OR “biib 028”[tiab] OR biib028[tiab] OR alvespimycin[tiab] OR “bms 826476”[tiab] OR bms826476[tiab] 
OR “kos 1022”[tiab] OR kos1022[tiab] OR “nsc 707545”[tiab] OR nsc707545[tiab] OR Debio0932[tiab] OR “debio 0932”[tiab]) 
#7 Search ("Proto-Oncogene Proteins c-akt"[mh] OR “AKT1 protein, human” [Supplementary Concept] OR "AKT2 protein, human" [Supplementary 
Concept] OR "AKT3 protein, human" [Supplementary Concept] OR ((Akt[tiab] OR “c akt”[tiab]) AND (kinase[tiab] OR protein[tiab] OR proteins[tiab]))) 
53,287 
#8 Search (“standard of care”[mh] OR ((gold[tiab] OR golden[tiab]) AND standard[tiab]) OR “best supportive care”[tiab] OR “standard of care”[tiab] OR 
(BSC[tiab] AND (best[tiab] OR supportive[tiab] OR care[tiab])) OR (SOC[tiab] AND (standard[tiab] OR care[tiab]))) 
74,023 
#9 Search (“placebos”[mh] OR placebo*[tiab]) 196,068 
#10 Search ("docetaxel"[Supplementary Concept] OR "Paclitaxel"[mh] OR daxotel[tiab] OR dexotel[tiab] OR docefrez[tiab] OR docetaxel*[tiab] OR “lit 
976”[tiab] OR lit976[tiab] OR deacetyltaxol[tiab] OR “nsc 628503”[tiab] OR nsc628503[tiab] OR oncodocel[tiab] OR “rp 56976”[tiab] OR rp56976[tiab] 
OR taxoter[tiab] OR taxotere*[tiab] OR texot[tiab] OR taxespira[tiab] OR “abi 007”[tiab] OR abi007[tiab] OR abraxane[tiab] OR anzatax[tiab] OR 
asotax[tiab] OR biotax[tiab] OR “bms 181339”[tiab] OR bms181339[tiab] OR bristaxol[tiab] OR britaxol[tiab] OR coroxane[tiab] OR formoxol[t iab] OR 
genexol[tiab] OR “genexol pm”[tiab] OR hunxol[tiab] OR ifaxol[tiab] OR infinnium[tiab] OR intaxel[tiab] OR “mbt 0206”[tiab] OR mbt0206[tiab] OR 
medixel[tiab] OR mitotax[tiab] OR “nab paclitaxel”[tiab] OR “nsc 125973”[tiab] OR nsc125973[tiab] OR oncogel[tiab] OR onxol[tiab] OR pacitaxel[tiab] 
OR paclitaxel*[tiab] OR “paclitaxel nab”[tiab] OR pacxel[tiab] OR padexol[tiab] OR parexel[tiab] OR paxceed[tiab] OR paxene[tiab] OR paxus[tiab] OR 
praxel[tiab] OR taxocris[tiab] OR taxol[tiab] OR taxus[tiab] OR taycovit[tiab] OR yewtaxan[tiab]) 
42,194 
#11 Search ("Pemetrexed"[mh] OR “carboplatin”[mh] OR “cisplatin”[mh] OR "gemcitabine" [Supplementary Concept] OR "vinorelbine" [Supplementary 
Concept] OR pemetrexed*[tiab] OR alimta*[tiab] OR ciambra[tiab] OR elimta[tiab] OR “ly 231514”[tiab] OR ly231514[tiab] OR blastocarb[tiab] OR 
boplatex[tiab] OR carboplat[tiab] OR carboplatin*[tiab] OR carbosin[tiab] OR “carbosin lundbeck”[tiab] OR carbotec[tiab] OR carplan[tiab] OR 
CBDCA[tiab] OR cycloplatin[tiab] OR “delta west carboplatin”[tiab] OR erbakar[tiab] OR ercar[tiab] OR ifacap[tiab] OR “jm 8”[tiab] OR kemocarb[tiab] 
OR “nsc 241240”[tiab] OR oncocarbin[tiab] OR paraplatin*[tiab] OR platinum*[tiab] OR abiplatin[tiab] OR biocisplatinum[tiab] OR biocysplatinum[tiab] 
OR blastolem[tiab] OR briplatin[tiab] OR “cddp ti”[tiab] OR “cis ddp”[tiab] OR “cis diamine dichloroplatinum”[tiab] OR “cis diaminechloroplatinum”[tiab] 
OR “cis diaminedichloroplatinum”[tiab] OR “cis diammine dichloroplatinum”[tiab] OR “cis diamminedichloroplatinum”[tiab] OR “c is 
dichloridiammineplatinum”[tiab] OR “cis dichloroadiamine platinum”[tiab] OR “cis dichlorodiamine platinum”[tiab] OR “cis 
dichlorodiammineplatinum”[tiab] OR “cis platinous diamino dichloride”[tiab] OR “cis platinum”[tiab] OR (cis[tiab] AND platinum*[tiab]) OR cisplatin*[tiab] 
OR cisplatyl[tiab] OR citoplatino[tiab] OR cytoplatin[tiab] OR cytosplat[tiab] OR “diamine dichloroplatinum”[tiab] OR diaminodichloroplatinum[tiab] OR 
diamminedichloroplatinum[tiab] OR “dichlorodiamine platinum”[tiab] OR dichlorodiammineplatinum[tiab] OR docistin[tiab] OR elvecis[tiab] OR 
kemoplat[tiab] OR lederplatin[tiab] OR lipoplatin[tiab] OR “liposomal cisplatin”[tiab] OR “mpi 5010”[tiab] OR mpi5010[tiab] OR neoplatin[tiab] OR 
niyaplat[tiab] OR “nk 801”[tiab] OR noveldexis[tiab] OR “nsc 119875”[tiab] OR platamine[tiab] OR “platamine rtu”[tiab] OR platiblastin[tiab] OR 
platidiam[tiab] OR platimine[tiab] OR platinex[tiab] OR platinil[tiab] OR platinol*[tiab] OR platinoxan[tiab] OR platiran[tiab] OR platistil[tiab] OR 
platistin[tiab] OR platosin[tiab] OR randa[tiab] OR romcis[tiab] OR sicatem[tiab] OR “spi 077”[tiab] OR tecnoplatin[tiab] OR gemcitabine*[tiab] OR 
gemzar*[tiab] OR difluorodeoxycytidine[tiab] OR gemcite[tiab] OR “ly 188011”[tiab] OR ly188011[tiab] OR vinorelbine*[tiab] OR 
noranhydrovinblastine[tiab] OR anhydrovinblastine[tiab] OR “anx 530”[tiab] OR anx530[tiab] OR eunades[tiab] OR exelbine[tiab] OR “kw 2307”[tiab] 
OR kw2307[tiab] OR navelbin[tiab] OR navirel[tiab] OR vinbine[tiab] OR vinelbine[tiab]) 
106,752 
#12 Search ("Programmed Cell Death 1 Ligand 2 Protein"[mh] OR "nivolumab" [Supplementary Concept] OR "pembrolizumab" [Supplementary Concept] 
OR "avelumab" [Supplementary Concept] OR "atezolizumab" [Supplementary Concept] OR "tremelimumab" [Supplementary Concept] OR “PD 
7622 
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L1”[tiab] OR PDL1[tiab] OR “PD 1”[tiab] OR PD1[tiab] OR nivolumab*[tiab] OR “bms 936558”[tiab] OR bms936558[tiab] OR “mdx 1106”[tiab] OR 
mdx1106[tiab] OR “ono 4538”[tiab] OR ono4538[tiab] OR opdivo[tiab] OR pembrolizumab*[tiab] OR keytruda[tiab] OR lambrolizumab[tiab] OR “mk 
3475”[tiab] OR mk3475[tiab] OR avelumab*[tiab] OR “msb 0010718c”[tiab] OR msb0010718c[tiab] OR atezolizumab*[tiab] OR “mpdl 3280a”[tiab] OR 
mpdl3280a[tiab] OR “mpdl 3280a”[tiab] OR mpdl3280a[tiab] OR “rg 7446”[tiab] OR rg7446[tiab] OR durvalumab*[tiab] OR medi4736[tiab] OR “medi 
4736”[tiab] OR ticilimumab*[tiab] OR tremelimumab*[tiab] OR “cp 675 206”[tiab] OR “cp 675, 206”[tiab] OR “cp 675206”[tiab] OR “cp675 206”[tiab] OR 
“cp675, 206”[tiab] OR cp675206[tiab]) 
#13 Search (rabusertib*[tiab] OR LY2603618[tiab] OR “LY 2603618”[tiab] OR prexasertib*[tiab] OR “ly 2606368”[tiab] OR ly2606368[tiab] OR ((“CHK 
1”[tiab] OR CHK1[tiab]) AND inhibitor*[tiab])) 
1015 
#14 Search ("Insulin-Like Growth Factor I"[mh] OR "figitumumab" [Supplementary Concept] OR figitumumab*[tiab] OR “cp 751871”[tiab] OR 
cp751871[tiab] OR “insulin like growth factor”[tiab] OR “IGF type 1”[tiab] OR “IGF 1r”[tiab] OR IGF1R[tiab] OR “IGF 1 receptor”[tiab]) 
50,057 
#15 Search ("afatinib" [Supplementary Concept] OR "Canertinib" [Supplementary Concept] OR "PF 00299804" [Supplementary Concept] OR "Erlotinib 
Hydrochloride"[mh] OR "gefitinib" [Supplementary Concept] OR "Genistein"[mh] OR "icotinib" [Supplementary Concept] OR "lapatinib" [Supplementary 
Concept] OR "N-(4-(3-chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide" [Supplementary Concept] 
OR "osimertinib" [Supplementary Concept] OR "EKB 569" [Supplementary Concept] OR "HM781-36B" [Supplementary Concept] OR "rociletinib" 
[Supplementary Concept] OR afatinib[tiab] OR canertinib[tiab] OR dacomitinib[tiab] OR erlotinib[tiab] OR gefitinib[tiab] OR genistein[tiab] OR 
icotinib[tiab] OR lapatinib[tiab] OR naquotinib[tiab] OR nazartinib[tiab] OR neratinib[tiab] OR olmutinib[tiab] OR osimertinib[tiab] OR pelitinib[tiab] OR 
poziotinib[tiab] OR rociletinib[tiab] OR sapitinib[tiab] OR tarloxotinib[tiab] OR varlitinib[tiab] OR ((“EGF receptor”[tiab] OR “epidermal growth factor 
receptor”[tiab]) AND inhibit*[tiab])) 
34,979 
#16 Search ("Bevacizumab"[mh] OR bevacizumab*[tiab] OR altuzan[tiab] OR avastin[tiab] OR “nsc 704865”[tiab] OR nsc704865[tiab]) 13,625 
#17 Search ("Antineoplastic Agents"[mh] OR "Antineoplastic Agents"[Pharmacological Action] OR “immunotherapy”[mh] OR “drug therapy”[mh] OR 
"Protein-Tyrosine Kinases"[mh]) 
2,257,283 
#18 Search (#5 OR #6 OR #7 OR #8 OR #9 OR #10 OR #11 OR #12 OR #13 OR #14 OR #15 OR #16 OR #17) 2,579,793 
#19 Search ((“Review”[pt] OR “meta-analysis”[pt] OR “Network Meta-Analysis”[mh] OR metaanalysis[tiab] OR “meta analysis”[tiab] OR “systematic 
review”[tiab] OR “adjusted indirect comparison”[tiab] OR (systematic*[tiab] AND review*[tiab]) OR ((mixed[tiab] OR indirect[tiab]) AND treatment*[tiab] 
AND comparison*[tiab]) OR (simulated[tiab] AND (treatment*[tiab] OR tx[tiab]) AND comparison*[tiab]) OR (match*[tiab] AND adjust*[tiab] AND 
(indirect[tiab] OR comparison*[tiab])) OR (nma[tiab] AND (network[tiab] OR metaanalysis[tiab] OR “meta analysis”[tiab])) OR (itc[tiab] AND 
(indirect[tiab] OR treatment*[tiab] OR comparison*[tiab])) OR (mtc[tiab] AND (mixed[tiab] OR treatment*[tiab] OR comparison*[tiab])) OR (maic[tiab] 
AND (match*[tiab] OR adjust*[tiab] OR indirect[tiab] OR comparison*[tiab])) OR (stc[tiab] AND (simulated[tiab] OR treatment*[tiab] OR 
comparison*[tiab])) OR (NMA[tiab] AND (FP[tiab] OR “fractional polynomial”[tiab])))) AND ("2012/01/01"[Date - Publication] : "3000"[Date - 
Publication]) 
578,004 
#20 Search (“controlled clinical trial”[mh] OR “controlled clinical trial”[pt] OR randomized[tiab] OR randomised[tiab] OR randomly[tiab] OR placebo*[tiab] 
OR trial[tiab]) 
1,121,737 
#21 Search (((“single arm”[tiab] OR “single agent”[tiab]) AND (trial[tiab] OR study[tiab])) OR (historical*[tiab] AND control*[tiab]) OR (“case series”[tiab] 
AND prospective*[tiab])) 
35,699 
#22 Search ("Clinical Trial, Phase II"[Publication Type] OR "Clinical Trial, Phase III"[Publication Type] OR "Clinical Trial, Phase IV"[Publication Type] OR 605,119 
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"Product Surveillance, Postmarketing"[mh] OR bayesian[tiab] OR “expanded access”[tiab] OR ((postmarketing[tiab] OR “post marketing”[tiab]) AND 
surveillance[tiab]) OR ((“2 arm”[tiab] OR “3 arm”[tiab] OR “4 arm”[tiab] OR “non inferiority”[tiab] OR superiority[tiab] OR “proof of concept”[tiab] OR 
“proof of principle”[tiab] OR “proof of correlation”[tiab] OR “phase 1 2”[tiab] OR “phase1 2”[tiab] OR “phase i ii”[tiab] OR “phasei ii”[tiab] OR “phase 
ii”[tiab] OR “phaseii”[tiab] OR “phase 2”[tiab] OR “phase2”[tiab] OR “ph ii”[tiab] OR phii*[tiab] OR “ph 2”[tiab] OR ph2*[tiab] OR “phase 2 3”[tiab] OR 
“phase2 3”[tiab] OR “phase ii iii”[tiab] OR “phaseii iii”[tiab] OR “phase iii”[tiab] OR phaseiii*[tiab] OR “phase 3”[tiab] OR phase3*[tiab] OR “ph 3”[tiab] 
OR ph3*[tiab] OR “ph iii”[tiab] OR phiii*[tiab] OR “phase iv”[tiab] OR phaseiv*[tiab] OR “phase 4”[tiab] OR phase4*[tiab] OR “ph 4”[tiab] OR ph4*[tiab] 
OR “ph iv”[tiab] OR phiv*[tiab] OR pivotal[tiab] OR efficacy[tiab] OR adaptive[tiab]) AND (trial[tiab] OR study[tiab] OR design[tiab])) OR (extension[tiab] 
AND (trial[tiab] OR study[tiab] OR phase[tiab])) OR (control*[tiab] AND (“clinical trial”[tiab] OR “clinical study”[tiab]))) 
#23 Search (#20 OR #21 OR #22) 1,512,299 
#24 Search (((“phase 1”[title] OR “phase i”[title] OR “phase 1a”[title] OR “phase 1b”[title] OR “phase Ia”[title] OR “phase Ib”[title] OR phase1[title] OR 
phasei[title]) NOT (“phase 1 2”[title] OR “phase 1b 2”[title] OR “phase 1b 2a”[title] OR “phase 1 2a”[title] OR “phase I II”[title] OR “phase Ib II”[title] OR 
“phase Ib IIa”[title] OR “phase I IIa”[title] OR “phase1 2”[title] OR “phase1b 2”[title] OR “phase1b 2a”[title] OR “phase 1 2a”[title] OR “phaseI II”[title] OR 
“phaseIb II”[title] OR “phaseIb IIa”[title] OR “phaseI IIa”[title] OR “phase 1 and 2”[title] OR “phase I and II”[title]))) 
11,576 
#25 Search (#23 NOT #24) 1,504,232 
#26 Search (#19 OR #25) 2,015,137 
#27 Search (#1 AND #4 AND #18 AND #26) 733 
#28 Search (#27) AND (pubstatusaheadofprint OR inprocess[sb]) 104 
 
Database: Cochrane Library 
Platform: Wiley 
URL: http://onlinelibrary.wiley.com/cochranelibrary/search/ 
Date searched: 2nd February 2017 at 14:00 GMT 
Hits: 92 
Cochrane Database of Systematic Reviews (CDSR) Issue 2 of 12, February 2017: 0 
Database of Abstracts of Reviews of Effect (DARE) Issue 2 of 4, April 2015: 0 
Cochrane Central Register of Controlled Trials (CENTRAL) Issue 1 of 12, January 2017: 92 
No. Query Results 
#1 MeSH descriptor: [Carcinoma, Non-Small-Cell Lung] explode all trees 2918 
#2 MeSH descriptor: [Central Nervous System Neoplasms] explode all trees 1820 
#3 (((lung or poumon) near/3 (neoplasm* or cancer* or carcinoma* or adenocarcinoma* or angiosarcoma* or chrondosarcoma* or sarcoma* or teratoma* 
or blastoma* or microcytic* or carcinogenesis or tumour* or tumor* or metasta* or métastasé or métastatique or avancé or "progression localisée")) or 
NSCLC* or mNSCLC* or "m NSCLC" or aNSCLC* or "a NSCLC" or msqNSCLC* or "msq NSCLC" or nonsqNSCLC or "non sqNSCLC" or "non sq 
NSCLC" or SqCLC* or "ns NSCLC" or nsNSCLC* or "n s NSCLC" or "la NSCLC" or laNSCLC* or CPNPC* or (LAC near/3 (lung or adenocarcinoma)) 
14,182 
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or ((SCC near/3 "squamous cell carcinoma") and lung) or (non near/3 small near/3 cell near/3 lung near/3 (cancer* or carcinoma*)) or (("non small" or 
nonsmall) near/3 lung near/3 cell near/3 (cancer* or carcinoma*)) or (("non small" or nonsmall) near/3 cell near/3 lung near/3 (cancer* or carcinoma*)) 
or (bronchial near/3 ("non small" or nonsmall) near/3 cell near/3 (cancer* or carcinoma*)) or ("non small cell" near/3 (lung or bronchial or pulmonary or 
bronchopulmonary or bronchus) near/3 (cancer* or carcinoma*)) or ("non small" near/3 cell near/3 (cancer* or carcinoma*) near/3 lung*) or (pulmonary 
near/3 "non small cell" near/3 (cancer* or carcinoma*)) or (large near/3 cell near/3 lung near/3 (cancer* or carcinoma*)) or ((squamous or non-
squamous or "non squamous") near/5 (cell or "non small cell") near/3 lung near/3 (cancer* or carcinoma*)) or (bronchus near/3 squamous near/3 cell 
near/3 (cancer* or carcinoma*)) or (lung near/3 epidermoid near/3 (cancer* or carcinoma*)) or (lung near/3 squamous near/3 cell near/3 (cancer* or 
carcinoma*)) or ((lung or poumon) and (NSCLC* or CPNPC* or "non small" or nonsmall or large or squamous or "non squamous" or non-squamous or 
"non à petites cellules")) or ((adenocancer or adenocarcinoma) near/3 (lung or pulmonary)) or (((cancer or tumeur) near/3 (poumon or bronchique)) 
and ("non à petites cellules" or "non-lié à de petites cellules")) or ((brain or CNS or "central nervous system" or cerebral) near/3 (metastasis or 
metastases or metastatic))):ti,ab,kw  
#4 #1 or #2 or #3  15,643 
#5 (ALK or ALKfusion or EML4ALK* or (anaplastic near/3 lymphoma near/3 kinase*) or (ALK* and (anaplastic or lymphoma or kinase))):ti,ab,kw  618 
#6 (L1196M or G1269A or C1156Y or L1152* or 1151Tins or G1202R or V118L or I1171T or S1206Y or F1174C or D1203N or G1269A or G1123S* or 
((crizotinib* or ceritinib* or alectinib* or "alk tki" or alktki or ALKi) near/3 (experienced or treated or pretreated or "pre treated" or "previously treated" or 
"treated previously" or resistan* or refractory or naïve))):ti,ab,kw  
12 
#7 #5 or #6  619 
#8 ("ALK TKI" or ALKTKI or (ALK near/3 (inhibitor or inhibitors)) or ((anaplastic near/3 lymphoma near/3 kinase) and (inhibitor or inhibitors)) or alectinib* 
or "af 802" or af802 or "ch 5424802" or ch5424802 or RO5424802 or RG7853 or Alecensa or crizotinib* or "pf 02341066" or pf02341066 or "pf 1066" 
or pf1066 or "pf 2341066" or pf2341066 or xalkori or ceritinib* or "ldk 378" or ldk378 or "nvp ldk 378" or "nvp ldk378" or "nvp ldk378nx" or zykadia or 
entrectinib* or "nms e 628" or "nms e628" or "rxdx 101" or rxdx101 or brigatinib* or "ap 26113" or ap26113 or lorlatinib* or "pf 06463922" or 
pf06463922 or "tsr 011" or tsr011 or "asp 3026" or asp3026 or "CEP 37440" or CEP37440 or "X 396" or X396 or "X 276" or X276 or "asp 3026" or 
asp3026 or "nvp tae 684" or "nvp tae684" or "tae 684" or tae684 or "CEP 28122" or CEP28122 or "CEP 14083" or CEP14083 or "CEP 14513" or 
CEP14513 or "GSK 1838705A" or GSK1838705A or CM118 or "CM 118"):ti,ab,kw  
76 
#9 MeSH descriptor: [HSP90 Heat-Shock Proteins] explode all trees 9 
#10 ("hsp 90 inhibitor" or "hsp90 inhibitor" or luminespib* or "auy 922" or auy922 or "nvp auy 922" or "nvp auy922" or "ver 52296" or ver52296 or 
ganetespib* or "sta 9090" or sta9090 or onalespib* or "AT 13387" or AT13387 or ribociclib* or "lee 011" or lee011 or "IPI 504" or IPI504 or 
retaspimycin or tanespimycin* or "kos 953" or kos953 or "nsc 330507" or nsc330507 or geldanamycin* or "nsc 122750" or nsc122750 or 
gamendazole* or gambogic* or "beta guttiferin" or "guttic acid" or celastrol* or tripterin or "biib 028" or biib028 or alvespimycin or "bms 826476" or 
bms826476 or "kos 1022" or kos1022 or "nsc 707545" or nsc707545 or Debio0932 or "debio 0932"):ti,ab,kw  
29 
#11 MeSH descriptor: [Proto-Oncogene Proteins c-akt] explode all trees 81 
#12 ((Akt or "c akt") near/3 (kinase or protein or proteins)):ti,ab,kw  159 
#13 MeSH descriptor: [Standard of Care] explode all trees 164 
#14 (((gold or golden) near/3 standard) or "best supportive care" or "standard of care" or (BSC near/3 (best or supportive or care)) or (SOC near/3 
(standard or care))):ti,ab,kw  
7249 
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#15 MeSH descriptor: [Placebos] explode all trees 23,137 
#16 placebo*:ti,ab,kw  188,991 
#17 MeSH descriptor: [Taxoids] explode all trees 2784 
#18 (daxotel or dexotel or docefrez or docetaxel* or "lit 976" or lit976 or deacetyltaxol or "nsc 628503" or nsc628503 or oncodocel or "rp 56976" or rp56976 
or taxoter or taxotere* or texot or taxespira or "abi 007" or abi007 or abraxane or anzatax or asotax or biotax or "bms 181339" or bms181339 or 
bristaxol or britaxol or coroxane or formoxol or genexol or "genexol pm" or hunxol or ifaxol or infinnium or intaxel or "mbt 0206" or mbt0206 or medixel 
or mitotax or "nab paclitaxel" or "nsc 125973" or nsc125973 or oncogel or onxol or pacitaxel or paclitaxel* or "paclitaxel nab" or pacxel or padexol or 
parexel or paxceed or paxene or paxus or praxel or taxocris or taxol or taxus or taycovit or yewtaxan):ti,ab,kw  
7728 
#19 MeSH descriptor: [Pemetrexed] explode all trees 188 
#20 MeSH descriptor: [Carboplatin] explode all trees 1162 
#21 MeSH descriptor: [Cisplatin] explode all trees 3646 
#22 (pemetrexed* or alimta* or ciambra or elimta or "ly 231514" or ly231514 or blastocarb or boplatex or carboplat or carboplatin* or carbosin or "carbosin 
lundbeck" or carbotec or carplan or CBDCA or cycloplatin or "delta west carboplatin" or erbakar or ercar or ifacap or "jm 8" or kemocarb or "nsc 
241240" or oncocarbin or paraplatin* or platinum* or abiplatin or biocisplatinum or biocysplatinum or blastolem or briplatin or "cddp ti" or "cis ddp" or 
"cis diamine dichloroplatinum" or "cis diaminechloroplatinum" or "cis diaminedichloroplatinum" or "cis diammine dichloroplatinum" or "cis 
diamminedichloroplatinum" or "cis dichloridiammineplatinum" or "cis dichloroadiamine platinum" or "cis dichlorodiamine platinum" or "cis 
dichlorodiammineplatinum" or "cis platinous diamino dichloride" or "cis platinum" or (cis* near/3 platinum*) or cisplatin* or cisplatyl or citoplatino or 
cytoplatin or cytosplat or "diamine dichloroplatinum" or diaminodichloroplatinum or diamminedichloroplatinum or "dichlorodiamine platinum" or 
dichlorodiammineplatinum or docistin or elvecis or kemoplat or lederplatin or lipoplatin or "liposomal cisplatin" or "mpi 5010" or mpi5010 or neoplatin or 
niyaplat or "nk 801" or noveldexis or "nsc 119875" or platamine or "platamine rtu" or platiblastin or platidiam or platimine or platinex or platinil or 
platinol* or platinoxan or platiran or platistil or platistin or platosin or randa or romcis or sicatem or "spi 077" or tecnoplatin or gemcitabine* or gemzar* 
or difluorodeoxycytidine or gemcite or "ly 188011" or ly188011 or vinorelbine* or noranhydrovinblastine or anhydrovinblastine or "anx 530" or anx530 
or eunades or exelbine or "kw 2307" or kw2307 or navelbin or navirel or vinbine or vinelbine):ti,ab,kw  
14,225 
#23 ("PD L1" or PDL1 or "PD 1" or PD1 or nivolumab* or "bms 936558" or bms936558 or "mdx 1106" or mdx1106 or "ono 4538" or ono4538 or opdivo or 
pembrolizumab* or keytruda or lambrolizumab or "mk 3475" or mk3475 or avelumab* or "msb 0010718c" or msb0010718c or atezolizumab* or "mpdl 
3280a" or mpdl3280a or "mpdl 3280a" or mpdl3280a or "rg 7446" or rg7446 or durvalumab* or medi4736 or "medi 4736" or ticilimumab* or 
tremelimumab* or "cp 675 206" or "cp 675, 206" or "cp 675206" or "cp675 206" or "cp675, 206" or cp675206):ti,ab,kw  
409 
#24 (rabusertib* or LY2603618 or "LY 2603618" or prexasertib* or "ly 2606368" or ly2606368 or (("CHK 1" or CHK1) near/3 inhibitor*)):ti,ab,kw  8 
#25 MeSH descriptor: [Insulin-Like Growth Factor I] explode all trees 1536 
#26 MeSH descriptor: [Receptor, IGF Type 1] explode all trees 24 
#27 (figitumumab* or "cp 751871" or cp751871 or "insulin like growth factor" or "IGF type 1" or "IGF 1r" or IGF1R or "IGF 1 receptor"):ti,ab,kw  2358 
#28 MeSH descriptor: [Receptor, Epidermal Growth Factor] explode all trees 538 
#29 (afatinib or canertinib or dacomitinib or erlotinib or gefitinib or genistein or icotinib or lapatinib or naquotinib or nazartinib or neratinib or olmutinib or 
osimertinib or pelitinib or poziotinib or rociletinib or sapitinib or tarloxotinib or varlitinib or (("EGF receptor" or "epidermal growth factor receptor") near/3 
inhibit*)):ti,ab,kw  
1927 
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#30 MeSH descriptor: [Bevacizumab] explode all trees 680 
#31 (bevacizumab* or altuzan or avastin or "nsc 704865" or nsc704865):ti,ab,kw  2423 
#32 MeSH descriptor: [Antineoplastic Agents] explode all trees 11,910 
#33 MeSH descriptor: [Immunotherapy] explode all trees 7784 
#34 MeSH descriptor: [Drug Therapy] explode all trees 131,020 
#35 MeSH descriptor: [Protein Kinase Inhibitors] explode all trees 673 
#36 #8 or #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16 or #17 or #18 or #19 or #20 or #21 or #22 or #23 or #24 or #25 or #26 or #27 or #28 or #29 
or #30 or #31 or #32 or #33 or #34 or #35  
309,094 
#37 MeSH descriptor: [Review] explode all trees 55 
#38 MeSH descriptor: [Meta-Analysis] explode all trees 166 
#39 (metaanalysis or "meta analysis" or "systematic review" or "adjusted indirect comparison" or (systematic* near/3 review*) or ((mixed or indirect) near/3 
treatment* near/3 comparison*) or (simulated near/3 (treatment* or tx) near/3 comparison*) or (match* near/4 adjust* near/3 (indirect or comparison*)) 
or (nma near/3 (network or metaanalysis or "meta analysis")) or (itc near/3 (indirect or treatment* or comparison*)) or (mtc near/3 (mixed or treatment* 
or comparison*)) or (maic near/4 (match* or adjust* or indirect or comparison*)) or (stc near/3 (simulated or treatment* or comparison*)) or (NMA 
near/3 (FP or "fractional polynomial"))):ti,ab,kw  
45,571 
#40 #37 or #38 or #39 Publication Year from 2012 to 2017 22,171 
#41 MeSH descriptor: [Controlled Clinical Trial] explode all trees 170 
#42 (randomized or randomised or randomly or placebo or trial):ti,ab,kw  670,855 
#43 MeSH descriptor: [Case Reports] explode all trees 1 
#44 ((("single arm" or "single agent") near/3 (trial or study)) or (historical* near/3 control*) or ("case series" and prospective*)):ti,ab,kw  2268 
#45 MeSH descriptor: [Clinical Trial, Phase II] explode all trees 0 
#46 MeSH descriptor: [Clinical Trial, Phase III] explode all trees 1 
#47 MeSH descriptor: [Clinical Trial, Phase IV] explode all trees 0 
#48 MeSH descriptor: [Product Surveillance, Postmarketing] explode all trees 242 
#49 (bayesian or "expanded access" or ((postmarketing or "post marketing") near/2 surveillance) or (("2 arm" or "3 arm" or "4 arm" or "non inferiority" or 
superiority or "proof of concept" or "proof of principle" or "proof of correlation" or "phase 1 2" or "phase1 2" or "phase i ii" or "phasei ii" or "phase ii" or 
"phaseii" or "phase 2" or "phase2" or "ph ii" or phii* or "ph 2" or ph2* or "phase 2 3" or "phase2 3" or "phase ii iii" or "phaseii iii" or "phase iii" or 
phaseiii* or "phase 3" or phase3* or "ph 3" or ph3* or "ph iii" or phiii* or "phase iv" or phaseiv* or "phase 4" or phase4* or "ph 4" or ph4* or "ph iv" or 
phiv* or pivotal or efficacy or adaptive) near/5 (trial or study or design)) or (extension near/3 (trial or study or phase)) or (control* near/3 ("clinical trial" 
or "clinical study"))):ti,ab,kw  
182,498 
#50 #41 or #42 or #43 or #44 or #45 or #46 or #47 or #48 or #49  678,501 
#51 (("phase 1" or "phase i" or "phase 1a" or "phase 1b" or "phase Ia" or "phase Ib" or phase1 or phasei) not ("phase 1 2" or "phase 1b 2" or "phase 1b 2a" 
or "phase 1 2a" or "phase I II" or "phase Ib II" or "phase Ib IIa" or "phase I IIa" or "phase1 2" or "phase1b 2" or "phase1b 2a" or "phase 1 2a" or "phaseI 
II" or "phaseIb II" or "phaseIb IIa" or "phaseI IIa" or "phase 1 and 2" or "phase I and II")):ti  
3338 
#52 #50 not #51  675,858 
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#53 #40 or #52  688,831 
#54 #4 and #7 and #36 and #53  92 
#55 #54 in Cochrane Reviews (reviews and protocols), other reviews and trials 92 
Abbreviation: MesH=Medical Subject Headings. 
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DESCRIPTION OF THE EVIDENCE USED  
 
Guidelines for diagnosis and management  
 
Table A10. Overview of guidelines 
Name of 
society/organisation 
issuing guidelines 
Date of 
issue  
Countries to 
which guideline 
applies 
Summary of recommendations 
(level of evidence/grade of 
recommendation for the indication under 
assessment) 
European Society for 
Medical Oncology [8] 
2016 European Union 
members 
For patients with ALK-positive metastatic 
NSCLC, crizotinib as first-line treatment is 
the preferred option (level of evidence: 
evidence from at least one large 
randomised controlled trial of good 
methodological quality [low potential for 
bias] or meta-analyses of well-conducted 
randomised trials without heterogeneity; 
grade of recommendation: strongly 
recommended). Ceritinib and alectinib 
(‘currently in clinical development’ at the 
time of the last update of this guideline) are 
recommended for ALK-positive NSCLC 
patients whose disease progresses while 
they are receiving treatment with crizotinib 
(level of evidence: prospective cohort 
studies; grade of recommendation: strongly 
recommended).  
For the treatment of CNS metastases, next-
generation TKIs are recommended to 
restore control of brain disease and delay 
cranial radiotherapy in patients with a 
druggable oncogene driver and clinically 
asymptomatic brain metastases (level of 
evidence: prospective cohort studies; grade 
of recommendation: strongly 
recommended). For ALK-positive patients 
whose disease progresses while they are 
receiving crizotinib, ceritinib or alectinib is 
recommended because of their activity 
against CNS disease (level of evidence: 
prospective cohort studies; grade of 
recommendation: strongly recommended) 
American Society of 
Clinical Oncology  
2017 United States If patients have stage IV NSCLC and ALK 
rearrangements, first-line crizotinib therapy 
is recommended (type: evidence based; 
benefits outweigh harms evidence quality: 
intermediate strength of recommendation: 
moderate) 
National 
Comprehensive 
Cancer Network  
2017 
(version 9) 
United States Alectinib, crizotinib and ceritinib are all 
considered as category 1 agents (based on 
high-level evidence, there is uniform 
National Comprehensive Cancer Network  
consensus that the intervention is 
appropriate) first-line therapy after detection 
of ALK-positive NSCLC, but alectinib has 
been awarded category 1 ’preferred’ status. 
If the ALK rearrangement is discovered 
during first-line chemotherapy, the 
chemotherapy should be interrupted or 
completed and treatment with alectinib, 
crizotinib or ceritinib should be initiated 
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College of American 
Pathologists, the 
International 
Association for the 
Study of LungCancer 
and the Association 
for Molecular 
Pathology [49] 
2014 United States Recommendation: Laboratories should use 
an ALK FISH assay using dual-labelled 
break-apart probes for selection of patients 
for ALK TKI therapy; ALK IHC, if carefully 
validated, may be considered as a 
screening method to select specimens for 
ALK FISH testing 
Recommendation: RT-PCR is not 
recommended as an alternative to FISH for 
selection of patients for ALK inhibitor 
therapy 
Expert consensus opinion: A pathologist 
should be involved in the selection of 
sections for ALK FISH testing, by assessing 
tumour architecture, cytological aspects and 
specimen quality 
Expert consensus opinion: A pathologist 
should participate in the interpretation of 
ALK FISH slides, either by performing the 
analysis directly or by reviewing the 
interpretations of cytogeneticists or 
technologists with specialised training in 
solid tumour FISH analysis 
Expert consensus opinion: Testing for 
secondary mutations in ALK associated with 
acquired resistance to ALK inhibitors is not 
currently required for clinical management 
Abbreviations: ALK=anaplastic lymphoma kinase; CNS=central nervous system; FISH=fluorescence in situ hybridisation; 
IHC=immumohistochemistry; NSCLC=non-small cell lung cancer; RT-PCR=reverse transcription polymerase chain 
reaction; TKI=tyrosine kinase inhibitor. 
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Table A11. Estimated treatment population in absolute numbers in 2017, (%) 
 France Germany Italy Spain United Kingdom 
Total lung cancer incident population 45,222 (100) 56,099 (100)  41,300 (100) 27,696 (100) 46,403 (100) 
NSCLC incident population 37,263 (82.4) 47,469 (84.6) 35,105 (85.0) 23,899 (86-3) NA 
De novo advanced/metastatic (stage IIIB/IV) 
disease patientsa 
30,108 (66.6) 38,452 (68.6) 29,839 (72.3) 19,525 (70.5) NA 
Total ALK-positive NSCLC patients eligible for first-
line treatment 
NA 1,923 (3.4) NA  976 (3.5) NA 
Total ALK-positive NSCLC patients who received 
first-line treatmentb 
626 (1.4) 661 (1.2) 492 (1.2) 400 (1.4) 429 (0.9) 
Abbreviations: NA=not applicable; NSCLCnon-small cell lung cancer 
aRecurrent patients from early stages plus de novo advanced/metastatic disease patients.  
bALK positivity rate is assumed to be 5%; however, there is expected to be variation in this rate across Europe and testing rates may differ between squamous and non-squamous NSCLC patients. 
Tissue availability, testing rate, direct treatment rate and exclusion of patients in clinical trials (for 2017) need to be considered to reach the total number of treated patients. The rates are expected to 
differ across France, Italy, Germany, Spain and the United Kingdom. 
Source: [17] 
The target population of treatment-naïve adult patients with ALK-positive advanced NSCLC was estimated from epidemiology data from five countries (France, 
Italy, Germany, Spain, United Kingdom) provided by the MAH in the submission file. From the absolute numbers provided, the respective percentages were 
calculated for each country based on the total lung cancer incident population. These probabilities were then applied to calculate a range for the overall numbers 
in Europe based on the total lung cancer incident population by GLOBOCAN [54].  
 
PTJA03 - Alectinib as monotherapy for the first line treatment of ALK-positive advanced NSCLC 
 
 
Version 1.3, 22th January 2018 EUnetHTA Joint Action 3 WP4 96 
 
Evidence tables of individual studies included for clinical effectiveness and safety 
 
Table A12. Summary of efficacy for the ALEX trial  
Title: A randomized, multicentre, Phase III, open-label study of alectinib versus crizotinib in treatment-naïve ALK-positive 
advanced NSCLC  
Study identifier  BO28984  
Design  Open-label, randomised, comparative study  
Duration of main phase:  
Hypothesis  Superiority  
Treatments groups  Alectinib  600 mg BID alectinib, orally 
continuously (cycles of 28 days) until 
disease progression, death, or 
withdrawal, number randomized: 152 
patients  
Crizotinib  250 mg crizotinib BID, orally continuously (Cycles of 28 
days) until disease progression, death, or withdrawal, 
number randomized: 151 patients  
Endpoints and definitions  Primary endpoint  PFS by INV  Progression-free survival  
Key secondary endpoint  PFS by IRC  Progression-free survival 
Title: A randomized, multicentre, Phase III, open-label study of alectinib versus crizotinib in treatment-naïve ALK-positive 
advanced NSCLC  
Study identifier  BO28984  
Design  Open-label, randomised, comparative study  
Duration of main phase:  
Hypothesis  Superiority  
Treatments groups  Alectinib  600 mg BID alectinib, orally 
continuously (cycles of 28 days) until 
disease progression, death, or 
withdrawal, number randomized: 152 
patients  
Crizotinib  250 mg crizotinib BID, orally continuously (Cycles of 28 
days) until disease progression, death, or withdrawal, 
number randomized: 151 patients  
Endpoints and definitions  Primary endpoint  PFS by INV  Progression-free survival  
Key secondary endpoint  PFS by IRC  Progression-free survival 
Assessment report 
EMA/CHMP/833519/2017 Page 42/77 
Secondary endpoints other  
Time to CNS progression (IRC)  
ORR (INV)  
OS  
DoR (INV)  
CNS ORR CNS DoR  
Overall response rates  
Overall survival  
Duration of response  
CNS Overall response rates by IRC  
CNS Duration of response by IRC  
Database lock  31 March 2017  
Results and Analysis  
Analysis description  Primary Analysis  
Analysis population and time point description  Intent to treat  
Descriptive statistics and 
estimate variability  
Treatment group  Crizotinib  Alectinib  Hazard ratio  
Number of subjects  n=151  n=152  NA  
PFS (INV)  
(Months)  
11.1  NE  0.47  
95% CI  [9.1-13.1]  [17.7-NE]  [0.34-0.65]  
PFS (IRC)  
(Months)  
95% CI  
10.4  
[7.7-14.6]  
25.7  
[19.9-NE]  
0.50  
[0.36-0.70]  
OS  
(Months)  
NR  NR  NA  
ORR  
(%)  
76 %  83 %  NA  
95% CI  [67.8-82.1]  [76.0-88.5]  NA  
DOR  
(Months)  
11.1  NE  
95% CI  [7.9-13.0]  NE  
Abbreviations: INV=investigator  IRC=independent review committee; CI=confidence interval; HR=hazard ratio; NE=not 
estimable;  ORR=objective response rate; OS=overall survival; DOR=duration of response; PFS=progression-free survival 
Source: Alecensa EPAR variation II/0001, Table 17  
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Table A13. Summary of efficacy for the ASCEND-4 trial 
Title: A phase III multicenter, randomized study of oral LDK378 versus standard 
chemotherapy in previously untreated adult patients with ALK rearranged (ALK-positive), stage IIIB or IV, non-
squamous non-small cell lung cancer 
Study identifier CLDK378A2301 (ASCEND-4) 
Design Open-label, randomised vs. chemotherapy in first line 
Duration of main phase: 
Duration of run-in phase: 
Duration of extension phase: 
 
Study ongoing 
Hypothesis Superiority 
Treatments groups Ceritinib Ceritinib 750 mg once daily. 189 patients 
Chemotherapy Pemetrexed (500 mg/m2 IV every 21 days) plus 
cisplatin (75mg/m² IV every 21 days) or 
pemetrexed (500 mg/m2 IV every 21 days) plus 
carboplatin (AUC 5-6 IV every 21 days) for four 
cycles of treatment (induction) followed by 
pemetrexed alone as a single agent (maintenance) 
every 21 days in patients without progressive 
disease after induction chemotherapy. 187 patients 
  Treatment with ceritinib or chemotherapy was 
continued until the patient experienced 
progressive disease, unacceptable toxicity, 
pregnancy or start of a new anticancer therapy or 
discontinued treatment at the discretion of the 
patient or investigator, was lost to follow-up or 
died or the study was terminated by sponsor 
Endpoints and 
definitions 
Primary 
endpoint 
PFS by BIRC Time from the date of randomisation to the date of 
the first radiologically documented disease 
progression per BIRC assessment or death from 
any cause 
Secondary OS Time from date of randomisation to date of death 
from any cause 
Secondary ORR by BIRC Proportion of patients with a best overall response 
of complete response or partial response 
Database lock 11th September 2016 
Results and analysis 
Analysis description Primary analysis 
Analysis population and time 
point description 
Intent to treat 
Descriptive statistics and 
estimate variability 
Treatment group Ceritinib Chemotherapy 
Number of participants 189 187 
Median PFS, months 16.6 8.1 
95% CI, months 12.6–27.2 5.8–11.1 
Median OS, months NE 26.2 
95% CI, months 29.3 to NE 22.8 to NE 
ORR (%) 72.5 26.7 
95% CI 65.5–78.7 20.5–33.7 
Effect estimate per 
comparison 
PFS Comparison groups Ceritinib vs. chemotherapy 
HR 0.55 
95% CI 0.42–0.73 
p <0.001 
OS Comparison groups Ceritinib vs. chemotherapy 
HR 0.73 
95% CI 0.50–1.08 
p 0.056 
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Notes The data cutoff date for this primary analysis was 24th June 2016, when 202 PFS events 
had been documented as per BIRC assessment and 218 PFS events had been 
documented as per investigator assessment. The analyses are presented with use of data 
locked on 11th September 2016. The study is ongoing. The median duration between 
randomisation and t h e  data cutoff date for all patients was 19.7 months 
Abbreviations: AUC=area under the curve; BRIC=blinded independent review committee; CI=confidence interval; 
HR=hazard ratio; IRC=independent review committee; IV=intravenously; NE=not estimable; OR=odds ratio; 
ORR=objective response rate; OS=overall survival; PFS=progression-free survival. 
Source: Zykadia EPAR variation II/12, Table 23. 
Table A14. Summary of efficacy for the PROFILE 1014 trial 
Title: Phase 3, Randomized, Open-Label Study of the Efficacy and Safety of Crizotinib Versus 
Pemetrexed/Cisplatin or Pemetrexed/Carboplatin in Previously Untreated Patients with Non-Squamous Carcinoma of 
the Lung Harboring a Translocation or Inversion Event Involving the Anaplastic Lymphoma Kinase (ALK) Gene Locus 
Study identifier A8081014 (PROFILE 1014) 
Design Open-label, multicentre, randomised, phase III study 
Duration of main phase: until disease progression, unacceptable 
toxicity, death or patient consent withdrawal 
Duration of run-in phase: not applicable 
Duration of extension phase: not applicable 
Hypothesis Superiority 
Treatments groups Crizotinib 250 mg twice daily, continuous daily dosing schedule, 172 
patients randomised 
Chemotherapy Pemetrexed 500 mg/m
2 
IV plus cisplatin 75 mg/m
2 
IV, 
every 3 weeks 
 
Pemetrexed 500 mg/m
2 
IV plus carboplatin AUC 5–6 mg 
mL/min, every 3 weeks 
 
Maximum 6 cycles 
171 patients randomised 
Endpoints and definitions Primary 
endpoint 
PFS Time from the date of randomisation to the date of 
the first documentation of objective tumour progression 
(by IRR) or death during the study from any cause, 
whichever occurred first 
Secondary 
endpoints 
OS Time from randomisation to the date of death from any 
cause 
ORR Percentage of patients with CR or PR according to 
RECIST 1.1, as determined by IRR 
TTR Time from randomisation to first documentation of 
objective tumour response (CR or PR), as determined by 
IRR 
DR Time from the first documentation of objective tumour 
response (CR or PR), as determined by IRR, to the first 
documentation of objective tumour progression or to 
death from any cause, whichever occurred first 
DCR Percentage of patients with CR, PR or stable disease at 
12 weeks according to RECIST 1.1, as determined by IRR 
TTP Time from randomisation to first documentation of 
objective tumour progression, as determined by IRR 
IC-TTP Time from randomisation to first documentation of 
objective intracranial disease progression, based on 
either new brain metastases or progression of existing 
brain metastases, as determined by IRR 
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EC-TTP Time from randomisation to first documentation of 
objective extracranial disease progression, based on 
either new extracranial lesions or progression of existing 
extracranial lesions, as determined by IRR 
PRO TTD in pain in chest, dyspnoea and cough as the time 
from randomisation to the earliest date the patient’s 
scale scores showed a 10 point or greater increase after 
the baseline in any of these three symptoms 
Data cutoff date 30th November 2013 
Results and analysis  
Analysis description Primary analysis 
Analysis population and time 
point description 
Full analysis population 
Descriptive statistics and 
estimate variability 
 
Treatment group Crizotinib Chemotherapy 
Number of participants 172 171 
Primary endpoint 
PFS (IRR) 
Participants with events, n 
(%) 
 
100 (58.1) 
 
137 (80.1) 
PFS (median), months 10.9 (8.3–13.9) 7.0 (6.8–8.2) 
(95% CI) 
Stratified hazard ratio 0.45 (0.35–0.60) 
(95% CI) 
p (one-sided stratified log-
rank test) 
<0.0001 
Secondary endpoints 
OS 
Participants with events, n 
(%) 
 
44 (25.6) 
 
46 (26.9) 
OS (median), months Not reached Not reached 
Stratified hazard ratio 0.82 (0.54–1.26) 
(95% CI) 
p (one-sided stratified log-
rank test) 
0.18 
ORR (CR plus PR), 
n (%) 
 
128 (74.4) 
 
77 (45.0) 
Risk ratio, % (95% CI) 
(two-sided CMH chi-square 
test stratified) 
1.66 (1.38–2.01) 
p (two-sided Pearson chi-
square test) 
<0.0001 
TTR (median), weeks 
(range) 
 
6.1 (2.7-41.4) 
 
12.1 (5.1-36.7) 
Duration of response 
(median), weeks (95% CI) 
 
49.0 (35.1–60.0) 
 
22.9 (18.0–25.1) 
DCR (CR plus PR plus SD), 
n (%) 
95% CI, months 
135 (79) 
72–84 
117 (68) 
61–75 
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p (two-sided Pearson chi-
square test) 
0.038 
TTP, n (%) 
Median, months 
95% CI, months 
 
89 (51.7) 
13.6 
8.5–15.0 
 
132 (77.2) 
7.0 
6.8–8.3 
Hazard ratio 
95% CI 
p (one-sided unstratified 
log-rank test) 
0.44 
0.33–0.58 
<0.0001 
IC-TTP 
n (%) 
Median, months 
95% CI, months 
 
25 (14.5) 
Not reached 
 
26 (15.2) 
17.8 
(13.9–) 
Hazard ratio 
(95% CI) 
0.59 (0.34–1.05)  
p (one-sided unstratified 
log-rank test) 
0.034  
EC-TTP 
n (%) 
Median, months 
95% CI, months 
 
71 (41.3) 
15.2 
12.6–21.9 
 
119 (69.6) 
7.2 
6.9–8.5 
Hazard ratio 
(95% CI) 
0.38 (0.29–0.52)  
p (one-sided unstratified 
log-rank test) 
<0.0001  
Abbreviations: AUC=area under the curve; CI=confidence interval; CMH= Cochran-Mantel-Haenszel; CR=complete 
response; DCR=disease control rate; DR= duration of response; EC-TTP=extracranial time to progression; IC-TTP= 
intracranial time to progression; IRR=independent radiological review; IV=intravenously; ORR=objective response rate; 
OS=overall survival; PFS=progression-free survival; PR=partial response; PRO=patient-reported outcome; 
RECIST=Response Evaluation Criteria in Solid Tumors; SD=stable disease; TTD=time to deterioration; TTP=time to 
progression; TTR=.time to tumour response 
Source: Xalkori EPAR variation II/24. 
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Table A15: Characteristics of other relevant studies  
Study 
reference/ID 
Objective Study design Key disease-related eligibility 
criteria 
Intervention/compar
ator 
(number enrolled) 
Primary outcome 
measure 
Key secondary 
outcome measures 
ALEX 
(BO28984) 
(NCT02075840) 
To evaluate and 
compare the efficacy 
of alectinib vs. 
crizotinib  
Phase III, randomised, 
active-controlled, 
multicentre, open-label 
study 
Advanced (stage IIIB) or metastatic 
(stage IV) ALK-positive NSCLC 
ALK-positive confirmed by IHC 
No prior systemic treatment for 
NSCLC  
Prior brain or leptomeningeal 
metastases allowed if asymptomatic 
ECOG PS 2 
ALEC 600 mg BID 
(152) 
CRZ 250 mg BID 
(151) 
PFS (INV) by 
RECIST 1.1 
ORR (INV), C-TTP 
(IRC), PFS (IRC), DOR, 
OS, AEs (%), TTD 
(EORTC QLQ-C30, 
QLQ-LC13), HRQoL 
(EORTC QLQ-C30, 
QLQ-LC13) 
Safety endpoints 
PROFILE 1014 
(NCT01154140) 
To evaluate and 
compare the efficacy 
of crizotinib vs. 
chemotherapy 
Phase III, randomised, 
active-controlled 
multicentre, open-label 
study 
Locally advanced, recurrent or 
metastatic non-squamous NSCLC 
ALK-positive NSCLC determined by 
FISH centrally 
No prior systemic treatment for 
NSCLC 
Patients with brain metastases only 
if treated and neurologically stable 
with no ongoing requirement for 
corticosteroids 
ECOG PS 2 
CRZ 250 mg BID 
(172) 
PEM 500 mg/m2 plus 
CIS 75 mg/m2 or 
CARB AUC 
56 mg/mL/min 3-
week cycle, 
maximum of 
six cycles (171) 
PFS (IRC) ORR, OS, OS at 12 and 
18 months, safety, 
PROs, C-TTP, TTD 
(chest pain, dyspnoea, 
cough), C-PD 
Safety endpoints 
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Study 
reference/ID 
Objective Study design Key disease-related eligibility 
criteria 
Intervention/compar
ator 
(number enrolled) 
Primary outcome 
measure 
Key secondary 
outcome measures 
PROFILE 1029 
(NCT01639001) 
To evaluate and 
compare the efficacy 
of crizotinib vs. 
chemotherapy in an 
East Asian 
population of China, 
Hong Kong, 
Malaysia, Taiwan 
and Thailand 
Phase III, randomised, 
active-controlled 
multicentre, open-label 
study 
Locally advanced, recurrent or 
metastatic non-squamous NSCLC 
ALK-positive NSCLC determined by 
FISH 
No prior systemic treatment for 
NSCLC 
Patients with brain metastases only 
if treated and neurologically stable 
with no ongoing requirement for 
corticosteroids 
ECOG PS 2 
CRZ 250 mg BID 
(104) 
PEM 500 mg/m2 plus 
CIS 75 mg/m2 or 
CARB AUC 56 
mg/mL/min 3-week 
cycle, 
maximum of 6 cycles 
(103) 
PFS (IRC) ORR, OS, DCR 
(12 weeks), landmark 
survival (1 year, 
18 months), DOR (IRC), 
TTP (IRR), C-TTP, 
extracranial TTP, PROs 
(QLQ-C30, QLQ-LC13, 
EQ-5D VAS and index 
change from baseline), 
safety endpoints 
ASCEND-4 
(NCT01828099) 
To evaluate and 
compare the efficacy 
of ceritinib vs. 
chemotherapy 
Phase III, randomised, 
parallel assignment, 
multicentre, open-label 
study 
Locally advanced, recurrent or 
metastatic non-squamous NSCLC 
ALK-positive NSCLC by IHC 
No prior systemic treatment for 
NSCLC 
Patients with brain metastases only 
if neurologically stable and who 
have not required increasing doses 
of steroids 
ECOG PS 2 
Ceritinib (189) 
Chemotherapy (187) 
PFS (IRC) by 
RECIST 1.1 
OS, PFS (INV), ORR, 
DOR, DCR, time to 
response (IRC or INV), 
C-ORR, C-DCR, C-
DOR, C-CBR, PROs, 
safety, ceritinib PK 
Abbreviations: AEadverse event; ALECalectinib; AUCarea under the concentration–time curve; BIDtwice daily; C30core 30; CARBcarboplatin; CBR=; C-CBR=central nervous system; C-
DCR=central nervous system disease control rate; C-DOR=central nervous system duration of response; CIScisplatin; C-ORR central nervous system objective response rate; C-PD=central nervous 
system progressive disease; CRZcrizotinib; C-TTP=central nervous system time to progression; DCRdisease control rate; DORduration of response; ECOG PSEastern Cooperative Oncology 
Group performance status; EORTCEuropean Organisation for Research and Treatment of Cancer; FISHfluorescence in situ hybridisation; HRQoLhealth-related quality of life; 
IHCimmunohistochemistry; INVinvestigator assessed; IRCindependent review committee; IRRindependent radiological review; L13lung cancer module; NSCLCnon-small cell lung cancer; 
ORRobjective response rate; OSoverall survival; PDprogressive disease; PEMpemetrexed; PFSprogression-free survival; PKpharmacokinetics; PROpatient-reported outcome; QLQquality-of-
life questionnaire; RECISTResponse Evaluation Criteria in Solid Tumors; TTDtime to deterioration; TTPtime to progression; VASvisual analogue scale. 
Source: ClinicalTrials.gov. 
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Ongoing and planned studies 
 
Table A16. Ongoing studies of alectinib monotherapy for ALK-positive non-small cell lung cancer 
Study 
identifier 
Estimated 
completion 
date 
Study 
type 
Number of 
patients 
Intervention Comparator Patient 
population 
Endpoints 
BO39694 - 
ROP 
NA 
/LPLV Q2 
2024 
Rollover 
(ROP) 
All Alectinib All ROP 
comparators 
ALK-positive 
NSCLC 
This is a rollover study for patients with ALK-positive or RET-positive 
cancer treated with alectinib or crizotinib. 
Primary Objective: To provide continued treatment with alectinib or 
crizotinib as applicable to patients with ALK-positive or RET-positive 
cancer who were previously enrolled in any Roche-sponsored alectinib 
study and who are deriving continued clinical benefit from alectinib or 
crizotinib in the parent trial at the time of parent trial closure 
Secondary Objective: To assess long-term safety of alectinib therapy 
NP28673 
ACCALIA 
G second 
line 
Data: Q4 
2017, 
/LPLV Q3 
2017 
Phase II 153 
 
Alectinib NA 
 
ALK-positive 
NSCLC 
Objectives: Part 1 – determination of a phase II recommended dose – 
dose escalation study 
Primary Objectives: The primary objectives for part 1 of the study are as 
follows: 
• To determine the RP2D of RO5424802 to be used in 
part 2 of the study 
• To evaluate the safety and tolerability of 600-mg and 900-mg (if 900 mg 
is reached) 
doses of RO5424802 administered twice daily to patients with locally 
advanced (AJCC stage IIIB) NSCLC not amenable to curative therapy or 
metastatic (AJCC stage IV) NSCLC who have ALK rearrangement and in 
whom prior crizotinib 
therapy has failed 
• To characterise DLTs, if any, associated with RO5424802 after 21 days 
of treatment when administered twice daily at 600- and 900-mg (if 900 
mg is reached) doses to patients with locally advanced (AJCC stage IIIB) 
NSCLC not amenable to curative therapy or metastatic (AJCC stage IV) 
NSCLC who have ALK rearrangement 
and in whom prior crizotinib therapy has failed 
• To characterise the PK of RO5424802 and its major metabolites 
Part 2 – evaluation of safety and efficacy of RO5424802 in ALK-positive 
NSCLC patients with ALK rearrangements 
Efficacy objectives 
Primary efficacy::To evaluate efficacy of RO5424802 by ORR as per 
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Study 
identifier 
Estimated 
completion 
date 
Study 
type 
Number of 
patients 
Intervention Comparator Patient 
population 
Endpoints 
central IRC review of radiographs using RECIST 1.1 in the overall 
population (with and without prior exposure to cytotoxic chemotherapy) 
Secondary efficacy: To evaluate efficacy of RO5424802 by ORR as per 
central IRC using RECIST 1.1 in patients without prior exposure to 
cytotoxic chemotherapy. 
Additional secondary objectives for the overall population of patients with 
prior exposure to cytotoxic chemotherapy and patients without prior 
exposure to cytotoxic chemotherapy are as follows: 
• To evaluate efficacy of RO5424802 by ORR per investigator review of 
radiographs 
using RECIST 1.1 
• To evaluate DCR of RO5424802 based on IRC and investigator review 
of radiographs 
• To assess DOR in patients treated with RO5424802 based on IRC and 
investigator review of radiographs 
• To evaluate the PFS in patients treated with RO5424802 based on IRC 
and investigator review of radiographs 
• To evaluate C-ORR in patients with CNS metastases who have 
measurable disease in the CNS at the baseline, based on IRC review of 
radiographs 
• To assess C-DOR in patients who have a CNS objective response 
based on IRC review of radiographs 
• To assess C-PRs at 3, 6, 9 and 12 months based on cumulative 
incidence by IRC review of radiographs 
• To assess OS 
Safety Objectives: The safety objectives for this study are as follows: 
• To evaluate the safety profile of RO5424802 using NCI CTCAE version 
4.03 
• To assess the effect of RO5424802 on cardiac repolarisation (QTc) 
Pharmacokinetic objectives: The pharmacokinetic objectives for this 
study are as follows: 
• To evaluate the PK of RO5424802 and metabolite(s) in patients with 
ALK-mutated 
NSCLC 
o To characterise the PK of RO5424802 and metabolite(s) in Taiwanese 
and Korean patients (for Taiwan and Korea sites only) 
o To evaluate the effect of multiple oral dosing of RO5424802 on the PK 
of a single oral dose of midazolam, an in vivo probe substrate of CYP3A 
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Study 
identifier 
Estimated 
completion 
date 
Study 
type 
Number of 
patients 
Intervention Comparator Patient 
population 
Endpoints 
activity in a subset of cancer patients 
Exploratory objectives: The exploratory objectives for this study are as 
follows: 
• To evaluate ORR in patients with EGFR mutation who have 
experienced disease 
progression while receiving RO5424802 alone and who are subsequently 
treated with a combination of RO5424802 and erlotinib (part 3) 
• To evaluate the PK of RO5424802 and its major metabolite(s) and 
erlotinib in patients with EGFR mutation who have experienced disease 
progression while receiving RO5424802 alone and who receive the 
combination of RO5424802 and erlotinib (part 3) 
• To evaluate the safety profile of RO5424802 in combination with 
erlotinib using NCI CTCAE version 4.03 (part 3) 
• To evaluate the ALK mutations in tumour and blood samples and 
correlate the mutation rate 
with response to RO5424802 where possible 
• To evaluate the coexpression of EGFR mutation with ALK translocation 
and ALK mutation status 
• To investigate potential bypass mechanisms of ALK inhibition, such as 
c-MET, KRAS and c-KIT 
 
NP28761 
NA3L 
 
Data: Q4 
2017 
/LPLV Q3 
2017 
 
Phase II 
 
134 
 
Alectinib 
 
NA 
 
ALK-positive 
NSCLC 
Phase I portion: 
Primary objective: To determine the recommended dose of 
CH5424802/RO5424802 for use in the phase II portion 
Secondary objectives: In patients with locally advanced (AJCC stage 
IIIB) NSCLC not amenable to curative therapy or 
metastatic (AJCC stage IV) ALK-positive NSCLC: 
• To measure pharmacokinetic parameters of CH5424802/RO5424802, 
under fasting and fed conditions, to determine whether 
CH5424802/RO5424802 should be administered under fasting or fed 
conditions in the phase II portion 
• To assess tumour response 
• To evaluate safety of CH5424802/RO5424802. 
• To assess the clinical benefit of CH5424802/RO5424802 
Phase II portion: 
Primary objective: To evaluate efficacy of CH5424802/RO5424802 
based on the ORR (RECIST 1.1) as per IRC in patients with 
locally advanced (AJCC stage IIIB) NSCLC not amenable to curative 
therapy or metastatic (AJCC stage IV) ALK-positive NSCLC in whom 
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Study 
identifier 
Estimated 
completion 
date 
Study 
type 
Number of 
patients 
Intervention Comparator Patient 
population 
Endpoints 
crizotinib has failed 
Secondary objectives: 
• To determine ORR according to RECIST 1.1 based on investigator 
review of radiographs 
• To evaluate DCR, DOR PFS according to RECIST 1.1 by IRC and 
investigator review of radiographs 
• To evaluate OS 
• To evaluate the safety of CH5424802/RO5424802 
• To characterise the PK of CH5424802/RO5424802 and metabolite(s) 
• To assess the QoL using EORTC QLQ-C30 and QLQ-LC13 
• To evaluate C-ORR in patients with CNS metastases 
who have measurable disease in the CNS at the baseline, based on IRC 
review of radiographs by RECIST 1.1 and RANO criteria 
• To assess C-DOR in patients who have a CNS objective response 
based on IRC review of radiographs by RECIST 1.1 and RANO criteria 
• To assess C-PRs at 3, 6, 9 and 12 months based on cumulative 
incidence by IRC review of radiographs by RECIST 1.1 and RANO 
criteria 
Exploratory objectives: 
• To assess blood-based methods to detect point mutations in plasma 
• To identify molecular determinants of clinical resistance to ALK 
inhibitors 
• To identify potential genetic determinants of pharmacokinetic variability 
and safety 
parameters (pharmacogenomics research) 
• To assess CH5424802/RO5424802 CNS penetration by measuring the 
CSF/plasma 
concentration ratio 
YO29449 
ALESIA 
(APAC) – 
first line 
Data: Q2/Q3 
2018, 
LPLV Q4 
2019 
Phase III 
(APAC) 
187 Alectinib Crizotinib ALK-positive 
NSCLC 
Primary efficacy objective: To evaluate and compare the efficacy of 
alectinib and crizotinib in Asian patients with treatment-naïve ALK-
positive advanced NSCLC, as measured by investigator-assessed PFS. 
This objective is to reliably determine whether the benefit (in terms of 
PFS) of administrating alectinib in this study is consistent with the benefit 
observed in global study BO28984. 
Secondary efficacy objectives: 
• To evaluate and compare the ORR and DOR 
• To evaluate and compare the time to disease progression in the CNS 
on the basis of review of patient radiographs by an IRC with the use of 
PTJA03 - Alectinib as monotherapy for the first line treatment of ALK-positive advanced NSCLC 
 
Version 1.3, 22th January 2018 EUnetHTA Joint Action 3 WP4 107 
Study 
identifier 
Estimated 
completion 
date 
Study 
type 
Number of 
patients 
Intervention Comparator Patient 
population 
Endpoints 
RECIST 1.1 and RANO criteria, as well as to evaluate the C-ORR) in 
patients with CNS metastases who have measurable disease in the CNS 
at the baseline 
• To assess the C-DOR in patients who have a CNS objective response 
• To assess C-PRs at 6, 12, 18 and 24 months on the basis of cumulative 
incidence 
• To evaluate and compare the PFS assessment by an IRC by treatment 
arm 
• To evaluate and compare the OS by treatment arm 
 
Safety objective: The safety objective for this study is to evaluate the 
safety and tolerability of alectinib compared with crizotinib. 
Pharmacokinetic objective: The pharmacokinetic objective for this 
study is to characterise the PK of alectinib (and metabolite[s], if 
appropriate) 
 
Patient-reported outcome objectives: The PRO objectives for this 
study are as follows: 
• To evaluate and compare the TTD with patient-reported lung cancer 
symptoms of cough, dyspnoea (single-item and multi-item subscales), 
chest pain, arm/shoulder pain and fatigue as measured by EORTC QLQ-
C30, the supplemental EORTC QLQ-LC13 and a composite of the 
following three symptoms: cough, dyspnoea and chest pain 
• To evaluate and compare PROs regarding HRQoL, daily functioning 
and side effects of treatment as measured by EORTC QLQ-C30 and 
EORTC QLQ LC13 
 
Exploratory objectives: The exploratory objectives for this study are as 
follows: 
• To investigate molecular mechanisms of resistance to ALK inhibitors 
• To investigate detection of mutations in ALK and other genes involved 
in cancer in plasma 
MO29750 
ALUR 
Data: Q1 
2017, 
LPLV Q2 
2019 
Phase III 120 Alectinib Chemothera
py 
ALK-positive 
NSCLC 
Primary efficacy objective: 
To evaluate and compare between treatment groups the efficacy of 
alectinib therapy vs. chemotherapy in patients with ALK-positive 
advanced NSCLC who were previously treated with chemotherapy and 
crizotinib (disease progression or intolerant to crizotinib) as measured by 
investigator-assessed PFS 
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Study 
identifier 
Estimated 
completion 
date 
Study 
type 
Number of 
patients 
Intervention Comparator Patient 
population 
Endpoints 
Key secondary efficacy objective: To evaluate and compare between 
treatment groups the C-ORR in patients with measurable CNS 
metastases at the baseline as assessed by an IRC 
Other secondary efficacy objectives: To evaluate and compare 
between treatment arms: 
 
ORR, DCR and DOR in all patients according to RECIST 1.1 
(assessment by investigator and IRC) 
investigator and IRC) 
metastases and 
patients without baseline CNS metastases (assessment by IRC) 
-DOR, C-DCR and C-ORR for all patients with baseline CNS 
metastasis (assessment by IRC) 
-DOR and C-DCR for patients with baseline measurable CNS 
metastasis (assessment by IRC) 
 
Pharmacokinetic objective: The pharmacokinetic objective for this 
study was to characterise the PK of alectinib and its major metabolites 
Safety objective: The safety objective for this study was to evaluate the 
safety and tolerability of alectinib compared with chemotherapy in all 
patients and patients with CNS metastases at the baseline 
PRO objectives: The PRO objectives for this study were as follows: 
-reported lung cancer 
symptoms of cough, chest pain (single item), dyspnoea (single-item and 
multi-item subscales), pain in arm/shoulder and fatigue as measured by 
the EORTC QLQ-C30 and QLQ-LC13, as well as by a composite of three 
symptoms (cough, dyspnoea [multi-item QLQ-LC13 subscales] and chest 
pain). Analysis was performed for all patients, as well as in the subgroup 
of patients with CNS metastases 
HRQoL, patient 
functioning and side effects of treatment as measured by EORTC QLQ-
C30, EORTC QLQ-LC13 and the EQ-5D-5L questionnaire. Analysis was 
performed for all patients, as well as in the subgroup of patients with CNS 
metastases 
Exploratory objectives: The exploratory objectives for this study were 
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Study 
identifier 
Estimated 
completion 
date 
Study 
type 
Number of 
patients 
Intervention Comparator Patient 
population 
Endpoints 
as follows: 
specific questions from the EORTC QLQ-BN20 
alectinib mechanism of action (including but not limited to ALK genetic 
alterations) and their association with disease status, clinical outcome, 
efficacy and safety 
 
ALK 
mutations/fusions in plasma/tumour and to establish performance 
characteristics of these assays 
B-FAST 
BO29554  
 
ALK-
positive 
cohort 
RET-
positive 
cohort 
ALK-positive 
cohort 
Data: Q2 
2019 
LPLV: 2021–
2023 
 
 
 
RET-positive 
cohort 
 
Data: Q3 
2020 
LPLV: 2021–
2023 
 
ALK-
positive 
cohort 
 
Phase II/III 
(cohort 
phase II) 
 
 
RET-
positive 
cohort 
 
Phase II/III 
(cohort 
phase Ib/II) 
 
ALK-
positive 
cohort 
 
78 
 
 
 
RET-
positive 
cohort 
 
52–62 
Alectinib NA ALK-positive 
NSCLC 
• ALK-
positive 
advance
d or 
metastat
ic stage 
IIIB/IV 
NSCLC 
previous
ly 
untreate
d 
ALK-positive cohort 
Primary efficacy: To evaluate the efficacy of alectinib in patients with 
ALK-positive advanced or metastatic NSCLC as determined by the bSMP 
assay; investigator assessed ORR based on confirmed objective 
response (indicated by two objective response assessments based on 
RECIST 1.1 separated by at least 4 weeks) 
Secondary efficacy: Investigator-assessed DOR, CBR, and PFS per 
RECIST version 1.1; IRF-assessed ORR, DOR, CBR and PFS per 
RECIST 1.1; OS 
Safety objective: To evaluate the safety and tolerability of alectinib; 
incidence, type and severity of adverse events (based on NCI CTCAE 
version 4.0), including SAEs and AEs of special interest; changes in vital 
signs, physical findings and clinical laboratory results during the following 
administration of protocol-specified IMPs 
PRO objectives: To evaluate the impact of alectinib on PROs in patients 
with ALK-positive advanced or metastatic NSCLC as determined by the 
bSMP assay; proportion of patients whose condition improved compared 
with the baseline in patient-reported lung cancer symptoms of cough, 
dyspnoea and chest pain as measured by SILC; Mean change from 
baseline in HRQoL, patient functioning and symptoms as measured by 
the EORTC QLQ-C30 and SILC, to evaluate and compare patients’ 
health status to generate utility scores for use in economic models for 
reimbursement; health status as assessed by the EQ-5D-5L 
questionnaire 
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Study 
identifier 
Estimated 
completion 
date 
Study 
type 
Number of 
patients 
Intervention Comparator Patient 
population 
Endpoints 
Biomarker objective: To assess prognostic effect and 
pharmacodynamics of exploratory biomarkers in blood, and their 
association with disease status, mechanisms of resistance and/or 
response to alectinib; relationship between circulating biomarkers related 
to alectinib efficacy 
Exploratory objectives: To explore the antitumour effect of alectinib in 
patients with CNS disease identified at the baseline, investigator 
assessed ORR per RECIST 1.1 in patients with CNS disease, 
Investigator assessed DOR per RECIST 1.1 in patients with CNS 
disease, investigator assessed CBR per RECIST 1.1 in patients with 
CNS disease; to evaluate the efficacy of alectinib in patients with ALK-
positive advanced or metastatic NSCLC as determined by the bSMP 
assay, investigator-assessed TIR according to RECIST 1.1. 
RET-positive cohort 
Primary efficacy: Investigator-assessed ORR based on confirmed 
objective response (indicated by two objective response assessments 
based on RECIST 1.1 separated by at least 4 weeks) 
Secondary efficacy: Investigator-assessed DOR, CBR and PFS per 
RECIST 1.1; IRF-assessed ORR, DOR, CBR and PFS per RECIST 1.1; 
OS 
Safety objective: To assess the safety and tolerability of alectinib at 
increasing dose levels in patients with advanced RET-positive NSCLC so 
as to determine the MTD and the RP2D; DLTs, if any, associated with 
alectinib at escalating doses. To assess safety and tolerability of alectinib 
as a single agent in patients with RET-positive advanced or metastatic 
NSCLC at the RP2D, Incidence, type and severity of adverse events 
(based on NCI CTCAE version 4.0), including SAEs and AEs of special 
interest; changes in vital signs, physical findings and clinical laboratory 
results during the following administration of protocol-specified IMPs 
Pharmacokinetic objective: To explore the pharmacokinetic 
characteristics of alectinib; pharmacokinetic parameters of alectinib, 
population PK analysis for alectinib, standard pharmacokinetic 
parameters of alectinib for dose finding 
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Study 
identifier 
Estimated 
completion 
date 
Study 
type 
Number of 
patients 
Intervention Comparator Patient 
population 
Endpoints 
PRO objectives: To evaluate the impact of alectinib on PROs in patients 
with RET-positive advanced or metastatic NSCLC as determined by the 
bSMP assay; proportion of patients whose condition improved compared 
with the baseline in patient-reported lung cancer symptoms of cough, 
dyspnoea and chest pain as measured by SILC; TTD in patient-reported 
lung cancer symptoms of cough, dyspnoea and chest pain as measured 
by SILC 
Mean change from the baseline in HRQoL, patient functioning and 
symptoms as measured by EORTC QLQ-C30 and SILC to evaluate and 
compare patients’ health status to generate utility scores for use in 
economic models for reimbursement; health status as assessed by the 
EQ-5D-5Lquestionnaire 
 
Biomarker objective: To assess the prognostic effect and 
pharmacodynamics of exploratory biomarkers in blood, and their 
association with disease status, mechanisms of resistance and/or 
response to alectinib; relationship between circulating biomarkers related 
to alectinib efficacy 
 
Exploratory objectives: To explore the antitumour effect of alectinib in 
patients with CNS disease identified at the baseline, investigator-
assessed ORR per RECIST 1.1 in patients with CNS disease, 
investigator-assessed DOR per RECIST 1.1 in patients with CNS 
disease, investigator-assessed CBR per RECIST 1.1 in patients with 
CNS disease; to evaluate the efficacy of alectinib in patients with RET-
positive advanced or metastatic NSCLC as determined by the bSMP 
assay, investigator-assessed TIR according to RECIST 1.1 
MO39084 
(QoL and 
resource 
utilisation) 
Data: Q4 
2017 
RWD 162 N/A N/A CNS 
metastases 
QoL and health resource utilisation in CNS mets patients 
BO28984 Data: Q3 
2019 
Phase III 303 Alectinib Crizotinib Treatment-
naïve ALK-
Primary objectives: To evaluate and compare the efficacy of alectinib 
compared with crizotinib in patients with treatment-naïve ALK-positive 
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Study 
identifier 
Estimated 
completion 
date 
Study 
type 
Number of 
patients 
Intervention Comparator Patient 
population 
Endpoints 
LPLV Q2 
2019 
positive 
advanced 
NSCLC 
advanced NSCLC as measured by investigator-assessed PFS 
Secondary objectives: To evaluate and compare the ORR and DOR; to 
evaluate and compare the time to progression in the CNS on the basis of 
IRC review of radiographs by RECIST 1.1 and RANO criteria, as well as: 
• To evaluate C-ORR in patients with CNS metastases who have 
measurable disease in the CNS at the baseline 
• To assess C-DOR in patients who have a CNS objective response 
• To assess C-PRs at 6, 12, 18 and 24 months on the basis of cumulative 
incidence 
• To evaluate and compare the PFS assessment by the IRC 
To evaluate and compare the OS 
Secondary safety objective: To evaluate the safety and tolerability of 
alectinib compared with crizotinib. 
Secondary pharmacokinetic objective: To characterise the 
pharmacokinetics of alectinib and metabolite(s) 
Secondary PRO objectives: 
• To evaluate and compare TTD in patient-reported lung cancer 
symptoms of cough, dyspnoea (single-item and multi-item subscales), 
chest pain, arm and shoulder pain and fatigue as measured by EORTC 
QLQ-C30 EORTC QLQ-LC13 as well as a composite of three symptoms 
(cough, dyspnoea and chest pain) 
• To evaluate and compare PROs of HRQoL, patient functioning and side 
effects of treatment as measured by EORTC QLQ-C30 and EORTC 
QLQ-LC13 
Exploratory objectives: 
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Study 
identifier 
Estimated 
completion 
date 
Study 
type 
Number of 
patients 
Intervention Comparator Patient 
population 
Endpoints 
• To evaluate and compare patient’s health status as assessed by the 
EQ-5D-3L questionnaire to generate utility scores for use in economic 
models for reimbursement 
• To evaluate and compare the onset of hypogonadism in adult men by 
measuring total testosterone and free testosterone (either by direct 
measurement or by calculation using albumin and sex hormone-binding 
globulin), follicle-stimulating hormone and luteinising hormone levels in 
blood 
• To evaluate and compare efficacy in patients with treatment-naïve ALK-
positive NSCLC as assessed by the Vysis ALK Break Apart FISH Probe 
Kit (Abbott) 
• To evaluate and compare efficacy and safety in patients with treatment-
naïve ALK-positive NSCLC as assessed by plasma ALK assays (PCR 
and/or sequencing) 
• To determine the correlation between ALK status as assessed by 
plasma ALK PCR and/or plasma ALK sequencing tests and ALK status 
obtained with use of the Ventana ALK IHC and Vysis ALK Break Apart 
FISH Probe Kit (Abbott). 
• To investigate molecular mechanisms of resistance to ALK inhibitors 
• To investigate detection of ALK mutations/fusions in plasma 
Abbreviations: AE=adverse event; AJCC=American Joint Committee on Cancer; ALK=anaplastic lymphoma kinase; APAC=; AUC=area under the curve; bSMP=;CBR=; C-DCR=central nervous system 
disease control rate; C-DOR=central nervous system duration of response; CNS=central nervous system; C-ORR central nervous system objective response rate; C-PR=central nervous system 
progression rate; CSF=cerebrospinal fluid; CYP3A=cytochrome P450 3A; DCR=disease control rate: DLT=dose-limiting toxicity; DOR=duration of response, EORTC=European Organisation for Research 
and Treatment of Cancer; EQ-5D-3L=EuroQoL five dimension three level; EQ-5D-5L=EuroQoL five dimension five level; HRQoL=health-related quality of life; IMP=; IRC=independent review committee; 
IRF=independent review facility; LPLV=; MTD=; NA=; NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events; NSCLC=non-small cell lung cancer; ORR=objective 
response rate; OS=overall survival; PCR=polymerase chain reaction; PFS=progression-free survival; PK=pharmacokinetics; PRO=patient-reported outcome; Q1=quarter 1; Q2=quarter 2; Q3=quarter 3; 
Q4=quarter 4; QLQ-BN20=Quality of Life Questionnaire Brain Neoplasm-20; QLQ-C30=Quality-of-Life Questionnaire Core-30; QLQ-LC13=Quality of-Life Questionnaire Lung Cancer-13;QoL=quality of 
life; QTc=corrected QT interval; RANO=Response Assessment in Neuro-Oncology; RECIST=Response Evaluation Criteria in Solid Tumors; ROP=;RP2D=recommended phase II dose; RWD=; 
SAE=serious adverse event; SILC=; TIR=; TTD=time to deterioration. 
Sources: Roche internal clinical trial management sources. 
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Table A17. Finished studies of alectinib monotherapy for ALK-positive non-small cell lung cancer 
Study 
identifier 
Estimated 
completion 
date 
Study 
type 
Number of 
patients 
Intervention Comparator Patient 
population 
Endpoints 
ALEX Q1 2017 Phase III 303 Alectinib Crizotinib ALK-positive 
advanced 
NSCLC 
Primary: To evaluate and compare the efficacy of alectinib compared 
with crizotinib in patients with treatment-naïve ALK-positive advanced 
NSCLC as measured by investigator-assessed PFS 
Secondary efficacy: To evaluate and compare the ORR and DOR, to 
evaluate and compare the time to progression in the CNS on the basis of 
IRC review of radiographs by RECIST 1.1 and RANO criteria and to 
evaluate C-ORR in patients with CNS metastases who have measurable 
disease in the CNS at the baseline, to assess C-DOR in patients who 
have a CNS objective response, to assess C-PRs at 6, 12, 18 and 24 
months on the basis of cumulative incidence, to evaluate and compare 
the PFS assessment by the IRC, to evaluate and compare the OS 
Safety objective: To evaluate the safety and tolerability of alectinib 
compared with crizotinib  
Pharmacokinetic objective: To characterise the PK of alectinib and 
metabolite(s) 
PRO objectives: To evaluate and compare TTD in patient-reported lung 
cancer symptoms of cough, dyspnoea (single-item and multi-item 
subscales), chest pain, arm and shoulder pain and fatigue as measured 
by EORTC QLQ-C30 and the supplemental lung cancer module (QLQ-
LC13) as well as a composite of three symptoms (cough, dyspnoea and 
chest pain); to evaluate and compare PROs of HRQoL, patient 
functioning and side effects of treatment as measured by EORTC QLQ-
C30 and EORTC QLQ-LC13 
Exploratory objectives: The exploratory objectives for this study are to 
evaluate and compare patient's health status as assessed by the EQ-5D-
3L questionnaire to generate utility scores for use in economic models for 
reimbursement; to evaluate and compare the onset of hypogonadism in 
adult men by measuring total testosterone and free testosterone (either 
by direct measurement or by calculation using albumin and sex hormone-
binding globulin), follicle-stimulating hormone) and luteinising hormone 
levels in blood; to evaluate and compare efficacy in patients with 
treatment-naïve ALK-positive NSCLC as assessed by the Vysis
 
ALK 
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Study 
identifier 
Estimated 
completion 
date 
Study 
type 
Number of 
patients 
Intervention Comparator Patient 
population 
Endpoints 
Break Apart FISH Probe Kit (Abbott); to evaluate and compare efficacy 
and safety in patients with treatment-naïve ALK-positive NSCLC as 
assessed by plasma ALK assays (PCR and/or sequencing); to determine 
the correlation between ALK status as assessed by plasma ALK PCR 
and/or plasma ALK sequencing tests and ALK status obtained with use of 
the Ventana ALK IHC and Vysis ALK Break Apart FISH Probe Kit 
(Abbott); to investigate molecular mechanisms of resistance to ALK 
inhibitors; To investigate detection of ALK mutations/fusions in plasma 
J-ALEX Q3 2016  Phase III 207 Alectinib Crizotinib ALK-positive 
NSCLC 
Primary endpoint: PFS (assessed by IRF) 
 
Secondary endpoints: 
Efficacy: OS, response rate, DOR, time to response, time to progression 
of brain metastasis in patients with brain metastasis at the baseline, time 
to onset of brain metastasis in patients without brain metastasis at the 
baseline and QOL scores based on EORTC QLQ-C30 and QLQ-LC13 
Safety 
 
PK: Plasma alectinib concentration and plasma CH5468924 
concentration 
 
Exploratory endpoints: ALK genetic mutations, etc., and biomarkers 
related to efficacy 
NP29783 
(second-
line 
postappro
val 
commitme
nt) 
Data: Q1 
2017, 
/LPLV Q4 
2016 
Phase I 
(hepatic 
Impairm
ent) 
28 Alectinib  NA ALK-positive 
NSCLC 
Primary objectives: To assess the PK of alectinib in participants with 
hepatic impairment and in matched healthy participants after a single oral 
dose 
 
Secondary objectives: 
• To assess the PK of the major active metabolite of alectinib, M4, and 
the combined exposure of alectinib and M4 (alectinib plus M4) in 
participants with hepatic impairment and in matched healthy participants 
after a single oral dose 
 
• To investigate safety and tolerability of alectinib in participants with 
hepatic impairment and in matched healthy participants 
Exploratory: 
 
• To evaluate the relationship, if any, between measures of hepatic 
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Study 
identifier 
Estimated 
completion 
date 
Study 
type 
Number of 
patients 
Intervention Comparator Patient 
population 
Endpoints 
impairment (e.g., Child–Pugh scores, NCI criteria for hepatic impairment 
categories, albumin concentration, bilirubin concentration, aspartate 
aminotransferase concentration, alanine aminotransferase concentration, 
prothrombin time, etc.) and pharmacokinetic parameters for alectinib 
and/or M4, as appropriate 
Abbreviations: ALK=anaplastic lymphoma kinase; C-DOR=central nervous system duration of response; CNS=central nervous system; C-ORR=central nervous system objective response rate; C-
PR=central nervous system progression rate; DOR=duration of response; EORTC=European Organisation for Research and Treatment of Cancer; EQ-5D-3L=EuroQoL five dimension three level; 
HRQoL=health-related quality of life; IRC=independent review committee; IRF=independent review facility; LPLV=; NA=; NCI=National Cancer Institute; NSCLC=non-small cell lung cancer; 
ORR=objective response rate; OS=overall survival; PCR=polymerase chain reaction; PFS=progression-free survival; PK=pharmacokinetics; PRO=patient-reported outcome; Q1=quarter 1; Q3=quarter 3; 
Q4=quarter 4; QLQ-C30=Quality of Life Questionnaire − Core; RANO=Revised Assessment in Neuro-Oncology; RECIST=Response Evaluation Criteria in Solid Tumors; TTD=time to deterioration. 
Sources: Roche internal clinical trial management sources. 
Table A18. Planned studies of alectinib monotherapy for ALK-positive non-small cell lung cancer 
Study 
identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of patients 
Intervention Comparator Patient 
population 
Endpoints 
BO40336 
Adjuvant 
Data: Q2 
2023, 
LPLV Q3 
2023 
Phase III 255 Alectinib Chemothera
py 
Resected 
stage IB–
IIIA ALK-
positive NSC
LC 
 
Primary efficacy objective: To evaluate the efficacy of alectinib 
compared with platinum-based chemotherapy in patients with completely 
resected stage IB (tumours ³ 4 cm) to stage IIIA, ALK-positive NSCLC; 
DFS defined as the time from randomisation to the first documented 
recurrence of disease or new primary NSCLC, as determined by the 
investigator through use of an integrated assessment of radiographic 
data, biopsy sample results (if clinically feasible) and clinical status or 
death from any cause, whichever occurs first 
 
Secondary efficacy objective: To evaluate the efficacy of alectinib 
compared with platinum-based chemotherapy in patients with completely 
resected stage IB (tumours ³ 4 cm) to stage IIIA ALK-positive NSCLC; OS 
defined as the time from randomisation to death from any cause 
Safety objective: To evaluate the safety and tolerability of alectinib 
compared with platinum-based chemotherapy in patients with completely 
resected stage IB (tumours ³ 4 cm) to stage IIIA ALK-positive NSCLC; 
incidence of adverse events, with severity determined through use of NCI 
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Study 
identifier 
Estimated 
completion 
date 
Study 
type 
Number  
of patients 
Intervention Comparator Patient 
population 
Endpoints 
CTCAE version 4.0; safety laboratory values; vital signs; 
electrocardiogram 
Pharmacokinetic objective (alectinib arm only): To characterise the 
pharmacokinetics of alectinib and its major metabolite(s) in patients with 
completely resected stage IB (tumours ³ 4 cm) to stage IIIA ALK-positive 
NSCLC; plasma concentrations of alectinib and its major metabolite(s) at 
specified time points 
Exploratory biomarker objective: To investigate molecular 
mechanisms of resistance to alectinib in patients with completely 
resected stage IB (tumours ³ 4 cm) to stage IIIA ALK-positive NSCLC; 
relationship between biomarkers in blood and tumour tissue (listed 
in Table 2) and efficacy (DFS) 
Abbreviations: DFS=disease-free survival; LPLV=; NCI CTCAE=National Cancer Institute Common Terminology Criteria for Adverse Events; NSCLC=non-small cell lung cancer; OS=overall survival; 
Q2=quarter 2; Q3=quarter 3. 
Sources: Roche internal clinical trial management sources. 
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Risk of bias tables 
 
Table A19. Risk of bias – study level (randomised controlled trials) 
 
  
Trial Random sequence 
generation 
Allocation 
concealment 
Blinding of 
participants and 
personnel 
Blinding of outcome 
assessment (patient-
reported outcomes, all-
cause mortality) 
Incomplete 
outcome 
assessment 
Selective reporting 
ALEX [2] Low Low Higha Highb Low Low 
ASCEND-4 [56] Low Low Higha Low Low Low 
PROFILE 1014 
[57] 
Low Low Higha Low Low  Low 
PROFILE 1029 Unclearc Unclearc Higha Unclearc Unclearc Low  
aOpen label. 
bPrimary endpoint was investigator-assessed progression-free survival. 
c study not fully published, only limited information available 
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Table A20. Risk of bias – outcome level (randomised controlled trials) 
Outcome and trial 
Blinding – outcome 
assessors 
ITT principle 
adequately realised 
Selective outcome 
reporting unlikely 
No other aspects 
according to risk of 
bias 
Risk of bias – 
outcome level 
PFS 
ALEX [2] Higha Low Low Low Low 
ASCEND-4 [56] Low Low Low Low Low 
PROFILE 1014 [57] Low Low Low Unclearb Low 
OS 
ALEX Low Low Low Highc,d High 
ASCEND-4 Low Low Low Highe High 
PROFILE 1014 Low Low Low Highb,f High 
ORR      
ALEX High
g Low Low Low Lowh 
ASCEND-4 Low Low Low Low Low 
PROFILE 1014 Low Low Low Low Low 
Adverse events      
ALEX Highi Low Low Low High 
ASCEND-4 Highi Low Low Low High 
PROFILE 1014 Highi Low Low Low High 
Time to CNS progression 
ALEX  Low Low Low Low  Low 
Patient-reported outcomes 
ALEX Highi Highj Highj Low High 
Abbreviations: CNS=central nervous system; DOR=duration of response; ORR=overall response rate; OS=overall survival; PFS=progression-free survival. 
aInvestigator-assessed PFS was the primary outcome, but the results were consistent with the findings of independent review committee (IRC) assessment of PFS. 
bThe standard of care (i.e., chemotherapy regimen) has changed since the study was initiated; it remains unclear if this affected the results in the control group. 
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Outcome and trial 
Blinding – outcome 
assessors 
ITT principle 
adequately realised 
Selective outcome 
reporting unlikely 
No other aspects 
according to risk of 
bias 
Risk of bias – 
outcome level 
cOS was outside the test hierarchy since ORR was not statistically significant and the study will not be powered to demonstrate any statistically significant difference in the secondary endpoint of OS.  
dEven though per protocol crossover between trial groups was not allowed, patients will be treated at the discretion of the investigator according to local practice after disease progression. 
eOne hundred and five (72%) of 145 patients received an anaplastic lymphoma kinase inhibitor after discontinuation of chemotherapy. 
fOf the 171 patients randomly assigned to chemotherapy, 120 (70%) subsequently received crizotinib treatment. Of the 172 patients assigned to crizotinib therapy, 21 (12%) subsequently received 
platinum-based chemotherapy. This analysis was not adjusted for crossover. 
gSystemic responses were investigator  assessed, CNS responses were assessed by an IRC. 
hAlthough it was investigator assessed, objective assessment would most likely only further reduce statistical significance; the results are consistent with IRC assessment. 
iOpen label. 
jLow baseline values (~65 % of patients). 
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Table A21. Template for GRADE assessment (e.g., using GRADEproGDT) 
Quality assessment Summary of findings Importance 
Number of patients Effect  Quality 
Number 
of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision Other 
considerations 
Alectinib Crizotinib Relative 
HR (95% 
CI)* 
Absolute 
(95% CI) 
Alectinib vs. crizotinib 
OS (interim analysis) 
1 RCT Serious 
limitationb 
NA No serious 
limitation 
NAb  Serious 
limitationc 
152 151 0.76 
(0.48–
1.20) 
1-year 
survival rate: 
84.3% vs. 
82.5% 
Low Critical 
 
PFS 
1 RCT No serious 
limitation 
NA No serious 
limitation 
No serious 
limitation 
No serious 
limitation 
152 151 0.47 
(0.34–
0.65)  
Median: NE 
(17.7 months 
to NE) vs. 
11.1 months 
(9.1–13.1 
months) 
High Critical 
ORR 
1 RCT No serious 
limitation 
NA No serious 
limitation 
No serious 
limitation 
No serious 
limitation 
152 151 — 75.5% 
(67.8%–
82.1%) vs. 
82.9% 
(76.0%–
88.5%) 
High Important 
Time to CNS progression       
                                                     
b Not adequately powered; after progression treatment at the physician’s discretion. 
c Currently only results of an interim analysis are available. 
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Quality assessment Summary of findings Importance 
Number of patients Effect  Quality 
Number 
of 
studies 
Study 
design 
Risk of 
bias 
Inconsistency Indirectness Imprecision Other 
considerations 
Alectinib Crizotinib Relative 
HR (95% 
CI)* 
Absolute 
(95% CI) 
1 RCT No serious 
limitation 
NA No serious 
limitation 
No serious 
limitation 
No serious 
limitation 
Rate of 
events of 
CNS 
progression: 
18 (of 152) 
Rate of 
events of 
CNS 
progression: 
68 (of 151) 
Cause-
specific 
HR 0.16 
(0.10–
0.28); 
p<0.0001 
18 (12%) vs. 
68 (45%) 
High Critical 
Total number of patients with ≥1 AE 
1 RCT Serious 
limitationd 
NA No serious 
limitation 
NA No serious 
limitation 
152 151 97% vs. 
97% 
152 vs. 151  Modera
te 
Critical 
Total number of patients with serious AE 
1 RCT Serious 
limitationd 
NA No serious 
limitation 
NA No serious 
limitation 
152 151 28% vs. 
29% 
43 vs. 44  Modera
te 
Critical 
Time to deterioration in EORTC QLQ-30 global health score  
1 RCT Very 
serious 
limitationd,e 
NA No serious 
limitation 
Serious 
limitationf 
No serious 
limitation 
100 97 0.72 
(0.38–
1.39) 
— Very 
low  
Critical 
 
Because there are no clear instructions and specific methodological guidance how to proceed with risk of bias and GRADE related to interim outcomes, 
consensus was made by the authors of this assessment to rate the quality of evidence for OS according to standard GRADE methods and to include it in this 
assessment, despite uncertainties on the final result.  
                                                     
Abbreviations: CI=confidence interval; EORTC=European Organisation for Research and Treatment of Cancer; HR=hazard ratio; HRQoL=health-related quality of life; NA=not applicable; NE=not 
estimable; OS=overall survival; ORR=objective response rate; PFS=progression-free survival; RCT=randomised controlled trial. 
*HR if not otherwise indicated. 
dOpen label 
eLow baseline values 
f Wide confidence intervall  
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Applicability tables 
 
Table A22. Summary table characterising the applicability of a body of studies 
Domain Description of applicability of evidence 
Population The newly licensed indication of alectinib will comprise ’advanced NSCLC’, which comprises 
besides metastatic disease (i.e., according to the TNM system stage IV disease) also stage IIIB 
disease. 
In the ALEX trial, only 3%–4% of enrolled patients had stage IIIB disease at the baseline and 
guidelines state that there is currently no role for targeted agents in stage III NSCLC outside 
clinical trials [11]. Thus the applicability to these patients is limited.  
In addition, most patients (>90%) had adenocarcinoma as the histological subtype; even 
though this represents the most common histological type, applicability to, for example, large 
cell carcinoma is limited. Also since most patients had an ECOG PS of 1 or less at the 
baseline, efficacy and safety in frail patients with a lower PS remain uncertain 
Intervention No issues were identified which might affect benefits or harms from alectinib, since the way of 
administration, dosing and frequency of cycles used for alectinib are consistent with the 
upcoming approved licensing 
Comparators The appropriateness of crizotinib and ceritinib as comparators is supported by recent clinical 
practice guidelines [9] 
Outcomes Direct OS outcome data are not mature yet. Because of further therapies at the investigator’s 
discretion after disease progression, OS data will have very limited applicability 
Setting Nearly half of the patients were of Asian origin. However, ethnicity was a stratification factor 
Abbreviations: ECOG=Eastern Cooperative Oncology Group; NSCLC=non-small cell lung cancer; OS=overall survival; 
PS=performance status; TNM=tumour, node, metastasis. 
Source: [17] 
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APPENDIX 3: REGULATORY AND REIMBURSEMENT STATUS 
Table A23. Regulatory status 
Country/
region 
Institution 
issuing 
approval 
Authori
sation 
status 
Verbatim wording of 
the (anticipated) 
indication(s) 
Date 
of 
approv
al 
Type of 
approval 
(full, 
condition
al, 
exception
al) 
Launc
hed 
yes/n
o 
 
Marketing 
authorisat
ion 
number 
(if 
available) 
Alectinib 
Japan Pharmaceutical
s and Medical 
Devices 
Agency 
 Alectinib is indicated for 
the treatment of patients 
with ALK-positive locally 
advanced or metastatic 
NSCLC whose disease 
has progressed with 
crizotinib therapy or who 
are intolerant of crizotinib 
4th July 
2014 
 Yes  
Europe European 
Medicines 
Agency 
 Alectinib as monotherapy 
is indicated for the 
treatment of adult patients 
with ALK-positive 
advanced NSCLC 
previously treated with 
crizotinib 
 
Alectinib as monotherapy 
is indicated for the first-
line treatment of adult 
patients with ALK-positive 
advanced NSCLC 
16th 
February 
2017 
 
 
 
 
21 
Decemb
er 2017 
Full Launched 
in the 
majority of 
European 
Union 
countries 
with the 
‘crizotinib 
failure’ 
indication 
 
United 
States 
US Food and 
Drug 
Administration 
 Alectinib is a kinase 
inhibitor indicated for the 
treatment of patients with 
ALK-positive metastatic 
NSCLC whose disease 
has progressed with 
crizotinib therapy or who 
are intolerant of crizotinib. 
This indication is 
approved under 
accelerated approval 
based on tumour 
response rate and 
duration of response. 
Continued approval for 
this indication may be 
contingent on verification 
and description of clinical 
benefit in confirmatory 
trials 
a  Alectinib as 
monotherapy is indicated 
for the first-line treatment 
of adult patients with ALK-
positive advanced 
NSCLC 
11th 
Decemb
er 2015 
 
 
 
 
 
 
 
 
 
 
6 
Novemb
er 2017 
Full Yes  
Switzerlan
d 
Swiss Agency 
for Therapeutic 
Products 
(Swissmedic) 
 Alectinib is indicated for 
the treatment of patients 
with ALK-positive locally 
advanced or metastatic 
NSCLC whose disease 
has progressed with 
crizotinib therapy or who 
are intolerant of crizotinib 
26th 
January 
2017 
 Yes  
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Proposed indication:b 
Alectinib is indicated for 
the first-line treatment of 
patients with ALK-positive 
locally advanced or 
metastatic NSCLC 
Israel Ministry of 
Health 
Pharmacy 
Department 
 Alectinib is indicated for 
the treatment of patients 
with ALK-positive locally 
advanced or metastatic 
NSCLC whose disease 
has progressed with 
crizotinib therapy or who 
are intolerant of crizotinib 
17th 
April 
2016 
 Yes  
Canada Health Canada  Alecensaro  (alectinib) is 
indicated as monotherapy 
for the treatment of 
patients with ALK-positive 
locally advanced (not 
amenable to curative 
therapy) or metastatic 
NSCLC whose disease 
has progressed with 
crizotinib therapy or who 
are intolerant of crizotinib 
29th 
Septemb
er 2016 
 Yes  
South 
Korea 
Ministry of 
Food and Drug 
Safety 
 The treatment of patients 
with ALK-positive locally-
advanced or metastatic 
NSCLC who were 
previously treated with 
crizotinib. The efficacy of 
alectinib was based on 
response rate and 
duration of response; 
there are no available 
data on increase of 
duration of survival 
26th 
October 
2016 
 Yes  
Kuwait Ministry of 
Health, Drug & 
Food Control 
 Alectinib is indicated for 
the treatment of patients 
with ALK-positive locally 
advanced or metastatic 
NSCLC whose disease 
has progressed with 
crizotinib therapy or who 
are intolerant of crizotinib 
24th 
Novemb
er 2016 
 Yes  
Hong 
Kong 
Drug Office, 
Department of 
Health 
 Alectinib is indicated for 
the treatment of patients 
with ALK-positive 
metastatic NSCLC whose 
disease has progressed 
with crizotinib therapy or 
who are intolerant of 
crizotinib 
9th 
Decemb
er 2016 
 Yes  
Taiwan Taiwan Food 
and Drug 
Administration 
 Alectinib is a kinase 
inhibitor indicated for the 
treatment of patients with 
ALK-positive metastatic 
NSCLC whose disease 
has progressed with 
crizotinib therapy or who 
are intolerant of crizotinibc 
27th 
February 
2017 
 Yes  
Australia Therapeutics 
Goods 
Administration 
 Alectinib is indicated for 
the treatment of patients 
with ALK-positive locally 
advanced or metastatic 
NSCLC whose disease 
has progressed with 
crizotinib therapy or who 
are intolerant of crizotinib. 
14th 
March 
2017 
 Yes  
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Proposed indication:d 
Alectinib is indicated for 
the treatment of patients 
with ALK-positive locally 
advanced or metastatic 
NSCLC 
Singapore Health 
Sciences 
Authority 
 Alectinib is indicated for 
the treatment of patients 
with ALK-positive locally 
advanced or metastatic 
NSCLC whose disease 
has progressed with 
crizotinib therapy or who 
are intolerant of crizotinib 
24th 
April 
2017 
 Yes  
India Central Drugs 
Standard 
Control 
Organization 
 Alectinib is indicated for 
the treatment of patients 
with ALK-positive 
metastatic NSCLC whose 
disease has progressed 
with crizotinib therapy or 
who are intolerant of 
crizotinib 
30th 
June 
2017 
 Yes  
Thailand Thai Food and 
Drug 
Administration 
 Alectinib is indicated for 
the treatment of patients 
with ALK-positive locally 
advanced or metastatic 
NSCLC whose disease 
has progressed with 
crizotinib therapy or who 
are intolerant of crizotinib 
3rd 
August 
2017 
 Yes  
Argentina Administración 
Nacional de 
Medicamentos, 
Alimentos y 
Tecnología 
Médica 
 Alectinib is indicated for 
the treatment of patients 
with ALK-positive 
metastatic NSCLC whose 
disease has progressed 
with crizotinib therapy or 
who are intolerant of 
crizotinibe 
28th 
August 
2017 
 Yes  
United 
Arab 
Emirates 
Ministry of 
Health and 
Prevention 
 Alectinib is indicated for 
the treatment of patients 
with ALK-positive locally 
advanced or metastatic 
NSCLC whose disease 
has progressed with 
crizotinib therapy or who 
are intolerant of crizotinib 
7th 
Septemb
er 2017 
 Yes  
Turkey Medicines and 
Medical 
Devices 
Agency 
 Alectinib as monotherapy 
is indicated until 
progression for the 
treatment of adult patients 
with ALK-positive 
metastatic NSCLC 
previously treated with 
crizotinib 
14th 
Septemb
er 2017 
 Yes  
Saudi 
Arabia 
Food and Drug 
Authority 
 Alectinib is indicated for 
the treatment of patients 
with ALK-positive locally 
advanced or metastatic 
NSCLC whose disease 
has progressed with 
crizotinib therapy or who 
are intolerant of crizotinib 
25th 
Septemb
er 2017 
 Yes  
Comparators 
Crizotinib 
United 
States 
  Treatment of patients with 
locally advanced or 
metastatic NSCLC that is 
ALK positive as detected 
August 
2011  
Accelerated 
approval 
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This table was last updated on 19 January 2018. 
Abbreviation: NSCLC=non-small cell lung cancer. 
Source: [17] 
eThe present indication is based on the tumour response rate and duration of response. Continued approval of this indication is 
subject to verification and description of clinical benefits in confirmatory trials. 
by a Food and Drug 
Administration-approved 
test 
Canada   As monotherapy for use 
in patients with ALK-
positive locally advanced 
(not amenable to curative 
therapy) or metastatic 
NSCLC 
April 2012 Notice of 
compliance 
with 
Conditions 
  
European 
Union 
  Treatment of adults with 
previously treated ALK-
positive advanced 
NSCLC 
October 
2012 
Conditional 
approval 
  
Brazil   Treatment of patients with 
advanced NSCLC whose 
tumours are ALK positive 
February 
2016 
   
Ceritinib 
United 
States 
  Treatment of patients with 
ALK-positive metastatic 
NSCLC whose disease 
has progressed crizotinib 
therapy with or who are 
intolerant of crizotinib 
Indication in the first-line 
setting: Treatment of 
patients with metastatic 
ALK-positive NSCLC 
First 
approval: 
April 2014 
  
Date of 
approval 
in first 
line: May 
2017 
Accelerated 
approval 
  
Canada   Treatment as 
monotherapy in patients 
with ALK-positive locally 
advanced (not amenable 
to curative therapy) or 
metastatic NSCLC whose 
disease has progressed 
with crizotinib therapy or 
who are intolerant of 
crizotinib 
March 
2015  
Notice of 
compliance 
with 
conditions 
  
European 
Union 
  Indication: As 
monotherapy for the 
treatment of adult patients 
with ALK-positive 
advanced NSCLC 
previously treated with 
crizotinib 
 
Indication in the first-line 
setting: As monotherapy 
for adult patients with 
ALK-positive advanced 
NSCLC 
May 2015  
 
 
 
 
 
Date of 
approval 
in first-
line 
setting: 
June 
2017 
Conditional 
approval 
  
aPriority review granted by US Food and Drug Administration for first-line indication. 
bFast track designation granted by Swissmedic for first-line indication. 
cThis indication is approved under accelerated approval based on tumour response rate and duration of response. Continued 
approval for this indication may be contingent on verification and description of clinical benefit in confirmatory trials. 
dPriority review granted by Therapeutics Goods Administration for first-line indication. 
PTJA03 - Alectinib as monotherapy for the first line treatment of ALK-positive advanced NSCLC 
 
Version 1.3, 22th January 2018 EUnetHTA Joint Action 3 WP4 128 
 Table A24. Overview of the reimbursement status of alectinib in the crizotinib-failure 
indication in selected European countries and the comparators for the approved indication 
Country and 
issuing 
organisation 
Reimbursement 
status 
Summary of 
(reimbursement)  
recommendations and 
restrictions 
Summary of reasons for 
recommendations, rejections 
and restrictions 
Alectinib – second-line treatment of ALK-positive NSCLC 
Austria –
Hauptverband der 
österreichischen 
Sozialversicherung
sträger (HVB) 
Ongoing   
Belgium –
Rijksinstituut voor 
Ziekte- en 
Invaliditeitsverzeker
ing (RIZIV-INAMI) 
Ongoing   
Bulgaria  National 
Council for Price 
and 
Reimbursement of 
Medicinal Product 
Preparing 
submission 
  
Croatia – Croatian 
Health Insurance 
Fund (Hrvatski 
zavod za 
zdravstveno 
osiguranje; HZZO) 
Ongoing   
Czech Republic - 
State Institute for 
Drug Control 
(SUKL) 
Not assessed   
Denmark - Danish 
Medicines Council 
(Laegemiddelstyrel
sen) 
Reimbursed   
England – National 
Institute for Health 
and Care 
Excellence, NICE) 
Ongoing   
Estonia – Estonian 
Health Insurance 
Fund (Eesti 
Haigekassa) 
Ongoing   
Finland – 
Pharmaceutical 
Pricing Board 
(Lääkkeiden 
hintalautakunta), 
HILA) 
Ongoing   
France - Haute 
Autorité de Santé 
(HAS) 
Ongoing   
Germany - 
Gemeinsamer 
Bundesausschuss 
(G BA) 
Ongoing 
 
 
Full reimbursement while the 
assessment is ongoing 
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Country and 
issuing 
organisation 
Reimbursement 
status 
Summary of 
(reimbursement)  
recommendations and 
restrictions 
Summary of reasons for 
recommendations, rejections 
and restrictions 
Greece – National 
Organisation for 
Medicines 
Ongoing   
Hungary – National 
Health Insurance 
Fund of Hungary 
(OEP) 
Ongoing   
Ireland - National 
Centre for 
Pharmacoeconomic
s (NCPE) 
Ongoing   
Italy - Agenzia 
Italiana del 
Farmaco (AIFA) 
Ongoing   
Latvia - State 
Agency of 
Medicines (SAM) 
Prearing 
submission 
  
Lithuania - 
Compulsory Health 
Insurance Fund 
(CHIF) 
Preparing 
submission 
  
Luxemburg - 
Ministère de la 
Sécurité Sociale 
Reimbursed   
Netherlands – 
ZorgInstituut 
Reimbursed   
Norway – 
Norwegian 
Medicines Agency 
Ongoing 
 
  
Poland – Ministry of 
Health 
(Ministerstwo 
Zdrowia, MZ) 
Ongoing   
Portugal - National 
Authority of 
Medicines and 
Health Products 
(Autoridade 
Nacional do 
Medicamento e 
Produtos de Saúde, 
I.P., INFARMED) 
Ongoing   
Romania - National 
Agency of 
Medicines and 
Medical Devices 
Not yet submitted   
Scotland (Scottish 
Medicines 
Consortium, SMC) 
Ongoing   
Slovakia - Ministry 
of Health 
(Ministervo 
zdravotníctva) 
Preparing 
submission 
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Country and 
issuing 
organisation 
Reimbursement 
status 
Summary of 
(reimbursement)  
recommendations and 
restrictions 
Summary of reasons for 
recommendations, rejections 
and restrictions 
Slovenia - Health 
Insurance Institute 
of Slovenia (Zavod 
za zdravstveno 
zavarovanje 
Slovenije, ZZZS) 
Ongoing   
Spain - Ministry of 
Health, Social 
Services and 
Equality (Ministerio 
de Sanidad, 
Servicios Sociales 
e Igualdad) 
Ongoing   
Sweden - The 
Dental and 
Pharmaceutical 
Benefits Agency 
(Tandvårds- och 
läkemedelsförmåns
verket, TLV) 
Reimbursed Remibursement restricted to 
adult patients with ALK-positive 
advanced NSCLC previously 
treated with crizotinib  
 
Switzerland - 
Federal Office of 
public health 
(Bundesamt für 
Gesundheit, BAG) 
Reimbursed 
 
  
Wales – All Wales 
Medicines Strategy 
Group, AWMSG)) 
Ongoing   
Crizotinib - Second line ALK-positive NSCLC 
Belgium Yes   
Bulgaria Yes   
Croatia Yes   
Denmark Yes   
Finland Yes   
France Yes   
Germany Yes   
Greece Yes   
Ireland Yes   
Italy Yes   
Netherlands Yes   
Poland Yes   
Portugal Yes   
Slovenia Yes   
Sweden Yes   
Spain Yes   
Switzerland Yes   
United Kingdom Yes   
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Country and 
issuing 
organisation 
Reimbursement 
status 
Summary of 
(reimbursement)  
recommendations and 
restrictions 
Summary of reasons for 
recommendations, rejections 
and restrictions 
Crizotinib – first-line treatment of ALK-positive NSCLC 
Croatia Yes   
Denmark Yes   
France Yes   
Germany Yes   
Greece Yes   
Ireland Yes   
Italy Yes   
Luxembourg Yes   
Netherlands Yes   
Norway Yes   
Slovenia Yes   
Spain Yes   
Sweden Yes   
United kingdom Yes   
Ceritinib – second-line treatment of ALK-positive NSCLC or in the case of crizotinib treatment failure  
Austria Yes   
Belgium (3L only) Yes   
Denmark Yes   
France Yes   
Germany Yes   
Greece Yes   
Ireland Yes   
Italy Yes   
Netherlands Yes   
Slovenia Yes   
Sweden Yes   
United Kingdom Yes   
Ceritinib – first-line treatment of ALK-positive NSCLC 
Denmark Yes   
Germany Yes   
Greece Yes   
Netherlands Yes   
Sweden Yes   
United Kingdom Ongoing at NICE   
Source: [17] This table was last updated on 19 January 2018 
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APPENDIX 4: CHECKLIST FOR POTENTIAL ETHICAL, ORGANISATIONAL, 
PATIENT AND SOCIAL AND LEGAL ASPECTS 
1 Ethical  
1.1 Does the introduction of the new technology and its potential use/non-use instead of 
the defined, existing comparator(s) give rise to any new ethical issues? 
No 
1.2 Does comparing the new technology to the defined, existing comparators point to 
any differences that may be ethically relevant? 
No 
2 Organisational  
2.1 Does the introduction of the new technology and its potential use/non-use instead of 
the defined, existing comparator(s) require organisational changes? 
No 
2.2 Does comparing the new technology to the defined, existing comparator(s) point to 
any differences that may be organisationally relevant? 
No 
3 Social  
3.1 Does the introduction of the new technology and its potential use/non-use instead of 
the defined, existing comparator(s) give rise to any new social issues? 
No 
3.2 Does comparing the new technology to the defined, existing comparator(s) point to 
any differences that may be socially relevant? 
No 
4 Legal  
4.1 Does the introduction of the new technology and its potential use/non-use instead of 
the defined, existing comparator(s) give rise to any legal issues? 
No 
4.2 Does comparing the new technology to the defined, existing comparator(s) point to 
any differences that may be legally relevant? 
No 
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APPENDIX 5. HEALTH-RELATED QUALITY OF LIFE 
Figure A9. Mean patient-reported European Organisation for Research and Treatment of 
Cancer QLQ-LC13 pain in chest score change from the baseline (patient-reported outcome-
evaluable population) (ALEX) 
 
Abbreviation: PRO=patient-reported outcome.  
Note: Decreases from the baseline correspond to abatement of symptoms. The numbers of patients decrease over time (no 
imputation for missing data). Patient numbers for crizotinib and alectinib, respectively: baseline n96 and n=100; week 48 n47 
and n=67; week 72 n34 and n=54; week 96 n=11 and n=22.  
Source: ALEX clinical study report. 
Figure A10. Mean patient-reported Outcome Score European Organisation for Research and 
Treatment QLQ-C30 fatigue score change from the baseline (patient-reported outcome-
evaluable population) (ALEX) 
 
Abbreviation: PRO=patient-reported outcome. 
Note: Decreases from the baseline correspond to abatement of symptoms. The numbers of patients decrease over time (no 
imputation for missing data). Patient numbers for crizotinib and alectinib, respectively: baseline n97 and n=100; week 48 n47 
and n=67; week 72 n34 and n=54; week 96 n=11 and n=22.  
Source: ALEX clinical study report. 
  
PTJA03 - Alectinib as monotherapy for the first line treatment of ALK-positive advanced NSCLC 
 
Version 1.3, 22th January 2018 EUnetHTA Joint Action 3 WP4 134 
Figure A11. Mean patient-reported Outcome Score European Organisation for Research and 
Treatment of Cancer QLQ-C30 pain score change from the baseline (patient-reported outcome-
evaluable population) (ALEX) 
 
Abbreviation: PRO=patient-reported outcome. 
Note: Decreases from the baseline correspond to abatement of symptoms. The numbers of patients decrease over time (no 
imputation for missing data). Patient numbers for crizotinib and alectinib, respectively: baseline n97 and n=100; week 48 n47 
and n=67; week 72 n34 and n=54; week 96 n=11 and n=22. 
Source: ALEX clinical study report. 
 
Figure A12. Mean patient-reported Outcome Score European Organisation for Research and 
Treatment of Cancer QLQ-LC13 pain in other parts score change from the baseline (patient-
reported outcome-evaluable population) (ALEX) 
 
Abbreviation: PRO=patient-reported outcome. 
Note: Decreases from the baseline correspond to abatement of symptoms. The numbers of patients decrease over time (no 
imputation for missing data). Patient numbers for crizotinib and alectinib, respectively: baseline n96 and n=100; week 48 n47 
and n=67; week 72 n34 and n=54; week 96 n11 and n=22.  
Source: ALEX clinical study report. 
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APPENDIX 6. INDIRECT COMPARISONS – STATISTICAL ASPECTS 
General remarks  
Included studies 
Despite the availability of indirect evidence/NMA, it has to be noted, that in ASCEND-4, four cycles of 
chemotherapy followed by maintenance therapy were used as a comparator. In contrast, in PROFILE 
1014, up to six cycles of the same chemotherapy were allowed, but without maintenance therapy. 
Given that there was a lack of direct evidence in the comparison of alectinib to ceritinib, a connected 
network of three trials (ALEX, PROFILE 1014, and ASCEND-4) were used to use indirect evidence to 
estimate the difference in treatment effect. As with all indirect comparison, there were differences 
within the three studies that should be noted as the differences may have affected the results of the 
NMA. Firstly, it has to be noted, that in ASCEND-4, four cycles of chemotherapy followed by 
maintenance therapy were used as a comparator. In contrast, in PROFILE 2295 1014, up to six 
cycles of the same chemotherapy were allowed, but without maintenance therapy. The difference 
between studies in time on treatment was 1.9 months (4.1 months on CHEMO in PROFILE 1014; 6 
months on CHEMO in ASCEND-4) and the difference between median PFS in the trials was 1.1 
months (median PFS was 7∙0 months for CHEMO in PROFILE 1014; median PFS of 8∙1 months for 
CHEMO in ASCEND-4). It is not known whether the difference of 1.1 months in median PFS is due to 
the maintenance or falls within the range of uncertainty due to other factors or sources of 
heterogeneity. It is assumed that there is no impact on response endpoints since response should be 
observed during induction phase (median time to response in CHEMO arm for PROFILE 1014 was 
2.8 months compared to 3.1 months in ASCEND-4). There may be an impact on the safety endpoints 
assuming that more adverse events would occur with longer treatment.  
There were higher frequencies in the ALEX study (approximately 40%) compared with less than 30% 
in PROFILE 1014 and approximately 30% in ASCEND-4. The higher frequency of CNS metastases at 
baseline observed in the ALEX study may be explained by the requirement for all patients to have 
CNS imaging at baseline.  
Because of these uncertainties involved and possible dependencies regarding the heterogeneity 
assumptions on the results in the NMA, these results are considered with caution. 
Bucher indirect comparison 
Indirect comparisons may suffer from the biases of observational studies [18]. Only adjusted instead 
of unadjusted indirect comparison methods should be used [10]. An adjusted indirect comparison 
method is the Bucher indirect comparison (Bucher IC), in which relative instead of absolute treatment 
effects are compared by use of a common comparator [10]. It is an underlying assumption of the 
Bucher IC that taking into account the common comparator implicitly accounts for differences 
between studies [63]. In the present case this assumption is not testable; because of the limited 
number of studies, the heterogeneity between studies cannot be assessed. The results presented for 
the Bucher IC depend on the validity of this assumption. 
Bayesian NMA 
In contrast to Bucher IC, in an NMA all the direct and indirect comparisons that can be derived from a 
complicated network structure are considered simultaneously when the effect estimates are 
computed.  
The base case analysis was performed with a Bayesian fixed effects model. The difference between 
such a model and a Bayesian random effects model lies in the prior assumption regarding the 
modelled between-trial heterogeneity. In a Bayesian random effects model a prior distribution is 
prespecified for the heterogeneity parameter. The Bayesian fixed effects model can be regarded as a 
special case of a Bayesian random effects model where a priori the whole probability mass of the 
between-trial heterogeneity is assigned to zero.  
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Sensitivity regarding heterogeneity assumptions of the Bayesian NMA 
The assumption on between-trial heterogeneity in the Bayesian fixed effects NMA is influential in the 
sense that increasing this parameter implies increasing the total variability of the model, which leads 
to wider credible intervals. With the exception of the comparison crizotinib versus chemotherapy, 
where theoretically two studies are available, the comparisons were performed with only a single 
study. Therefore in the base case the between-trial heterogeneity cannot be derived from the data. 
Thus the total variability of the model is partly based on an assumption, which cannot be verified 
empirically. 
Similar results in Bucher IC and the Bayesian fixed effects NMA 
The results are nearly identical because the network is elementary enough, such that the more 
complex fixed effects NMA does not use its additional capabilities in processing the data, compared 
with the simple Bucher method. Thus only the NMA is presented, with focus on the MAH base case 
fixed effect. Alectinib versus ceritinib (NMA, indirect comparison). 
Additional results with PROFILE 1029 included 
In Table A25 and Table A26, results are presented from the NMA for PFS and OS. In sensitivity 
analysis 1.2 (fixed effect), results from PROFILE 1029 were included. 
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Table A25. Network meta-analysis summary treatment effect estimates: progression-free survival by independent review committee, base case 
(fixed effect), sensitivity analysis 1.2 (fixed effect, including PROFILE 1029) and sensitivity analysis 1.3 (random effect, including PROFILE 1029) 
PFS by IRC   
Base case  
(ALEX, PROFILE 1014, ASCEND-4) 
Fixed effect NMA  
 
Sensitivity analysis SA1.2  
(ALEX, PROFILE 1014, PROFILE 1029, ASCEND-4) 
Fixed effect NMA  
 
Sensitivity analysis SA1.3  
(ALEX, PROFILE 1014, PROFILE 1029, ASCEND-4) 
Random effect NMA  
log hazard ratio                  
Treatment Vs.  Mean Median 
Lower 
95% 
CrL 
Upper 
95% CrI   
 
Mean Median 
Lower 
95% 
CrL 
Upper 
95% CrI   
 
Mean Median 
Lower 
95% 
CrL 
Upper 
95% CrI   
CRZ CHEMO -0.801 -0.800 -1.058 -0.546 -- 
 
-0.841 -0.840 -1.045 -0.638 --  -0.852 -0.844 -2.147 0.373 
 CER CHEMO -0.600 -0.600 -0.876 -0.330 -- 
 
-0.600 -0.600 -0.876 -0.330 --  -0.605 -0.600 -2.450 1.255 
 ALEC CHEMO -1.490 -1.490 -1.911 -1.068 -- -1.530 -1.530 -1.923 -1.138 --  -1.540 -1.524 -3.792 0.668  
Hazard ratios             
 
          
 
          
Treatment Vs.  Mean Median 
Lower 
95% CrI 
Upper 
95% CrI   
 
Mean Median 
Lower 
95% CrI 
Upper 
95% CrI   
 
Mean Median 
Lower 
95% CrI 
Upper 
95% CrI   
CRZ CHEMO 0.453 0.450 0.347 0.579 -- 
 
0.434 0.432 0.352 0.528 --  0.512 0.430 0.117 1.452 
 CER CHEMO 0.554 0.549 0.417 0.719 -- 
 
0.554 0.549 0.417 0.719 --  0.862 0.549 0.086 3.509 
 ALEC CHEMO 0.231 0.225 0.148 0.344 -- 0.221 0.217 0.146 0.321 --  0.471 0.218 0.023 1.950  
CHEMO CRZ 2.246 2.224 1.727 2.881 ++  2.331 2.317 1.894 2.844 ++  2.841 2.326 0.689 8.563  
CER CRZ 1.244 1.222 0.839 1.785   1.292 1.273 0.903 1.789   3.086 1.272 0.146 12.120  
ALEC CRZ 0.509 0.502 0.360 0.702 --  0.509 0.502 0.360 0.702 --  0.807 0.509 0.079 3.160  
CHEMO CER 1.840 1.821 1.391 2.401 ++  1.840 1.821 1.391 2.401 ++  2.863 1.822 0.285 11.620  
CRZ CER 0.834 0.818 0.560 1.192   0.798 0.786 0.559 1.108   1.740 0.786 0.083 6.883  
ALEC CER 0.424 0.411 0.248 0.674 --  0.406 0.395 0.244 0.634 --  2.502 0.399 0.021 6.559  
CHEMO ALEC 4.541 4.437 2.910 6.762 ++  4.713 4.619 3.120 6.846 ++  10.800 4.592 0.513 44.340  
CRZ ALEC 2.022 1.993 1.425 2.781 ++ 
 
2.022 1.993 1.425 2.781 ++  3.257 1.965 0.317 12.690 
 CER ALEC 2.515 2.432 1.483 4.029 ++ 
 
2.611 2.534 1.578 4.092 ++  15.530 2.510 0.153 47.920 
 Abbreviations: ALEC=alectinib; CER=ceritinib; CHEMO=chemotherapy; CrI=credible limit; CRZ=crizotinib; IRC=independent review committee; NMA=network meta-analysis; PFS=progression-free 
survival. 
-- significantly lower hazard for treatment versus comparator based on the 95% credible interval; ++ significantly higher hazard for treatment versus comparator based on the 95% credible interval. 
Source: MAH NMA report, Table 18. 
 
Table A26. Network meta-analysis summary treatment effect estimates: overall survival unadjusted, base case (fixed effect), sensitivity analysis 1.2 
(fixed effect, including PROFILE 1029) and sensitivity analysis 1.3 (random effect, including PROFILE 1029) 
OS unadjusted   
 Base case 
(ALEX, PROFILE 1014, ASCEND-4) 
Fixed effect NMA  
 
Sensitivity analysis 1.2 
(ALEX, PROFILE 1014, PROFILE 1029, ASCEND-4) 
Fixed effect NMA  
 
Sensitivity analysis 1.3 
(ALEX, PROFILE 1014, PROFILE 1029, ASCEND-4) 
Random effect NMA  
log hazard ratio                  
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Treatment Vs.  Mean Median 
Lower 
95% CrI 
Upper 
95% CrI   
 
Mean Median 
Lower 
95% CrI 
Upper 
95% CrI   
 
Mean Median 
Lower 
95% CrI 
Upper 
95% CrI   
CRZ CHEMO -0.201 -0.199 -0.617 0.212  -0.162 -0.161 -0.474 0.149   -0.163 -0.156 -1.548 1.189 
 CER CHEMO -0.310 -0.310 -0.685 0.057   -0.310 -0.310 -0.685 0.057   -0.306 -0.305 -2.170 1.611 
 ALEC CHEMO -0.470 -0.469 -1.085 0.140   -0.431 -0.431 -0.979 0.119   -0.441 -0.433 -2.787 1.894  
Hazard ratios             
 
          
 
          
Treatment Vs.  Mean Median 
Lower 
95% CrI 
Upper 
95% CrI   
 
Mean Median 
Lower 
95% CrI 
Upper 
95% CrI   
 
Mean Median 
Lower 
95% CrI 
Upper 
95% CrI   
CRZ CHEMO 0.836 0.819 0.539 1.237  0.862 0.852 0.623 1.160   1.052 0.855 0.213 3.283 
 CER CHEMO 0.746 0.734 0.504 1.058   0.746 0.734 0.504 1.058   1.194 0.737 0.114 5.007 
 ALEC CHEMO 0.656 0.625 0.338 1.151   0.676 0.650 0.376 1.126   1.572 0.648 0.062 6.643  
CHEMO CRZ 1.250 1.220 0.809 1.854   1.190 1.174 0.862 1.606   1.473 1.169 0.305 4.705  
CER CRZ 0.933 0.895 0.516 1.570   0.889 0.862 0.530 1.402   2.185 0.859 0.092 9.384  
ALEC CRZ 0.785 0.764 0.487 1.202   0.785 0.764 0.487 1.202   1.239 0.758 0.108 5.088  
CHEMO CER 1.389 1.363 0.945 1.983   1.389 1.363 0.945 1.983   2.202 1.356 0.200 8.758  
CRZ CER 1.161 1.117 0.637 1.939   1.196 1.160 0.714 1.888   2.700 1.164 0.107 10.99  
ALEC CER 0.911 0.853 0.415 1.728   0.938 0.888 0.455 1.707   5.018 0.876 0.042 17.80  
CHEMO ALEC 1.680 1.599 0.869 2.960   1.600 1.538 0.888 2.662   3.981 1.543 0.151 16.23  
CRZ ALEC 1.344 1.310 0.832 2.055   1.344 1.310 0.832 2.055   2.199 1.320 0.197 9.256 
 CER ALEC 1.254 1.173 0.579 2.413   1.194 1.126 0.586 2.199   7.274 1.142 0.056 23.81 
 Abbreviations: ALEC=alectinib; CER=ceritinib; CHEMO=chemotherapy; CrI=credible limit; CRZ=crizotinib; NMA=network meta-analysis; OS=overall survival. 
-- significantly lower hazard for treatment versus comparator based on the 95% credible interval; ++ significantly higher hazard for treatment versus comparator based on the 95% credible interval. 
Source: MAH NMA report 
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Table A27. Checklist table 
Mark  to indicate that the issue has been addressed satisfactorily, and  if there is any cause for concern for the item. The Comments column should be used 
to answer the question (YES, NO, NA: not applicable) and/or to spell out the reasons for any concerns, the need for sensitivity analyses, etc.  
 
Item 
satisfactory 
Comments  
A. DEFINITION OF THE DECISION PROBLEM 
A1. Target population for decision 
  
A1.1 Has the target patient population for decision been clearly 
defined? 
 Target population for NMA: ALK-positive NSCLC treatment-naïve patients. 
A2. Comparators   
A2.1 Decision comparator set: Have all the appropriate treatments 
in the decision been identified? 
 Yes; alectinib, crizotinib, ceritinib.  
A2.2 Synthesis comparator set: Are there additional treatments in 
the synthesis comparator set which are not in the decision 
comparator set? If so, is this adequately justified? 
 Yes; chemotherapies had to be included as additional treatments in the synthesis comparator set to make a 
connected network to perform indirect comparisons and the NMA. 
A3. Trial inclusion/exclusion   
A3.1 Is the search strategy technically adequate and appropriately 
reported? 
 Systematic literature review included all treatment lines, while NMA included only patients in the first-line 
setting. 
Search strategy was reported in detail, could be reproduced. 
 A3.2 Have all trials involving at least two of the treatments in the 
synthesis comparator set been included? 
 See  section 2.3 of this report and PRISMA flow chart. 
 
A3.3 Have all trials reporting relevant outcomes been included?   See  section 2.3 of this report and PRISMA flow chart. 
A3.4 Have additional trials been included? If so, is this adequately 
justified? 
 No additional trials have been included. 
A4. Treatment definition   
A4.1 Are all the treatment options restricted to specific doses and 
cotreatments, or have different doses and cotreatments been 
‘lumped’ together? If the latter, is it adequately justified? 
 In two studies (ASCEND-4 and PROFILE 1014) the comparator was chemotherapy; however, in ASCEND-4 a 
combination of pemetrexed plus either cisplatin or carboplatin was given for four cycles followed by 
pemetrexed maintenance therapy, while in PROFILE 1014 it was given for up to six cycles without pemetrexed 
maintenance therapy.Furthermore, the impact of post-progression cross-over on OS results were identified as 
a further source of uncertainty related to study treatments.   
The MAH provided the following rationale: 
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Item 
satisfactory 
Comments  
Chemo arms: The difference between studies in time on treatment was 1.9 months (4.1 months on CHEMO in 
PROFILE 1014; 6 months on CHEMO in ASCEND-4) and the difference between median PFS in the trials was 
1.1 months (median PFS was 7∙0 months for CHEMO in PROFILE 1014; median PFS of 8∙1 months for 
CHEMO in ASCEND-4). It is not known whether the difference of 1.1 months in median PFS is due to the 
maintenance or falls within the range of uncertainty due to other factors or sources of heterogeneity. Therefore, 
it was assumed that studies were "similar enough" to be connected in the evidence network. 
OS Rationale: Only PROFILE 1014 report OS data adjusted for treatment cross-over. However, patients could 
cross over from the CHEMO arm to the ALKi arm in three trials (PROFILE 1014, PROFILE 1029 and 
ASCEND-4); crossover from CRZ to ALEC was not allowed in the ALEX study. Only available for 
PROFILE1014 study but not available for the ASCEND-4 study therefore, an unadjusted OS was used within 
the base case analysis.  
While the identified uncertainties remain, they are considered adequately addressed by the MAH. 
A4.2 Are there any additional modelling assumptions?  No. 
A5. Trial outcomes and scale of measurement chosen for the 
synthesis 
  
A5.1 Where alternative outcomes are available, has the choice of 
outcome measure used in the synthesis been justified? 
 The MAH conducted a feasibility assessment, including a review of all endpoints within the trials and an 
evaluation for feasibility to connect the network.  
A5.2 Have the assumptions behind the choice of scale been 
justified? 
NA The endpoints used are standard oncology endpoints. 
A6. Patient population: trials with patients outside the target 
population 
  
A6.1 Do some trials include patients outside the target population? 
If so, is this adequately justified? 
 No inclusion of patients outside the target population. 
A6.2 What assumptions are made about the impact, or lack of 
impact, this may have on the relative treatment effects? Are 
they adequately justified? 
NA  
A6.3 Has an adjustment been made to account for these 
differences? If so, comment on the adequacy of the evidence 
presented in support of this adjustment, and on the need for 
a sensitivity analysis. 
NA  
A7. Patient population: heterogeneity within the target population   
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Item 
satisfactory 
Comments  
A7.1 Has there been a review of the literature concerning potential 
modifiers of treatment effect? 
 Not provided. 
A7.2 Are there apparent or potential differences between trials in 
their patient populations, albeit within the target population? If 
so, has this been adequately taken into account? 
 The percentage of patients with brain metastases ranges from 26% to 42% between ALEX, ASCEND-4 and 
PROFILE 1014. 
Previous therapies patients received differ between trials (e.g., previous treatment for CNS metastases differs 
between ALEX and ASCEND-4 and is not reported for PROFILE 1014). 
A8. Risk of bias   
A8.1 Is there a discussion of the biases to which these trials, or 
this ensemble of trials, are vulnerable? 
 Yes. 
A8.2 If a bias risk was identified, was any adjustment made to the 
analysis and was this adequately justified? 
 Factors were identified which are not possible to adjust for: 
PROFILE 1029 was identified as having a possible risk of bias because of the study population including Asian 
patients only; therefore PROFILE 1029 was excluded from the base case analysis of the NMA. 
All trials were open label, which could potentially impact the results. 
Differences in ASCEND-4 include that four cycles of chemotherapy followed by maintenance therapy was used 
as comparator, whereas in PROFILE 1014 up to six cycles of the same chemotherapy was allowed but without 
maintenance therapy. The regimen used in ASCEND-4 may be more efficacious than the one used in 
PROFILE 1014; therefore PFS HR for ceritinib vs. chemotherapy may be underestimated in the NMA, and the 
PFS HR for crizotinib vs. chemotherapy may be overestimated. 
A9. Presentation of the data   
A9.1 Is there a clear table or diagram showing which data have 
been included in the base case analysis? 
 Network diagram and characteristics of included studies was provided. 
A9.2 Is there a clear table or diagram showing which data have 
been excluded and why? 
 Not provided. 
B. METHODS OF ANALYSIS AND PRESENTATION OF RESULTS 
B1. Meta-analytic methods 
  
B1.1 Is the statistical model clearly described?  Statistical model is adequately described. 
B1.2 Has the software implementation been documented?  Software implementation has been described. 
B2. Heterogeneity in the relative treatment effects    
B2.1 Have numerical estimates been provided of the degree of 
heterogeneity in the relative treatment effects? 
 Because all considered comparisons are based on just one relevant study in the base case, the heterogeneity 
is completely assumption driven. Sensitivity analyses regarding the influence of the heterogeneity assumptions 
were not presented. 
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Item 
satisfactory 
Comments  
B2.2 Has a justification been given for the choice of random or 
fixed effect models? Should sensitivity analyses be 
considered? 
  A decision rule based on the deviance information criteria and the average residual deviance was prespecified, 
but considering the limited amount of data that can validate heterogeneity assumptions (which constitute the 
main difference between the fixed effects model and the random effects model), the presentation of extensive 
sensitivity analyses seems more adequate than deciding between the two extreme cases of absolute certainty 
about zero heterogeneity (fixed effects model) and high uncertainty regarding heterogeneity (random effects 
model with vague prior distribution). 
B2.3 Has there been an adequate response to heterogeneity? NA No observable heterogeneity because of only one trial per comparison, no covariate adjustment. 
B2.4 Does the extent of unexplained variation in relative treatment 
effects threaten the robustness of conclusions? 
NA Limited data; validation of heterogeneity assumptions not possible (see comment on B2.2). 
B2.5 Has the statistical heterogeneity between baseline arms 
been discussed? 
 Not provided. 
B3. Baseline model for trial outcomes   
B3.1 Are baseline effects and relative effects estimated in the 
same model? If so, has this been justified? 
NA No baseline model. 
B3.2 Has the choice of studies to inform the baseline model been 
explained? 
NA No baseline model. 
B4. Presentation of results of analyses of trial data    
B4.1 Are the relative treatment effects (relative to a placebo or 
‘standard’ comparator) tabulated, alongside measures of 
between-study heterogeneity if a random effects model is 
used? 
 The relative treatment effects are tabulated, but measures of between-study heterogeneity cannot be extracted 
from the data. 
B4.2 Are the absolute effects on each treatment, as they are used 
in the CEA, reported? 
NA CEA not done. 
B5. Synthesis in other parts of the natural history model   
B5.1 Is the choice of data sources to inform the other parameters 
in the natural history model adequately described and 
justified? 
NA No natural history model. 
B5.2 In the natural history model, can the longer-term differences 
between treatments be explained by their differences on 
NA No natural history model. 
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Item 
satisfactory 
Comments  
randomised trial outcomes?  
C. ISSUES SPECIFIC TO NETWORK SYNTHESIS 
C1. Adequacy of information on model specification and software 
implementation 
 The software implementation is adequate. 
C2. Multiarm trials   
C2.1 If there are multiarm trials, have the correlations between the 
relative treatment effects been taken into account? 
NA No multiarm trials included. 
C3. Connected and disconnected networks   
C3.1 Is the network of evidence based on randomised trials 
connected? 
 All included trials are (open-label) phase III RCTs with active control groups.  
C4. Inconsistency   
C4.1 How many inconsistencies could there be in the network? NA Inconsistencies not possible – no closed loops in the network.  
C4.2 Are there any a priori reasons for concern that 
inconsistency might exist because of systematic clinical 
differences between the patients in trials comparing 
treatments A and B, and the patients in trials comparing 
treatments A and C, etc? 
 Yes; percentage of patients with brain metastases ranges from 26% to 42% between ALEX, ASCEND-4 and 
PROFILE 1014; and previous treatment for CNS metastases differs between ALEX and ASCEND-4 and is not 
reported for PROFILE 1014. 
C4.3 Have adequate checks for inconsistency been made? NA Inconsistencies not possible – no closed loops in the network.  
C4.4 If inconsistency was detected, what adjustments were 
made to the analysis, and how were these justified? 
NA Inconsistencies not possible – no closed loops in the network.  
D. EMBEDDING THE SYNTHESIS IN A PROBABILISTIC CEA 
D1. Uncertainty Propagation 
  
D1.1 Has the uncertainty in parameter estimates been propagated 
through the CEA model? 
NA No CEA model. 
D2. Correlations   
D2.1 Are there correlations between parameters? If so, have the 
correlations been propagated through the CEA model? 
NA No CEA model. 
Abbreviations: CEA=cost-effectiveness analysis; CNS=central nervous system; HR=hazard ratio; MAH=marketing authorisation holder; NMA network meta-analysis; NSCLC=non-small cell lung 
cancer; OS=overall survival; PFS=progression-free survival; PRISMA=Preferred Reporting Items for Systematic Reviews and Meta-analyses; RCT=randomised controlled trial; NA=not applicable. 
Source: [17], NMA Report, NMA SAP, NMA FAS. 
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Table A28: Benefit assessment based on the original ESMO-MCBS and adapted benefit assessment based on the adapted ESMO-MCBS 
ESMO-
MCBS 
Active  
substance Indication Intention PE Form 
MG 
standard 
treatment 
Efficacy Safety 
AJ FM MG 
months 
HR 
(95% CI) 
Score calculation PM Toxicity QoL 
Adapted 
ESMO-
MCBS 
Alectinib NSCLC NC PFS 2b >6 months 
OS: NE 
PFS: NR 
OS: 0.76 (0.48–1.20) 
PFS: 0.47 (0.34–0.65) 
no score calculation 
was possible since 
neither mature data 
for PFS nor for OS is 
available 
x 
-9% grade ≥3 AEs,  
-2%discontinuation 
x x x 
Original 
ESMO-
MCBS 
Alectinib NSCLC NC PFS 2b >6 months 
OS: NE 
PFS: NR 
OS: 0.76 (0.48–1.20) 
PFS: 0.47 (0.34–0.65) 
x x x x x 
Abbreviations: AEs = adverse events, AJ = Adjustments, CI = confidence interval, FM = final adjusted magnitude of clinical benefit grade, HR = hazard ratio, MG = median gain, NC = non-curative, NE = not estimable, NSCLC = non-
small cell lung cancer, OS = overall survival, PE = primary endpoint, PFS = progression-free survival, PM = preliminary magnitude of clinical benefit grade, QoL = quality of life 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint of interest, and by score 
adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the exact same score resulting from the use of form 2c. To 
ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically favours drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this 
systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and outcomes that lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, 
therefore, a reason for confounding. Hence, we report the adjustments separately. 
 
 
 
